

# CITATION REPORT

List of articles citing

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators

DOI: 10.1056/nejm199612263352601

New England Journal of Medicine, 1996, 335, 1933-40.

**Source:** <https://exaly.com/paper-pdf/27621686/citation-report.pdf>

**Version:** 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2296	Palpitations and shortness of breath in a 69-year-old male. 57-60		
2295	Unsustained ventricular tachycardia--to treat or not to treat. <i>New England Journal of Medicine</i> , <b>1996</b> , 335, 1984-5	59.2	64
2294	Implantable defibrillators in patients with coronary artery disease at high risk for ventricular arrhythmia. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 1676; author reply 1677	59.2	2
2293	A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 1576-83	59.2	2492
2292	Clinical trials of implantable defibrillators. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 1621-3	59.2	32
2291	The Multicenter Automatic Defibrillator Implantation Trial. <b>1997</b> , 2, 229-238		1
2290	The Multicenter Automatic Defibrillator Implantation Trial. <b>1997</b> , 2, 234-237		1
2289	Cardiothoracic Surgery. <b>1997</b> , 277, 1843		
2288	Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function. <b>1997</b> , 2, 147-152		2
2287	Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 1569-75	59.2	779
2286	Systematic trial of pacing to prevent atrial fibrillation (STOP-AF). <b>1997</b> , 78, 224-5		16
2285	Cardiovascular Disease. <b>1997</b> , 277, 1845		
2284	Are we using too many pacemakers in Belgium?. <b>1997</b> , 52, 247-50		1
2283	Experience with implantable cardioverter defibrillator therapy in elderly patients. <b>1997</b> , 18, 1339-42		26
2282	Recipient Selection and Management Before Cardiac Transplantation. <b>1997</b> , 314, 139-152		
2281	On the distribution of a concomitant statistic in a sequential trial. <b>1997</b> , 16, 287-294		2
2280	Arrhythmias and sudden death in heart failure. <b>1997</b> , 61, 727-40		28

2279	Driving issues related to arrhythmic syncope. <b>1997</b> , 15, 327-39	9
2278	[Prevention of sudden death after myocardial infarction: should the "MADIT" strategy be generally applied? Arguments in favor]. <b>1997</b> , 50, 459-63	0
2277	[Prevention of sudden death after myocardial infarction: should the "MADIT" strategy be generally applied? Arguments against]. <b>1997</b> , 50, 464-6	1
2276	Antiarrhythmic therapies for the prevention of sudden cardiac death. <b>1997</b> , 54, 235-52	21
2275	Pharmacological management of arrhythmias in the elderly. <b>1997</b> , 11, 96-110	7
2274	Baseline characteristics of patients in the coronary artery bypass graft (CABG) Patch Trial. <b>1997</b> , 134, 787-98	18
2273	Adverse effects of amiodarone at low dose: plus ß change. <b>1997</b> , 30, 799-801	10
2272	Primary prevention of sudden cardiac death in heart failure: will the solution be shocking?. <b>1997</b> , 30, 1589-97	162
2271	Clinical trials with implications regarding heart failure therapy. <b>1997</b> , 12, 407-417	3
2270	The place of amiodarone: an overview of the four recent large controlled trials. <b>1997</b> , 27, 582-90	3
2269	Can catheter ablation in cardiac arrest survivors prevent ventricular fibrillation recurrence?. <b>1997</b> , 20, 1840-59	2
2268	The top ten fallacies of nonsustained ventricular tachycardia. <b>1997</b> , 20, 2825-47	5
2267	The ICD--progress, prospects, and problems. <b>1997</b> , 20, 2367-70	1
2266	Classification of sudden and arrhythmic death. <b>1997</b> , 20, 2545-52	35
2265	Use of left ventricular ejection fraction or wall-motion score index in predicting arrhythmic death in patients following an acute myocardial infarction. The TRACE Study Group. <b>1997</b> , 20, 2553-9	21
2264	Arrhythmia risk: electrophysiological studies and monophasic action potentials. <b>1997</b> , 20, 2560-5	6
2263	Inappropriate discharge of an implantable cardioverter defibrillator during atrial flutter and intermittent ventricular antibradycardia pacing. <b>1997</b> , 8, 1167-74	14
2262	Progress in Interventional Cardiology. <b>1997</b> , 10, 309-311	

2261	Quantification of Prevalence of Asymptomatic Ventricular Arrhythmias in Patients with Heart Failure. <b>1997</b> , 2, 346-352	5
2260	MADIT and the Implications for Holter Monitoring: Results of a 100-Physician Survey. <b>1997</b> , 2, 378-383	1
2259	Nonsustained Ventricular Tachycardia. <b>1997</b> , 2, 79-91	
2258	The psychological and emotional impact of living with an automatic internal cardioverter defibrillator (AICD): how can nurses help?. <b>1997</b> , 13, 316-23	14
2257	Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. <b>1997</b> , 40, 85-93	9
2256	Do MADIT results apply only to "MADIT patients"? Multicenter Automatic Defibrillator Implantation Trial. <b>1997</b> , 79, 27-30	9
2255	Which device should "MADIT protocol" patients receive? Multicenter Automatic Defibrillator Implantation Trial. <b>1997</b> , 79, 31-5	6
2254	The AVID trial: evidence based or randomized control trials--is the AVID study too late? Antiarrhythmics Versus Implantable Defibrillators. <b>1997</b> , 80, 194-7	12
2253	Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. <b>1997</b> , 80, 591-4	9
2252	Background, outcome, and clinical implications of the Multicenter Automatic Defibrillator Implantation Trial (MADIT). <b>1997</b> , 80, 28F-32F	18
2251	Approach to cost-effectiveness assessment in the MADIT trial. Multicenter Automatic Defibrillator Implantation Trial. <b>1997</b> , 80, 33F-41F	9
2250	Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study. <b>1997</b> , 80, 3F-9F	11
2249	What can we expect from prophylactic implantable defibrillators?. <b>1997</b> , 80, 20F-27F	18
2248	There should never be another antiarrhythmics versus implantable defibrillator (AVID) trial. <b>1997</b> , 80, 766-8	5
2247	Introduction: primary prevention against sudden cardiac death. <b>1997</b> , 80, 1F-2F	3
2246	Low variability of cycle lengths in nonsustained ventricular tachycardia as an independent predictor of mortality after myocardial infarction. <b>1997</b> , 80, 1347-50	3
2245	Controlling cardiac arrhythmias: an overview with a historical perspective. <b>1997</b> , 80, 4G-15G	19
2244	General principles of antiarrhythmic therapy for ventricular tachyarrhythmias. <b>1997</b> , 80, 31G-44G	6

2243	Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. <b>1997</b> , 80, 67G-73G	13
2242	The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. <b>1997</b> , 80, 90G-98G	33
2241	Antiarrhythmic therapy--future trends and forecast for the 21st century. <b>1997</b> , 80, 99G-104G	5
2240	Beta blockade, ventricular arrhythmias, and sudden cardiac death. <b>1997</b> , 80, 29J-34J	36
2239	Current status of implantable cardioverter-defibrillators. <b>1997</b> , 22, 641-707	6
2238	Nonsustained Ventricular Tachycardia. <b>1997</b> , 2, 1-2	
2237	Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction. <b>1997</b> , 20, 753-8	17
2236	Evaluating antiarrhythmic drugs in implantable device. <b>1998</b> , 2, 5-6	
2235	Implantable cardioverter-defibrillator therapy: influence of left ventricular function on long-term results. <b>1997</b> , 1, 211-20	5
2234	Clinical and interventional electrophysiology: a personal historical perspective. <b>1997</b> , 1, 243-54	2
2233	On MADIT and future clinical trials for prevention of sudden cardiac death. Multicenter Automatic Defibrillator Implantation Trial. <b>1997</b> , 1, 91-3	2
2232	Role of Amiodarone in Heart Failure. <b>1997</b> , 2, 3-10	1
2231	Advances in cardiology: the complementary roles of concept and technology. <b>1997</b> , 1, 317-26	
2230	Electrophysiology Studies in the Assessment and Management of Patients Involved in High Risk Occupations and Activities. <b>1997</b> , 1, 473-477	
2229	Ep Evaluation for MADIT-Eligible Patients. <b>1997</b> , 1, 468-469	
2228	Prediction of Sudden Death after Myocardial Infarction: Value of Electrophysiologic Parameters. <b>1997</b> , 1, 193-197	1
2227	[Defibrillator therapy 1997. Prerequisites--results--prospects]. <b>1997</b> , 92, 415-20	1
2226	[Drug therapy of ventricular arrhythmias]. <b>1997</b> , 92, 208-10	1

- 2225 [Change in therapy of cardiac arrhythmias. Current studies--initial results]. **1997**, 92, 211-4
- 2224 [What is reliable in therapy of tachycardic arrhythmias]. **1997**, 38, 1204-19
- 2223 Modelling in economic evaluation: an unavoidable fact of life. **1997**, 6, 217-27 404
- 2222 Can implantable defibrillators reduce non-arrhythmic mortality?. **1998**, 2, 371-5 4
- 2221 A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. **1998**, 2, 345-9 5
- 2220 Clinical Implications of the CABG Patch Trial: An Investigator's Perspective. **1998**, 2, 13-15
- 2219 Clinical Implications of MADIT, AVID, CIDS, CABG Patch Trial and CASH: A North American Perspective. **1998**, 2, 17-20
- 2218 Clinical Implications of the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). **1998**, 2, 23-25
- 2217 Oral Procainamide. **1998**, 2, 200-203
- 2216 Clinical Implications of ATRAMI: A Clinician's Perspective. **1998**, 2, 41-43 1
- 2215 Clinical Implications of the Multicenter Automatic Defibrillator Implantation Trial (MADIT): An Investigator's Perspective. **1998**, 2, 6-7
- 2214 Sequential Designs in Clinical Trials. **1998**, 2, 57-60 3
- 2213 Clinical Implications of MADIT, AVID, CIDS, the CABG Patch Trial and CASH: A European Perspective. **1998**, 2, 21-22
- 2212 Oral Amiodarone. **1998**, 2, 186-188 1
- 2211 [Status of intensified therapy and regionalized allocation of donor hearts in the management of patients with terminal heart failure]. **1998**, 87, 676-82
- 2210 Stepwise strategy on the cost of risk stratification after acute myocardial infarction: a retrospective simulation study. **1998**, 21, 603-9 3
- 2209 ICD trials: an extraordinary means of determining patient risk?. **1998**, 21, 1341-6 17
- 2208 The ICD in France: money problem or donkey syndrome?. **1998**, 21, 1683-5 4

2207	Worldwide clinical experience with a down-sized active can implantable cardioverter defibrillator in 162 consecutive patients. Worldwide 7221 ICD Investigators. <b>1998</b> , 21, 1778-83	21
2206	Implantable cardioverter defibrillators in the United States: understanding the benefits and limitations of implantable cardioverter defibrillator therapy based on clinical trial results. <b>1998</b> , 21, 2016-20	5
2205	Assessment of intersignal variability for discrimination of atrial fibrillation from atrial flutter. <b>1998</b> , 21, 2426-30	7
2204	Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: design and first results of the Marburg Cardiomyopathy Study. <b>1998</b> , 21, 2551-6	26
2203	T wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD recipients: prospective comparison with conventional risk markers. <b>1998</b> , 9, 1258-68	164
2202	A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators. <b>1998</b> , 9, 864-91	37
2201	Runaway pacemaker in an implantable cardioverter defibrillator. <b>1998</b> , 9, 1008-11	15
2200	A prospective evaluation of two defibrillation safety margin techniques in patients with low defibrillation energy requirements. <b>1998</b> , 9, 41-6	24
2199	Lidocaine's effect on defibrillation threshold are dependent on the defibrillation electrode system: epicardial versus endocardial. <b>1998</b> , 9, 312-20	6
2198	Effect of heart rate on T wave alternans. <b>1998</b> , 9, 703-8	50
2197	Body surface potentials during discharge of the implantable cardioverter defibrillator. <b>1998</b> , 9, 491-7	10
2196	Current concepts of ventricular defibrillation. <b>1998</b> , 9, 553-62	47
2195	AVID and Beyond: Lessons Learned. <b>1998</b> , 11, 217-226	2
2194	Prophylactic Trials With Implantable Cardioverter Defibrillators: MADIT and Beyond. <b>1998</b> , 11, 227-233	1
2193	Pharmacological Therapy for Ventricular Arrhythmias in the Era of the Implantable Cardioverter Defibrillator: Indispensable or Inadvisable?. <b>1998</b> , 11, 235-246	
2192	Noninvasive Electrocardiological Identification of Patients Who Will Benefit from an Implantable Defibrillator. <b>1998</b> , 3, 181-182	
2191	Changes in sample size and length of follow-up to maintain power in the coronary artery bypass graft (CABG) patch trial. <b>1998</b> , 19, 1-14	10
2190	On the necessity of the invasive predischarge test after implantation of a cardioverter-defibrillator. <b>1998</b> , 81, 933-5	14

2189	Successful percutaneous extraction of pacemaker leads with a novel (VascoExtor) pacing lead removal system. <b>1998</b> , 81, 935-8	21
2188	Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. <b>1998</b> , 81, 1253-6	68
2187	Indications for implantation of a dual-chamber pacemaker combined with an implantable cardioverter-defibrillator. <b>1998</b> , 81, 1360-2	30
2186	Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Cardiac Arrhythmia Suppression Trial. <b>1998</b> , 82, 683-5, A8	18
2185	Importance of beta blockade in the therapy of serious ventricular arrhythmias. <b>1998</b> , 82, 91-191	74
2184	Antiarrhythmic drugs and devices for the management of ventricular tachyarrhythmia in ischemic heart disease. <b>1998</b> , 82, 311-401	5
2183	Interactions between implantable cardioverter-defibrillators and class III agents. <b>1998</b> , 82, 411-481	26
2182	Comparison of results in two implantable defibrillators. Jewel 7219D Investigators. <b>1998</b> , 82, 875-80	20
2181	Initial experience with a laser sheath to extract chronic transvenous implantable cardioverter-defibrillator leads. <b>1998</b> , 82, 1293-5, A10	24
2180	The Problem of Asymptomatic Ventricular Arrhythmias Among Survivors of Acute Myocardial Infarction: Role of Amiodarone. <b>1998</b> , 7, 12-14	
2179	Current concepts in the treatment of patients with heart failure. <b>1998</b> , 7, 39-43	
2178	The use of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. <b>1998</b> , 7, 48-51	1
2177	Amiodarone zur Verhinderung des plötzlichen Herztodes: Allein, in Kombination mit EBlockern oder gar nicht?. <b>1998</b> , 9, S52-S56	
2176	[The renin-angiotensin system in cardiovascular diseases]. <b>1998</b> , 93, 416-25	4
2175	[Safe and unsafe indications to the electrophysiological examination]. <b>1998</b> , 23, 463-5	
2174	Sudden cardiac death in patients with congestive heart failure: toward a unified rational treatment approach. <b>1998</b> , 5, 80-5	
2173	Clinical experience with downsized lower energy output implantable cardioverter defibrillators. Ventak Mini II Clinical Investigators. <b>1998</b> , 66, 261-6	9
2172	Implantable cardioverter defibrillators--for whom?. <b>1998</b> , 352, 338-40	7



2171	Autonomic markers and prediction of cardiac death after myocardial infarction. <b>1998</b> , 351, 461-2	52
2170	Successes and failures of current treatment of heart failure. <b>1998</b> , 352 Suppl 1, S119-28	71
2169	Amiodarone reduced total mortality and arrhythmic/sudden death in patients with recent MI or with CHF. <b>1998</b> , 2, 51-2	
2168	Psychopathology following cardioverter defibrillator implantation. <b>1998</b> , 39, 305-10	20
2167	Management of recurrent ventricular tachycardia with ventricular assist device placement. <b>1998</b> , 66, 571-3	26
2166	ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). <b>1998</b> , 31, 1175-209	411
2165	Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. <b>1998</b> , 32, 739-45	97
2164	Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. <b>1998</b> , 32, 1056-62	40
2163	[Current indications for implantable automatic defibrillators]. <b>1998</b> , 51, 259-73	2
2162	Implantable cardioverter defibrillators. <b>1998</b> , 16, 463-89	1
2161	Identification of ventricular tachycardias by means of fast wavelet analysis.	1
2160	Ongoing and planned clinical trials of anti-arrhythmic drugs: an update. <b>1998</b> , 7, 427-35	1
2159	Heart rate changes preceding ventricular ectopy in patients with ventricular tachycardia caused by reentry, triggered activity, and automaticity. <b>1998</b> , 136, 425-34	17
2158	Current medical therapy for advanced heart failure. <b>1998</b> , 135, S231-48	38
2157	Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure. <b>1998</b> , 135, S264-84	28
2156	Current treatment recommendations in antiarrhythmic therapy. <b>1998</b> , 55, 331-46	15
2155	Is there a future for antiarrhythmic drug therapy?. <b>1998</b> , 56, 767-81	20
2154	Beta-blockade and amiodarone therapy: twin brothers from different parents. <b>1998</b> , 4, 289-94	1

2153	Clinical pharmacology of antiarrhythmic drugs. <b>1998</b> , 13, 51-70	7
2152	Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. <i>New England Journal of Medicine</i> , <b>1998</b> , 338, 1227-8	59.2 1
2151	Recent advances. <i>Cardiology</i> . <b>1998</b> , 316, 911-5	2
2150	Sudden cardiac death. <b>1998</b> , 98, 2334-51	1467
2149	Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). <b>1998</b> , 98, 1510-6	919
2148	Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. <b>1998</b> , 98, 1636-43	78
2147	Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. <b>1998</b> , 97, 1514-21	180
2146	The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. <b>1998</b> , 97, 2129-35	233
2145	Potential impact of antiarrhythmic drugs versus implantable defibrillators on the management of ventricular arrhythmias: the Midlands trial of empirical amiodarone versus electrophysiologically guided intervention and cardioverter implant registry data. <b>1998</b> , 80, 68-70	7
2144	The search for novel antiarrhythmic strategies. <i>Sicilian Gambit</i> . <b>1998</b> , 19, 1178-96	20
2143	Recognition and Management of Cardiac Arrhythmias: Part I. General Principles and Supraventricular Tachyarrhythmias. <b>1998</b> , 13, 15-31	
2142	Update on implantable cardioverter-defibrillators. New, safer devices have led to changes in indications. <b>1998</b> , 103, 115-6, 119-23, 129-30	1
2141	Predictors of outcome in patients with implantable cardioverter defibrillators. <b>1998</b> , 90, 180-6	11
2140	Management of older persons after myocardial infarction. <b>1998</b> , 46, 1459-68	10
2139	The search for novel antiarrhythmic strategies. <i>Sicilian Gambit</i> . <b>1998</b> , 62, 633-48	6
2138	Implantable defibrillators for life threatening ventricular arrhythmias. Are more effective than antiarrhythmic drugs in selected high risk patients. <b>1998</b> , 317, 762-3	7
2137	A new evidence base for implantable defibrillator therapy. <b>1998</b> , 19, 189-91	2
2136	Diagnosis and investigation of essential and secondary hypertension. <b>1998</b> , 19, 372-7	3

2135	Disparate effects of biphasic and monophasic shocks on postshock refractory period dispersion. <b>1998</b> , 274, H1943-9		2
2134	Demonstration of nonlinear components in heart rate variability of healthy persons. <b>1998</b> , 275, H1577-84		38
2133	The evolving role of ambulatory arrhythmia monitoring in general clinical practice. <b>1999</b> , 130, 848-56		88
2132	Ventricular Arrhythmias, Electrophysiologic Studies, and Devices *. <b>1999</b> , 11, 375-382		1
2131	Defibrillators. <b>1999</b> ,		
2130	Editorials. <b>1999</b> , 20, 319-326		3
2129	New Treatment Strategies in Patients with Impaired Left Ventricular Systolic Function. Part II: Treatment of Moderate to Severe Cardiac Dysfunction. <b>1999</b> , 317, 312-317		
2128	Distribution of spectral energy on the body surface: a physiological road map to improve identification of patients vulnerable to sustained ventricular arrhythmias. <b>1999</b> , 20, 1061-3		
2127	More good news on prophylactic arrhythmia management. <b>1999</b> , 20, 1684-5		
2126	Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems?. <b>1999</b> , 20, 1538-52		2
2125	Clinical consequences of electrocardiographic artifact mimicking ventricular tachycardia. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 1270-4	59.2	158
2124	Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 1855-62	59.2	353
2123	A 75-year-old man with congestive heart failure. <b>1999</b> , 281, 2321-8		1
2122	Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. <b>1999</b> , 99, 1416-21		129
2121	Sequential Designs for Monitoring Two Endpoints in a Clinical Trial. <b>1999</b> , 33, 417-426		14
2120	Design and results of the antiarrhythmics vs implantable defibrillators (AVID) registry. The AVID Investigators. <b>1999</b> , 99, 1692-9		98
2119	Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. <b>1999</b> , 14, 130-5		115
2118	Appropriate use of the implantable cardioverter defibrillator: a Canadian perspective. Canadian Working Group on Cardiac Pacing. <b>1999</b> , 22, 1-4		4

2117	Clinical significance of consecutive shocks in patients with left ventricular dysfunction treated with implantable cardioverter defibrillators. <b>1999</b> , 22, 187-91	11
2116	Late retesting of system performance in ICD patients without spontaneous shocks. <b>1999</b> , 22, 197-201	5
2115	Complications of third-generation implantable cardioverter defibrillator therapy. <b>1999</b> , 22, 206-11	65
2114	Multicenter evaluation of implantable cardioverter defibrillator testing after implant: the Post Implant Testing Study (PITS). <b>1999</b> , 22, 1769-76	17
2113	Inappropriate implantable cardioverter-defibrillator therapy due to the detection of premature ventricular complexes. <b>1999</b> , 22, 825-8	12
2112	Correlation waveform analysis to discriminate monomorphic ventricular tachycardia from sinus rhythm using stored electrograms from implantable defibrillators. <b>1999</b> , 22, 1146-51	4
2111	Defibrillation thresholds are increased by right-sided implantation of totally transvenous implantable cardioverter defibrillators. <b>1999</b> , 22, 1186-92	26
2110	Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. <b>1999</b> , 22, 1305-13	117
2109	Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems?. <b>1999</b> , 10, 1534-49	5
2108	Testing antiarrhythmic drugs with the ICD: useful, but inherently inaccurate. <b>1999</b> , 10, 1550-2	
2107	The effect of procainamide on T wave alternans. <b>1999</b> , 10, 649-54	31
2106	Value of programmed ventricular stimulation in patients with congenital heart disease. <b>1999</b> , 10, 1033-44	101
2105	Standard 12-Lead and 24-Hour Ambulatory Electrocardiographic Abnormalities in Survivors of Tachyarrhythmic Cardiac Arrest. <b>1999</b> , 4, 158-166	2
2104	Baroreflex Sensitivity. <b>1999</b> , 4, 219-231	
2103	Noninvasive Testing for Selection of Patients for Electrophysiological Study. <b>1999</b> , 4, 434-442	1
2102	Multicenter Automatic Defibrillator Implantation Trial II (MADIT II): Design and Clinical Protocol. <b>1999</b> , 4, 83-91	49
2101	Should all candidates for ICD therapy receive a dual chamber system?. <b>1999</b> , 3, 203-6	2
2100	Prevention of Cardiac Arrest: Risk Assessment after Myocardial Infarction. <b>1999</b> , 3, 180-183	

- 2099 Arrhythmias Associated with Dilated Cardiomyopathy. **1999**, 3, 187-193
- 2098 Epidemiology of Arrhythmic and Sudden Death in the Chronic Phase of Ischemic Heart Disease. **1999**, 3, 177-179 14
- 2097 Primary Prevention in Chronic Ischemic Heart Disease. **1999**, 3, 184-186
- 2096 Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. **1999**, 22, 481-9 232
- 2095 [Cardiology update. I: Electrophysiology]. **1999**, 94, 15-28 1
- 2094 Der plötzliche Herztod [Ein Überraschendes Ereignis?]. **1999**, 36, 485-492 4
- 2093 Amiodarone and implantable cardioverter-defibrillators in congestive heart failure. **1999**, 88, S036-9
- 2092 Value of antiarrhythmic drug therapy and the implantable cardioverter defibrillator in prolonging survival in patients with severe congestive failure. **1999**, 10, 23-29
- 2091 Studien über die Kosteneffizienz implantierbarer Defibrillatoren. **1999**, 10, S008-S014
- 2090 The Best + ICD Trial. **1999**, 10, S015-S022
- 2089 Refractory heart failure. **1999**, 1, 67-81 3
- 2088 Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias. **1999**, 1, 282-8 6
- 2087 The role of antiarrhythmic therapy in the management of nonsustained ventricular tachycardia. **1999**, 1, 297-301
- 2086 Evidence-based medicine and the implantable defibrillator. **1999**, 1, 135-41 2
- 2085 Sudden Electrical Death. **1999**, 1, 91-96
- 2084 Sudden Cardiac Death. **1999**, 1, 127-136
- 2083 Symptomatic Ventricular Tachycardia. **1999**, 1, 145-152
- 2082 Correspondence. **1999**, 83, 1A-38A 142

2081	Navigation in the mega-trials waters: reflections on the Multicenter Automatic Defibrillator Implantation Trial and the Antiarrhythmics Versus Implantable Defibrillators Study. <b>1999</b> , 83, 5D-7D	10
2080	Algorithm for the prevention of ventricular tachycardia onset: the Prevent Study. <b>1999</b> , 83, 45D-47D	10
2079	A preview of implantable cardioverter defibrillator systems in the next millennium: an integrative cardiac rhythm management approach. <b>1999</b> , 83, 48D-54D	12
2078	Impact of the Multicenter Automatic Defibrillator Implantation Trial on implantable cardioverter defibrillator indication trends. <b>1999</b> , 83, 79D-82D	41
2077	What risk should justify implantable cardioverter defibrillator therapy?. <b>1999</b> , 83, 101D-103D	4
2076	Has the survival of the heart failure population changed? Lessons from trials. <b>1999</b> , 83, 112D-119D	54
2075	Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. <b>1999</b> , 83, 143D-150D	120
2074	The implantable cardioverter defibrillator as a "bridge to transplant": a viable clinical strategy?. <b>1999</b> , 83, 151D-157D	25
2073	The implantable cardioverter defibrillator and primary prevention of sudden death: the Multicenter Automatic Defibrillator Implantation Trial and the Coronary Artery Bypass Graft (CABG)-Patch Trial. <b>1999</b> , 83, 74D-78D	10
2072	Managing atrial tachyarrhythmias in patients with implantable cardioverter defibrillators. <b>1999</b> , 83, 214D-217D	16
2071	Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart". <b>1999</b> , 83, 83D-87D	6
2070	Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design. <b>1999</b> , 83, 104D-111D	21
2069	Beta blockers: evidence versus wishful thinking. <b>1999</b> , 83, 64D-67D	2
2068	New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. <b>1999</b> , 83, 91D-97D	104
2067	Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation. <b>1999</b> , 84, 56R-62R	4
2066	Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias. <b>1999</b> , 84, 63R-68R	13
2065	Concomitant device and drug therapy: current trends, potential benefits, and adverse interactions. <b>1999</b> , 84, 69R-75R	16
2064	Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy. <b>1999</b> , 84, 103R-108R	10

2063	Evolution of diagnostic and interventional cardiac electrophysiology: a brief historical review. <b>1999</b> , 84, 115R-124R	13
2062	Sudden cardiac death. <b>1999</b> , 24, 461-538	10
2061	Methods of identifying patients at high risk of subsequent arrhythmic death after myocardial infarction. <b>1999</b> , 24, 117-60	2
2060	The secondary prevention of myocardial infarction. <b>1999</b> , 24, 617-77	2
2059	Cardiac pacemakers and implantable defibrillators in terminal care. <b>1999</b> , 18, 126-31	47
2058	Assessment of electrical devices for arrhythmia control and prevention: past and future. <b>1999</b> , 8, 47-50	
2057	The Proserba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. <b>1999</b> , 42, 2153-9	90
2056	Using missing data techniques to explore the lack of survival effect: illustration with the CABG patch trial. <b>1999</b> , 18, 1943-59	2
2055	A unified theory for sequential clinical trials. <b>1999</b> , 18, 2271-86	43
2054	Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. <b>1999</b> , 9, 163-8	106
2053	Studien über die Kosteneffizienz implantierbarer Defibrillatoren. <b>1999</b> , 10, S008-S014	
2052	Guías de práctica clínica de la Sociedad Española de Cardiología sobre el desfibrilador automático implantable. <b>1999</b> , 52, 1.083-1.104	12
2051	Caring for patients with an automatic internal cardioverter defibrillator: seeking a balance between technological nursing and patient- and family-centered care [Implications for practice]. <b>1999</b> , 3, 25-31	6
2050	Implantable cardioverter-defibrillators. <b>1999</b> , 13, 475-83	5
2049	Sudden death and tailored medical therapy in elective candidates for heart transplantation. <b>1999</b> , 18, 869-76	23
2048	Spatial features in body surface potential maps of patients with ventricular tachyarrhythmias with or without coronary artery disease. <b>1999</b> , 70, 109-18	2
2047	Effect of hemodialysis on the signal-averaged electrocardiogram. <b>1999</b> , 34, 1105-13	16
2046	Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. <b>1999</b> , 353, 1390-6	575

2045	Changes in health status and quality of life and the impact of uncertainty in patients who survive life-threatening arrhythmias. <b>1999</b> , 28, 251-60	58
2044	Risk stratification following myocardial infarction in the thrombolytic era: a two-step strategy using noninvasive and invasive methods. <b>1999</b> , 33, 131-8	35
2043	"Care," cancer and coenzyme Q10. <b>1999</b> , 33, 897-9	5
2042	Correspondence. <b>1999</b> , 33, 901-902	
2041	Cost-effectiveness of an ineffective therapy(?). <b>1999</b> , 33, 902-3	1
2040	Correspondence. <b>1999</b> , 33, 902	1
2039	Intraoperative arrhythmias and tissue damage during transmural laser revascularization. <b>1999</b> , 67, 423-31	22
2038	Causas de muerte sbita. Problemas a la hora de establecer y clasificar los tipos de muerte. <b>1999</b> , 52, 1.004-1.014	2
2037	Ventricular arrhythmias, electrophysiologic studies, and devices. <b>1999</b> , 17, 189-95, x	2
2036	Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias. <b>1999</b> , 33, 1989-95	5
2035	Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. <b>1999</b> , 33, 1895-902	83
2034	Shocks as predictors of survival in patients with implantable cardioverter-defibrillators. <b>1999</b> , 34, 204-10	57
2033	Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. <b>1999</b> , 33, 1964-70	158
2032	Should ICDs be implanted in all patients with dilated cardiomyopathy and unexplained syncope?. <b>1999</b> , 33, 1971-3	9
2031	Atrial defibrillation with a transvenous lead: a randomized comparison of active can shocking pathways. <b>1999</b> , 34, 358-62	20
2030	Management of ventricular arrhythmias: a trial-based approach. <b>1999</b> , 34, 621-30	11
2029	Learning more about indications for implantable cardioverter-defibrillators. <b>1999</b> , 34, 1096-8	3
2028	ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. <b>1999</b> , 34, 812-48	203



2027	HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. <b>1999</b> , 5, 357-382		261
2026	A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 1882-90	59.2	1938
2025	Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation. <b>1999</b> , 138, 133-6		20
2024	Implantable cardioverter-defibrillators. <b>1999</b> , 106, 446-58		30
2023	Development of ventricular fibrillations with different characteristics in the local electrocardiogram: large and small amplitude of activation, and its implication for implantable cardioverter defibrillator treatment. <b>1999</b> , 63, 1007-10		2
2022	An overview of contemporary approaches to antiarrhythmic therapy. <b>1999</b> , 63, 655-8		1
2021	Cardiac arrhythmia: current therapy. <b>1999</b> , 34, 27-8, 31-2, 35-8 passim		
2020	Management of ventricular arrhythmias: detection, drugs, and devices. <b>1999</b> , 281, 172-9		34
2019	Who needs an implantable defibrillator?. <b>1999</b> , 60, 578-83		
2018	Permanent pacemakers in older persons. <b>1999</b> , 47, 1125-35		24
2017	Management of the older person with ventricular arrhythmias. <b>1999</b> , 47, 886-95		6
2016	Treatment of arrhythmias in heart failure. <b>1999</b> , 1, 133-7		2
2015	Treatment and prevention of sudden cardiac death: effect of recent clinical trials. <b>1999</b> , 159, 1281-7		12
2014	Sudden death in heart failure: vascular or electrical?. <b>1999</b> , 1, 41-5		57
2013	Management of acute myocardial infarction with hypotension. <b>1999</b> , 116, 1464-7		
2012	Electrophysiologic parameters to predict clinical recurrence of ventricular tachycardia in patients under electrophysiologic study-guided effective pharmacological therapy. <b>1999</b> , 63, 674-80		10
2011	Probability of occurrence of life-threatening ventricular arrhythmias in Chagas' disease versus non-Chagas' disease. <b>2000</b> , 23, 1944-6		38
2010	Amiodarone: clinical trials. <b>2000</b> , 15, 64-72		43

2009	Relation between microvolt level T wave alternans and other potential noninvasive predictors of arrhythmic risk in the Marburg Cardiomyopathy Study. <b>2000</b> , 23, 1960-4	5
2008	Cardiac surgery: postoperative arrhythmias. <b>2000</b> , 28, N136-44	90
2007	Antiarrhythmic agents and proarrhythmia. <b>2000</b> , 28, N158-64	36
2006	Prevention of sudden cardiac death: management considerations. <b>2000</b> , 15, 304-8	2
2005	Management of malignant ventricular arrhythmias and cardiac arrest. <b>2000</b> , 28, N165-9	18
2004	Ischemia, metabolic disturbances, and arrhythmogenesis: mechanisms and management. <b>2000</b> , 28, N151-7	16
2003	Combination therapy with carvedilol and amiodarone in patients with severe heart failure. <b>2000</b> , 2, 71-9	32
2002	Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT. <b>2000</b> , 23, 1981-5	14
2001	Exact sequential tests for single samples of discrete responses using spending functions. <b>2000</b> , 19, 3051-64	16
2000	Sequential analysis of matched dichotomous data from prospective case-control studies. <b>2000</b> , 19, 3449-64	12
1999	Long-term clinical experience with the EGM width detection criterion for differentiation of supraventricular and ventricular tachycardia in patients with implantable cardioverter defibrillators. <b>2000</b> , 23, 1611-7	19
1998	Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?. <b>2000</b> , 1, 98-101	6
1997	Revisiting established medical options - antiarrhythmic drugs and beta-blocker combinations. <b>2000</b> , 45, S7-S10	
1996	Corrected confidence intervals following a sequential adaptive clinical trial with binary responses. <b>2000</b> , 91, 53-64	6
1995	Surgery for postinfarction ventricular tachycardia: is it obsolete?. <b>2000</b> , 23, 1295-301	10
1994	Testing secondary hypotheses following sequential clinical trials. <b>2000</b> , 56, 640-4	12
1993	Long-term reproducibility of ventricular tachycardia induction with electrophysiological testing in patients with coronary heart disease and depressed left ventricular ejection fraction. <b>2000</b> , 23, 47-53	10
1992	Electrophysiologist-implanted transvenous cardioverter defibrillators using local versus general anesthesia. <b>2000</b> , 23, 96-105	21

1991	Deciding against defibrillator replacement: second-guessing the past?. <b>2000</b> , 23, 2019-21	3
1990	Permanent explantation of implantable cardioverter defibrillators. <b>2000</b> , 23, 2024-9	3
1989	Lead noise with an active-fixation defibrillation lead. <b>2000</b> , 23, 2113-6	4
1988	The effect of psychological intervention on patients' long-term adjustment to the ICD: a prospective study. <b>2000</b> , 23, 450-6	112
1987	Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. <b>2000</b> , 23, 939-45	128
1986	Temporal and geographical trends in indications for implantation of cardiac defibrillators in Europe 1993-1998. Medtronic ICD System Investigators. <b>2000</b> , 23, 979-84	6
1985	The costs of inadequate data. <b>2000</b> , 7, 687-8	
1984	Advantages and disadvantages of trial designs: a review of analysis methods for ICD studies. AVID Investigators. <b>2000</b> , 23, 1029-38	4
1983	Nonsustained, asymptomatic ventricular tachycardia in patients with coronary artery disease: prognosis and incidence of sudden death of patients who are noninducible by electrophysiological testing. <b>2000</b> , 23, 1220-5	7
1982	Can sudden cardiac death be predicted from the T wave of the ECG? A critical examination of T wave alternans and QT interval dispersion. <b>2000</b> , 23, 1407-16	19
1981	Defibrillators in nonischemic cardiomyopathy treatment evaluation. <b>2000</b> , 23, 338-43	44
1980	Preliminary results with the simultaneous use of implantable cardioverter defibrillators and permanent biventricular pacemakers: implications for device interaction and development. <b>2000</b> , 23, 365-72	7
1979	Regional hyperkalemia increases ventricular defibrillation energy requirements: role of electrical heterogeneity in defibrillation. <b>2000</b> , 11, 634-41	25
1978	Defibrillator challenges for the new millennium: the marriage of device and patient-making and maintaining a good match. <b>2000</b> , 11, 697-709	6
1977	Signal-averaged isoharmonic body surface maps of patients with ischemic cardiomyopathy. <b>2000</b> , 11, 160-7	
1976	Sensing lead failure in implantable defibrillators: a comparison of two commonly used leads. <b>2000</b> , 11, 21-4	29
1975	Arrhythmias in heart failure: current concepts of mechanisms and therapy. <b>2000</b> , 11, 106-17	41
1974	Heart Failure and Cardiac Resynchronization Therapies: U.S. Experience in the Year 2000. <b>2000</b> , 5, 188-194	10

1973	Risk stratification after acute myocardial infarction in the reperfusion era. <b>2000</b> , 42, 273-309	37
1972	Modern management of acute myocardial infarction. <b>2000</b> , 25, 677-782	8
1971	HEART FAILURE SOCIETY OF AMERICA (HFSA) PRACTICE GUIDELINES. <b>2000</b> , 20, 495-522	24
1970	Advances in the treatment of congestive heart failure: new approaches for an old disease. <b>2000</b> , 20, 787-804	22
1969	Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. <b>2000</b> , 85, 981-5	85
1968	Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. <b>2000</b> , 85, 1481-5	27
1967	Predictive value of preoperative left ventricular ejection fraction and functional class for mortality and morbidity after high-risk coronary artery bypass grafting. <b>2000</b> , 85, 1489-91; A7	4
1966	Implantable cardioverter defibrillator therapy for patients with life-threatening ventricular arrhythmias and severe heart failure. <b>2000</b> , 86, 875-7	1
1965	Effect of stored electrograms on management in the paced patient. <b>2000</b> , 86, 101K-103K	4
1964	Prophylactic implantable cardioverter defibrillator trials: MUSTT, MADIT, and beyond. Multicenter Unsustained Tachycardia Trial. Multicenter Automatic Defibrillator Implantation Trial. <b>2000</b> , 86, 1214-5, A5	37
1963	Should stimulation therapy for congestive heart failure be combined with defibrillation backup?. <b>2000</b> , 86, 165K-158K	18
1962	Screening and therapy for patients with nonsustained ventricular tachycardia. <b>2000</b> , 86, 34K-39K	16
1961	Evidence rather than costs must guide use of the implantable cardioverter defibrillator. <b>2000</b> , 86, 52K-57K	6
1960	Matching cardiac rhythm management technology to patient needs: pacing/ablation/implantable cardioverter defibrillators. <b>2000</b> , 86, 58K-70K	1
1959	Pacing Therapies in Congestive Heart Failure II study. <b>2000</b> , 86, 138K-143K	38
1958	Changing concepts of electrophysiology testing for ventricular arrhythmias. <b>2000</b> , 4 Suppl 1, 17-9	
1957	Evaluating AVID, CASH, CIDS, CABG-patch and MADIT: are they concordant?. <b>2000</b> , 4 Suppl 1, 103-8	1
1956	Other primary prevention trials-what is clinically and economically necessary?. <b>2000</b> , 4 Suppl 1, 109-15	3

- 1955 The MUSTT study: evaluating testing and treatment. **2000**, 4 Suppl 1, 45-50 25
- 1954 The interpretation and clinical application of data from trials on sudden cardiac death. **2000**, 4 Suppl 1, 95-102 2
- 1953 Balancing Quality and Thoroughness with Efficiency in Invasive Cardiac Electrophysiology. **2000**, 4, 133-136 1
- 1952 EP Evaluation for MADIT-Eligible Patients: Year 2000 Update. **2000**, 4, 83-85
- 1951 Electrophysiology Studies in the Assessment and Management of Patients Involved in High Risk Occupations and Activities: An Update. **2000**, 4, 89-95
- 1950 Primary Prevention of Arrhythmic Death. **2000**, 4, 170-173
- 1949 The Role of Invasive EP Testing in the Evaluation and Management of Ventricular Tachyarrhythmias Associated with Ischemic Heart Disease. **2000**, 4, 54-57
- 1948 Perspectives: does amiodarone increase non-sudden deaths? If so, why?. **2000**, 4, 569-74 8
- 1947 Oral Procainamide. **2000**, 4, 284-287
- 1946 Amiodarone: what have we learned from clinical trials?. **2000**, 23, 73-82 31
- 1945 Electropharmacologic effect of a standard dose of intravenous procainamide in patients with sustained ventricular tachycardia. **2000**, 23, 171-4 2
- 1944 Implantable cardioverter defibrillator discharge rates in patients with unexplained syncope, structural heart disease, and inducible ventricular tachycardia at electrophysiologic study. **2000**, 23, 195-200 9
- 1943 The implantable cardioverter-defibrillator. **2000**, 23, 315-26 9
- 1942 Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy. **2000**, 2, 522-8 11
- 1941 Catheter ablation of ventricular tachycardia related to coronary artery disease: the role of noncontact mapping. **2000**, 2, 529-36 6
- 1940 Prophylactic defibrillator implantation in patients with coronary artery disease. **2000**, 2, 311-3
- 1939 Implantable dual-chamber cardioverter-defibrillator-pacemaker. **2000**, 2, 335-40 3
- 1938 Are implantable cardioverter- defibrillators cost-effective?. **2000**, 2, 341-5

1937 Ventricular Arrhythmias. **2000**, 2, 323-328

1936 Arrhythmias in Heart Failure. **2000**, 2, 329-339

2

1935 [Socioeconomic aspects of the treatment of arrhythmias]. **2000**, 25, 526-37

1934 Prediction of major arrhythmic events and sudden cardiac death in dilated cardiomyopathy. The Marburg Cardiomyopathy Study design and description of baseline clinical characteristics. **2000**, 25, 189-99

11

1933 Current concepts in secondary prevention after acute myocardial infarction. **2000**, 25, 47-60

3

1932 Chirurgische Therapiekonzepte der fortgeschrittenen Herzinsuffizienz als Alternativen zur Herztransplantation. **2000**, 14, 13-22

1931 Reduzierte gesundheitsbezogene Lebensqualität bei Patienten mit implantiertem Kardioverter/Defibrillator, Schockereignissen und Herzinsuffizienz. **2000**, 11, 52-58

0

1930 Sudden cardiac death—a reliable diagnosis?. **2000**, 11, 118-113

1929 Defibrillation for out-of-hospital cardiac arrest. **2000**, 172, 53-4

6

1928 Endocardial activation during ventricular fibrillation in normal and failing canine hearts. **2000**, 279, H1737-47

5

1927 The problem of ventricular dysrhythmias and sudden death mortality in heart failure: the impact of current therapy. **2000**, 93, 56-69

6

1926 Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. **2000**, 102, 876-82

154

1925 Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. **2000**, 101, 1660-4

163

1924 Phosphorus Doping and Sharp Profiles in Silicon and Silicon-Germanium Epitaxy by Rapid Thermal Chemical Vapor Deposition. **2000**, 147, 3541

20

1923 Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. **2000**, 21, 475-82

193

1922 Hospital readmission after transvenous cardioverter/defibrillator implantation; a single centre study. **2000**, 21, 1186-91

25

1921 Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator. **2000**, 21, 1979-83

20

1920 The utilization of the implantable defibrillator—a European enigma. **2000**, 21, 1998-2004

34

1919	Prevention of recurrent ventricular fibrillation by ventricular rate stabilization. <b>2000</b> , 2, 346-9	2
1918	The rapidly changing management of cardiac arrhythmias. <b>2000</b> , 161, 1070-3	3
1917	Hospitalization in ICD recipients. <b>2000</b> , 21, 1123-4	
1916	Arrhythmia Therapy in the Elderly. <b>2000</b> , 9, 151-158	
1915	The importance of considering trial design when interpreting clinical trial results. <b>2000</b> , 5, 17-25	
1914	Economic outcomes of implantable cardioverter-defibrillators. <b>2000</b> , 101, 1067-74	31
1913	American College of Cardiology/American Heart Association Clinical Competence Statement on invasive electrophysiology studies, catheter ablation, and cardioversion: A report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence. <b>2000</b> , 102, 2309-20	20
1912	Cost-effectiveness of catheter ablation in patients with ventricular tachycardia. <b>2000</b> , 101, 280-8	28
1911	Implantable Cardioverter Defibrillator: Current Progress and Management. <b>2000</b> , 4, 162-179	
1910	Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). <b>2000</b> , 102, 748-54	1081
1909	Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. <b>2000</b> , 102, 858-64	596
1908	Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. <b>2000</b> , 101, 1638-40	97
1907	Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. <b>2000</b> , 101, 40-6	169
1906	The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. <b>2000</b> , 139, S143-54	10
1905	Current medical therapy for advanced heart failure. <b>2000</b> , 29, 16-32	29
1904	Arrhythmia risk stratification in idiopathic dilated cardiomyopathy based on echocardiography and 12-lead, signal-averaged, and 24-hour holter electrocardiography. <b>2000</b> , 140, 43-51	32
1903	Expensive medical technologies and "indication extrapolation": the case of implantable cardioverter-defibrillators. <b>2000</b> , 140, 419-22	7
1902	The defibrillator in acute myocardial infarction trial (DINAMIT): study protocol. <b>2000</b> , 140, 735-9	52

1901	The role of surrogate outcome measures in evaluating medical devices. <b>2000</b> , 128, 379-85	8
1900	Cardiac transplantation in patients with refractory ventricular arrhythmias. <b>2000</b> , 19, S38-42	3
1899	Sudden death in heart failure patients: effects of optimized medical therapy. <b>2000</b> , 19, S32-7	1
1898	Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors. <b>2000</b> , 46, 1-123	2
1897	Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure. <b>2000</b> , 356, 651-2	227
1896	Proper use of antiarrhythmic therapy for reduction of mortality after myocardial infarction. <b>2000</b> , 16, 341-50	6
1895	Antiarrhythmic agents: drug interactions of clinical significance. <b>2000</b> , 23, 509-32	72
1894	Heart Failure. <b>2000</b> ,	
1893	Large clinical trials in the management of ventricular arrhythmias. Applying group results to individual cases. <b>2000</b> , 18, 337-56, viii	7
1892	[Prevention of sudden death in patients awaiting heart transplantation]. <b>2000</b> , 53, 736-45	1
1891	Therapeutic developments in sudden cardiac death. <b>2000</b> , 9, 2543-54	
1890	Wavelet analysis of bipolar endocardial electrograms for morphology based detection of ventricular tachycardias.	3
1889	Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. <b>2000</b> , 6, 276-85	250
1888	Application of noninvasive and invasive tests for risk assessment in patients with ventricular arrhythmias. <b>2000</b> , 18, 243-63, vii	8
1887	ICD therapy in the new millennium. <b>2000</b> , 18, 375-89	1
1886	Nonsustained ventricular tachycardia. <b>2000</b> , 18, 327-36, viii	9
1885	Management of postinfarct ventricular tachycardias. <b>2000</b> , 18, 293-307	2
1884	Management of arrhythmias. <b>2000</b> , 16, 593-618	5



1883	[Predictors of sudden death in coronary artery disease]. <b>2000</b> , 53, 440-62	3
1882	Introductory Note. <b>2000</b> , 5, 92-93	
1881	Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. <b>2000</b> , 36, 557-65	60
1880	Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. Ventak CHF Investigators. <b>2000</b> , 36, 824-7	195
1879	T-wave alternans and serious ventricular arrhythmias: a tale of two T-waves. <b>2000</b> , 36, 2254-6	5
1878	A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. <b>2000</b> , 36, 2247-53	229
1877	American College of Cardiology/American Heart Association clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion. A report of the American College of Cardiology/American Heart Association/American College of Physicians--American Society of Internal Medicine Task Force on clinical competence. <b>2000</b> , 36, 1725-36	20
1876	Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 365-73	59.2 774
1875	Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators. <b>2001</b> , 37, 1093-9	42
1874	Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group. <b>2001</b> , 37, 1910-5	46
1873	Is programmed stimulation in survivors of myocardial infarction helpful?. <b>2001</b> , 37, 1908-9	
1872	Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers. <b>2001</b> , 37, 1901-7	47
1871	Mindfully mining MUSTT. Multicenter Unsustained Tachycardia Trial. <b>2001</b> , 38, 352-4	1
1870	Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis. <b>2001</b> , 38, 344-51	26
1869	Temporal decline in defibrillation thresholds with an active pectoral lead system. <b>2001</b> , 38, 1150-5	14
1868	Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. <b>2001</b> , 38, 1902-11	141
1867	Nonsustained ventricular tachycardia. A guide to the clinical significance and management. <b>2001</b> , 85, 305-20, x	1
1866	Sudden death due to cardiac arrhythmias. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1473-82	59.2 1072

1865	Molecular biology and the prolonged QT syndromes. <b>2001</b> , 110, 385-98	97
1864	Prognosis determination in heart failure. <b>2001</b> , 110 Suppl 7A, 14S-36S	80
1863	The experiences of ICD patients and their partners with regards to adjusting to an imposed driving ban: A qualitative study. <b>2001</b> , 5, 80-88	21
1862	Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. <b>2001</b> , 142, 520-9	57
1861	Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. <b>2001</b> , 88, 516-20	74
1860	Number needed to treat: caveat emptor. <b>2001</b> , 54, 111-6	27
1859	Sudden cardiac death after coronary artery bypass grafting is not predicted by signal-averaged ECG. <b>2001</b> , 72, 1546-51	15
1858	The implantable cardioverter defibrillator. <b>2001</b> , 357, 1107-17	84
1857	Cost-effectiveness of the implantable cardioverter defibrillator?. <b>2001</b> , 357, 1817-8	19
1856	Taquiarritmias ventriculares. <b>2001</b> , 8, 2101-2110	
1855	[Evidence based medical treatment of heart failure]. <b>2001</b> , 54, 715-34	6
1854	Proarrhythmia. <b>2001</b> , 85, 503-26, xii	17
1853	[Ventricular arrhythmias induced by appropriate antibradycardia pacing in patients with implantable defibrillators]. <b>2001</b> , 54, 845-50	4
1852	Guías de práctica clínica de la Sociedad Española de Cardiología en arritmias cardíacas. <b>2001</b> , 54, 307-367	31
1851	Implantable cardiac defibrillators. <b>2001</b> , 85, 343-67, xi	11
1850	Advances in cardiac electrophysiology and pacing. <b>2001</b> , 17, 337-64	2
1849	Implantable cardioverter defibrillators in heart failure. <b>2001</b> , 19, 653-67	4
1848	El desfibrilador automático implantable para la prevención de la muerte súbita y el tratamiento de las taquiarritmias ventriculares. <b>2001</b> , 8, 2187-2200	

1847	Ventricular tachycardia syndromes. <b>2001</b> , 85, 267-304	12
1846	Postoperative arrhythmias and conduction disorders. <b>2001</b> , 85, 1171-89	8
1845	To anticoagulate or not to anticoagulate patients with cardiomyopathy. <b>2001</b> , 19, 605-15	6
1844	Prise en charge des troubles du rythme en r�animationManagement of arrhythmias in the intensive care unit.. <b>2001</b> , 10, 205-213	
1843	�Blockers are best antiarrhythmics for reducing post-MI mortality. <b>2001</b> , 17, 5-8	
1842	Mechanisms underlying ventricular arrhythmias in idiopathic dilated cardiomyopathy: implications for management. <b>2001</b> , 1, 105-18	10
1841	Electrotherapeutic management of patients with heart failure. <b>2001</b> , 1, 227-31	1
1840	COMPLETENESS FOR A BROWNIAN MOTION WITH POLYGONAL STOPPING BOUNDARIES. <b>2001</b> , 20, 201-208	1
1839	Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. <b>2001</b> , 103, 2072-7	553
1838	Opportunities for sudden death prevention: directions for new clinical and basic research. <b>2001</b> , 50, 177-85	42
1837	Predictors of Arrhythmic Events in Idiopathic Dilated Cardiomyopathy. <b>2001</b> , 31, 1290	
1836	Implantable Cardioverter Defibrillators for Ventricular Tachyarrhythmia: Current Status and Technological Evolution. <b>2001</b> , 24, 419-424	
1835	Docetaxel induced cardiotoxicity. <b>2001</b> , 86, 219	19
1834	A semi-automatic algorithm for reducing the time spent on routine follow-up of cardioverter defibrillators. <b>2001</b> , 24, 140-144	
1833	Ventricular arrhythmias in the athlete. <b>2001</b> , 16, 30-9	11
1832	Cardiac arrhythmias in the athlete. <b>2001</b> , 9, 21-30	27
1831	Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. <b>2001</b> , 3, 491-4	46
1830	Multicenter prospective nonrandomized study of long-term antiarrhythmic drug therapy in patients with tachyarrhythmias: Japanese Antiarrhythmics Long-Term Study-2 (JALT-2 Study). <b>2001</b> , 65, 275-8	14

1829	Risk stratification for sudden cardiac death in dilated cardiomyopathy using microvolt-level T-wave alternans. <b>2001</b> , 65, 76-80	25
1828	Leakage of energy to the body surface during defibrillation shock by an implantable cardioverter-defibrillator (ICD) system--experimental evaluation during defibrillation shocks through the right ventricular lead and the subcutaneous active-can in canines. <b>2001</b> , 65, 219-25	1
1827	Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. <b>2001</b> , 135, 870-83	52
1826	Syncope and arrhythmias: role of the electrophysiological study. <b>2001</b> , 322, 37-43	3
1825	Current status of the implantable cardioverter-defibrillator. <b>2001</b> , 119, 1210-21	24
1824	Anesthetic considerations in patients with cardiac arrhythmias, pacemakers, and AICDs. <b>2001</b> , 39, 21-42	2
1823	Cardiac rhythm management devices (part I): indications, device selection, and function. <b>2001</b> , 95, 1265-80	31
1822	Classic conditioning and dysfunctional cognitions in patients with panic disorder and agoraphobia treated with an implantable cardioverter/defibrillator. <b>2001</b> , 63, 231-8	45
1821	Prepulses reduce the pain of cutaneous electrical shocks. <b>2001</b> , 63, 275-81	25
1820	Therapeutic options in patients with reduced ejection fraction and nonsustained ventricular tachycardia. <b>2001</b> , 3, 219-23	
1819	Are drugs and catheter ablation effective for treating ventricular arrhythmias in populations that cannot afford implantable cardioverter defibrillators?. <b>2001</b> , 3, 459-66	1
1818	[Predictive value of frequency, duration and rate of ventricular salvos in ambulatory ECG for inducibility of sustained ventricular tachycardia]. <b>2001</b> , 90, 177-83	
1817	[Guidelines for the treatment of chronic heart failure. Issued by the Executive Committee of the German Society of Cardiology--Heart and Circulation Research, compiled on behalf of the Commission of Clinical Cardiology in cooperation with Pharmaceuic Commission of the German Physicians' Association]. <b>2001</b> , 90, 218-37	47
1816	[Adequate performance of a pectoral implanted defibrillator after high-dose radiation therapy for thyroid cancer]. <b>2001</b> , 12, 225-9	
1815	Der plötzliche Herztod bei Patienten mit einem implantierten Cardioverter-Defibrillator. <b>2001</b> , 12, 39-50	
1814	Frank Pantridge and mobile coronary care. <b>2001</b> , 48, 99-104	6
1813	Should all patients receive dual chamber pacing ICDs? The rationale for the DAVID trial. <b>2001</b> , 2, 215-217	7
1812	Interim analyses and sequential designs in phase III studies. <b>2001</b> , 51, 394-9	28

1811	A Randomized Double-Blind Sham-Controlled Trial of the Prosorba Column for Treatment of Refractory Rheumatoid Arthritis. <b>2001</b> , 5, 79-83	12
1810	Prevention of sudden death in heart failure. <b>2001</b> , 12, 112-4	39
1809	Clinical competency statement: implantation and follow-up of cardioverter defibrillators. <b>2001</b> , 12, 280-4	13
1808	Sudden cardiac death: exploring the limits of our knowledge. <b>2001</b> , 12, 369-81	203
1807	Worldwide clinical experience with a new dual-chamber implantable cardioverter defibrillator system. <b>2001</b> , 12, 521-8	66
1806	Supraventricular tachycardia-ventricular tachycardia discrimination algorithms in implantable cardioverter defibrillators: state-of-the-art review. <b>2001</b> , 12, 606-12	78
1805	Prognostic significance of risk stratifiers of mortality, including T wave alternans, after acute myocardial infarction: results of a prospective follow-up study. <b>2001</b> , 12, 645-52	117
1804	Role of wavelength adaptation in the initiation, maintenance, and pharmacologic suppression of reentry. <b>2001</b> , 12, 697-707	20
1803	Repolarization abnormalities detected by magnetocardiography in patients with dilated cardiomyopathy and ventricular arrhythmias. <b>2001</b> , 12, 772-7	20
1802	Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. <b>2001</b> , 12, 1247-53	85
1801	Clinical cardiac electrophysiology fellowship teaching objectives for the new millennium. <b>2001</b> , 12, 1433-43	3
1800	Clinical predictors and efficacy of antitachycardia pacing in patients with implantable cardioverter defibrillators: the importance of the patient's sex. <b>2001</b> , 24, 70-4	17
1799	Consensus statement on indications, guidelines for use, and recommendations for follow-up of implantable cardioverter defibrillators. North American Society of Electrophysiology and Pacing. <b>2001</b> , 24, 262-9	52
1798	Central clinical research issues in electrophysiology: report of the NASPE Committee. <b>2001</b> , 24, 526-34	2
1797	Sudden death in heart failure associated with reduced left ventricular function: substrates, mechanisms, and evidence-based management, Part II. <b>2001</b> , 24, 1002-22	8
1796	Unexpected ICD pulse generator failure due to electronic circuit damage caused by electrical overstress. <b>2001</b> , 24, 1046-54	34
1795	Prospective evaluation of catheter ablation in patients with implantable cardioverter defibrillators and multiple inappropriate ICD therapies due to atrial fibrillation and type I atrial flutter. <b>2001</b> , 24, 1061-6	10
1794	Young at heart: understanding the unique psychosocial adjustment of young implantable cardioverter defibrillator recipients. <b>2001</b> , 24, 1113-7	64

1793	Magnetocardiographic intra-QRS fragmentation analysis in the identification of patients with sustained ventricular tachycardia after myocardial infarction. <b>2001</b> , 24, 1179-86	14
1792	Far-field R wave oversensing in a dual chamber arrhythmia management device: predisposing factors and practical implications. <b>2001</b> , 24, 1240-6	28
1791	Catheter ablation of ventricular tachycardia in patients with coronary heart disease: part I: Mapping. <b>2001</b> , 24, 1261-77	60
1790	Absence of a morning peak in ventricular tachycardia and fibrillation events in nonischemic heart disease: analysis of therapies by implantable cardioverter defibrillators. <b>2001</b> , 24, 1602-6	10
1789	Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope. <b>2001</b> , 24, 1623-30	41
1788	Initial experience with an active-fixation defibrillation electrode and the presence of nonphysiological sensing. <b>2001</b> , 24, 1713-20	6
1787	Safety and potential cost savings of same-setting electrophysiologic testing and placement of transvenous implantable cardioverter-defibrillators. <b>2001</b> , 24, 592-6	
1786	Magnetocardiographic mapping of QRS fragmentation in patients with a history of malignant tachyarrhythmias. <b>2001</b> , 24, 682-8	5
1785	Inducible ventricular arrhythmias and patency of infarct-related artery in survivors of acute myocardial infarction. <b>2001</b> , 24, 782-5	
1784	The challenge of prediction and prevention of sudden cardiac death in congestive heart failure. <b>2001</b> , 5, 5-8	3
1783	Controversial Indications for ICD Therapy. <b>2001</b> , 5, 15-17	
1782	Who Should Be Implanting ICDs?. <b>2001</b> , 5, 66-69	
1781	Indications for Implantable Cardioverter Defibrillator Therapy in Year 2000. <b>2001</b> , 5, 6-14	1
1780	Tracking ICD Performance. <b>2001</b> , 5, 51-57	
1779	Sudden Death in Patients with Implanted Defibrillators. <b>2001</b> , 5, 379-384	
1778	The chain of survival. <b>2001</b> , 37, S5-16	19
1777	[2 year follow-up of 321 patients with an implantable cardioverter/defibrillator: comparison of patients with and without atrial fibrillation]. <b>2001</b> , 90, 906-15	5
1776	T-wave alternans and arrhythmia risk stratification. <b>2001</b> , 6, 323-32	13

1775	On estimating medical cost and incremental cost-effectiveness ratios with censored data. <b>2001</b> , 57, 1002-8	63
1774	Cardiovascular monitoring and therapy for HIV-infected patients. <b>2001</b> , 946, 236-73	14
1773	Results and significance of Holter monitoring after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction. <b>2001</b> , 87, 466-9, A7	3
1772	Mechanisms and immediate outcome of in-hospital cardiac arrest in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. <b>2001</b> , 87, 655-7, A10-1	25
1771	Gianturco-Grifka vascular occlusion device for closure of patent ductus arteriosus. <b>2001</b> , 87, 657-60, A11	12
1770	Myocardial imaging in patients with defibrillator patch electrodes. <b>2001</b> , 88, 448-52	1
1769	Long-term infection rates associated with the pectoral versus abdominal approach to cardioverter-defibrillator implants. <b>2001</b> , 88, 750-3	92
1768	Survey of current practices in use of amiodarone and implantable cardioverter defibrillators in pediatric patients with end-stage heart failure. <b>2001</b> , 88, 809-10	6
1767	Comparison of the two-sided single triangular test to the double triangular test. <b>2001</b> , 22, 503-14	17
1766	[Indications of automatic ventricular implantable defibrillator. Implications for daily practice]. <b>2001</b> , 50, 319-25	
1765	The implantable cardioverter-defibrillator: does everybody need one?. <b>2001</b> , 44, 169-94	7
1764	Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review. <b>2001</b> , 21, 556-75	11
1763	Guidelines for the diagnosis and treatment of chronic heart failure. <b>2001</b> , 22, 1527-60	1001
1762	Task Force on Sudden Cardiac Death of the European Society of Cardiology. <b>2001</b> , 22, 1374-450	520
1761	Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: Can we afford to do it? (Can we afford not to?). <b>2001</b> , 104, 1564-70	41
1760	Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. <b>2001</b> , 103, 2066-71	276
1759	New approaches to antiarrhythmic therapy, part II: emerging therapeutic applications of the cell biology of cardiac arrhythmias. <b>2001</b> , 104, 2990-4	10
1758	New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias. <b>2001</b> , 22, 2148-63	14

1757	A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. <b>2001</b> , 22, 2180-91	36
1756	Risk of sudden death after discharge following myocardial infarction. <b>2001</b> , 22, 1153-5	
1755	Cost-effectiveness of implantable cardioverter-defibrillators. <b>2001</b> , 22, 990-6	23
1754	Determinants of sudden death after discharge from hospital for myocardial infarction in the thrombolytic era. <b>2001</b> , 22, 1214-25	14
1753	In-vivo testing of digital cellular telephones in patients with implantable cardioverter-defibrillators. <b>2001</b> , 22, 1337-42	16
1752	Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. <b>2001</b> , 22, 1074-81	46
1751	Initial clinical experience with a new arrhythmia detection algorithm in dual chamber implantable cardioverter defibrillators. <b>2001</b> , 3, 181-6	13
1750	A prophylactic ICD? Who are the patients? What is the device?. <b>2001</b> , 3, 269-74	
1749	Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. <b>2001</b> , 22, 1601-12	38
1748	Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. <b>2001</b> , 104, 1622-6	50
1747	Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. <b>2001</b> , 86, 217-20	9
1746	Managing out-of-hospital cardiac arrest survivors: 2. Cardiological perspective. <b>2001</b> , 85, 123-4	2
1745	Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). <b>2001</b> , 103, 1416-21	96
1744	The Year in Review: Cardiology. <b>2001</b> , 14, 18-40	
1743	Will antiarrhythmic drug therapy guided by electrophysiology study survive in the new millennium?. <b>2001</b> , 6, 1-4	1
1742	Learning from mistakes: the case of clinical electrophysiology: a perspective on evidence-based rhythmology. <b>2001</b> , 104, 845-7	6
1741	Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. <b>2001</b> , 6, 69-87	11
1740	Ischaemic heart disease presenting as arrhythmias. <b>2001</b> , 59, 193-210	53



1739	Implantable cardioverter-defibrillator: A Volkswagen or a Rolls Royce: how much will we pay to save a life?. <b>2001</b> , 103, 1372-4	36
1738	Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. <b>2001</b> , 104, 436-41	136
1737	Predicting the Duration of Sequential Survival Studies. <b>2001</b> , 35, 1387-1400	7
1736	[Primary prevention of sudden cardiac death]. <b>2001</b> , 126, 435-8	0
1735	Improving survival from sudden cardiac arrest: the role of the automated external defibrillator. <b>2001</b> , 285, 1193-200	195
1734	Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. <b>2001</b> , 286, 793-9	139
1733	Surgical ventricular restoration in patients with postinfarction coronary artery disease: effectiveness on spontaneous and inducible ventricular tachycardia. <b>2001</b> , 13, 480-5	25
1732	Treatment of the elderly post-myocardial infarction patient. <b>2001</b> , 10, 316-22, 376	2
1731	Clinical treatment regimens for chronic heart failure: a review. <b>2002</b> , 3, 1569-76	4
1730	Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). <b>2002</b> , 106, 2694-9	59
1729	The role of approximate entropy in predicting ventricular defibrillation threshold. <b>2002</b> , 7, 45-52	5
1728	Implantable cardioverter-defibrillators in arrhythmias: a rapid and systematic review of effectiveness. <b>2002</b> , 87, 438-42	11
1727	Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. <b>2002</b> , 106, 233-8	61
1726	Medical management of advanced heart failure. <b>2002</b> , 287, 628-40	294
1725	Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). <b>2002</b> , 105, 1453-8	467
1724	Is prophylaxis the best use of the ICD?. <b>2002</b> , 23, 700-5	3
1723	Can catheter ablation cure post-infarction ventricular tachycardia?. <b>2002</b> , 23, 352-4	1
1722	Low recurrence of syncope in patients with inducible sustained ventricular tachyarrhythmias treated with an implantable cardioverter-defibrillator. <b>2002</b> , 23, 901-7	16

1721	The need for European Registries in inherited cardiomyopathies. <b>2002</b> , 23, 1972-4		3
1720	Task Force on Sudden Cardiac Death, European Society of Cardiology. <b>2002</b> , 4, 3-18		84
1719	Expanding indications for implantable cardiac defibrillators. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 931-3	59.2	61
1718	[Indications for implantable cardioverter-defibrillator]. <b>2002</b> , 127, 2120-4		1
1717	Near-fatal arrhythmia caused by hyperkalaemia. <b>2002</b> , 88, 578		2
1716	Sequential tests and estimators after overrunning based on maximum-likelihood ordering. <b>2002</b> , 89, 699-708		13
1715	Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. <b>2002</b> , 105, 2049-57		99
1714	Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 877-83	59.2	5079
1713	Impact of age and sex on sudden cardiovascular death following myocardial infarction. <b>2002</b> , 88, 573-8		23
1712	ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). <b>2002</b> , 106, 2145-61		749
1711	Cardiac arrhythmias in the athlete: the evolving role of electrophysiology. <b>2002</b> , 1, 75-85		16
1710	Outcome studies with device therapy in patients with heart failure. <b>2002</b> , 13, S73-91		30
1709	Geographic differences in implantable cardioverter defibrillator usage. <b>2002</b> , 13, S100-5		10
1708	Treatment paradigms in heart failure. <b>2002</b> , 63, 80-7		1
1707	Implantable cardioverter-defibrillators with or without cardiac resynchronization therapy? multiple therapy in a single device: a review with special reference to the PACIVIAN study. <b>2002</b> , 4, D88-D94		
1706	End-stage heart failure: which options?. <b>2002</b> , 4, D122-D130		
1705	Dietary prevention of sudden cardiac death. <b>2002</b> , 23, 277-85		17
1704	Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. <b>2002</b> , 10, 173-81		30

1703	Psychosocial impact of the implantable cardioverter defibrillator: nursing implications. <b>2002</b> , 16, 53-61	12
1702	Management of arrhythmias in heart failure. <b>2002</b> , 10, 8-14	28
1701	Pacemakers, recent directions and developments. <b>2002</b> , 15, 681-6	5
1700	Implantable cardioverter defibrillator trials: what's new?. <b>2002</b> , 17, 29-35	1
1699	Radiofrequency ablation for post infarction ventricular tachycardia. Report of a single centre experience of 112 cases. <b>2002</b> , 23, 1699-705	34
1698	Programmed ventricular stimulation: influence of early versus late introduction of a third extrastimulus, a randomized, prospective study. <b>2002</b> , 4, 77-85	3
1697	A better control for ICD patients?. <b>2002</b> , 23, 1972	
1696	The implantable cardioverter defibrillator. <b>2002</b> , 63, 672-5	
1695	End-stage heart failure: which options?. <b>2002</b> , 4, D122-D130	1
1694	Future of device therapy for arrhythmias. <b>2002</b> , 13, S122-4	1
1693	Advances in implantable cardioverter defibrillators. <b>2002</b> , 17, 24-8	5
1692	Indications for implantable cardioverter defibrillator therapy. <b>2002</b> , 4, 166-70	1
1691	Evolution of implantable cardioverter defibrillator indications: comparison of guidelines in the United States and Europe. <b>2002</b> , 13, S96-9	1
1690	The past, present, and future of the implantable cardioverter defibrillator. <b>2002</b> , 112, 577-9	1
1689	The past, present, and future of the implantable cardioverter defibrillator. <b>2002</b> , 113, 82-4	4
1688	Prevention of sudden death in patients with coronary artery disease: do lipid-lowering drugs play a role?. <b>2002</b> , 5, 177-82	12
1687	Primary prevention of sudden death using ICD therapy: incremental steps. <b>2002</b> , 39, 788-9	5
1686	Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. <b>2002</b> , 39, 780-7	76

1685	Pathophysiological basis and clinical application of T-wave alternans. <b>2002</b> , 40, 207-17	95
1684	ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). <b>2002</b> , 40, 1703-19	347
1683	Heart failure and Implantable Cardioverter Defibrillator (ICD) therapy: Update and perspective on current primary prevention trials. <b>2002</b> , 8, 161-6	4
1682	Implantable defibrillators for heart failure: a siren's song or a brave new world?. <b>2002</b> , 6, 109-11	
1681	In-vivo electrophysiological study in mice with chronic anterior myocardial infarction. <b>2002</b> , 6, 121-32	20
1680	Electrocardiografía ambulatoria. Técnicas de electrocardiografía de señal promediada. Estudio electrofisiológico cardíaco. <b>2002</b> , 14, 90-106	
1679	Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death. <b>2002</b> , 20, 727-38	7
1678	Surgical coronary revascularization and antiarrhythmic therapy in survivors of out-of-hospital cardiac arrest. <b>2002</b> , 74, 1510-6	5
1677	Prophylactic implantation of a defibrillator improves survival in people with prior myocardial infarction and advanced left ventricular dysfunction. <b>2002</b> , 6, 141-142	
1676	The Low Energy Safety Study (LESS): rationale, design, patient characteristics, and device utilization. <b>2002</b> , 143, 199-204	17
1675	Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease. <b>2002</b> , 144, 390-6	29
1674	Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995. <b>2002</b> , 144, 397-403	15
1673	Life after a ventricular arrhythmia. <b>2002</b> , 144, 404-12	20
1672	Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995. <b>2002</b> , 144, 413-21	13
1671	Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. <b>2002</b> , 144, 422-30	21
1670	Management of ventricular arrhythmias in diverse populations in California. <b>2002</b> , 144, 431-9	12
1669	Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. <b>2002</b> , 144, 440-8	66
1668	Prognostic value of baseline electrophysiology studies in patients with sustained ventricular tachyarrhythmia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. <b>2002</b> , 144, 478-84	33

1667	Implantable cardioverter defibrillator implantation rates in the Olmsted County, Minnesota, population: 1989-1999. <b>2002</b> , 55, 458-61	7
1666	Implantable cardioverter defibrillators in Israel: utilization and implantation trends. <b>2002</b> , 82, 17-23	7
1665	MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?. <b>2002</b> , 82, 1-5	19
1664	Value of combination of QT variability and late potentials in identification of patients with ventricular tachycardia after myocardial infarction. <b>2002</b> , 83, 263-5	3
1663	Atrioventricular block and problems with atrioventricular conduction. <b>2002</b> , 18, 229-51	0
1662	When is intracardiac electrophysiologic evaluation indicated in the older or very elderly patient? Complications rates and data. <b>2002</b> , 18, 339-60	1
1661	Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials. <b>2002</b> , 4, D31-D42	
1660	Therapeutic options and heart failure survival score predictability in an academic heart failure center: an analysis of 120 consecutive patients during a 1-year period. <b>2002</b> , 4, 207-14	3
1659	Should Heart Failure Be Treated with Antithrombotic Drugs?. <b>2002</b> , 2, 295-302	
1658	Best approach to nonsustained ventricular tachycardia?. <b>2002</b> , 112, 99	
1657	Primary prevention of sudden cardiac death using implantable cardioverter defibrillators. <b>2002</b> , 325, 1050-1	2
1656	Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials. <b>2002</b> , 4, D31-D42	0
1655	Implantable card ioverter-defibrillators with or without cardiac resynchronization therapy □ multiple therapy in a single device: a review with special reference to the PACIVIAN study. <b>2002</b> , 4, D88-D94	
1654	Ventricular Arrhythmias. <b>2002</b> , 30, 151-158	
1653	Assessment of risk for sudden cardiac death. <b>2002</b> , 27, 246-66	1
1652	Electrical therapy in patients with congestive heart failure introduction. <b>2002</b> , 27, 45-93	1
1651	Significance of sustained monomorphic ventricular tachycardia induced with short coupling intervals in patients with ischemic cardiomyopathy. <b>2002</b> , 89, 987-90	2
1650	Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. <b>2002</b> , 89, 1072-6	46

1649	Who needs an ICD?. <b>2002</b> , 11, 77-81	1
1648	Management After Myocardial Infarction. <b>2002</b> , 4, 41-54	
1647	Arrhythmias in Patients with Heart Failure. <b>2002</b> , 4, 467-485	18
1646	End-stage Heart Failure: Surgical Therapy and Implantable Devices. <b>2002</b> , 4, 511-520	
1645	Management of ventricular arrhythmias in adults with congenital heart disease. <b>2002</b> , 4, 76-80	4
1644	Automatic Implantable Cardiac Defibrillators. <b>2002</b> , 4, 287-293	4
1643	[Secondary prevention in postinfarct patients]. <b>2002</b> , 43 Suppl 1, S99-104	
1642	[Arrhythmias during remodeling after myocardial infarction]. <b>2002</b> , 27, 740-9	1
1641	Sudden cardiac death in dilated cardiomyopathy -- therapeutic options. <b>2002</b> , 27, 750-9	19
1640	Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. <b>2002</b> , 13, 38-43	65
1639	Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks. <b>2002</b> , 13, 144-50	61
1638	Prognostic significance of nonsustained ventricular tachycardia after revascularization. <b>2002</b> , 13, 342-6	25
1637	Long-term follow-up after radiofrequency catheter ablation of ventricular tachycardia: a successful approach?. <b>2002</b> , 13, 417-23	86
1636	Management of patients with hemodynamically stable ventricular tachycardia in the setting of structural heart disease. <b>2002</b> , 13, 424-6	4
1635	T wave alternans: predictor of arrhythmic events?. <b>2002</b> , 13, 513-4	2
1634	Outcome of women versus men with ventricular tachyarrhythmias treated with the implantable cardioverter defibrillator. <b>2002</b> , 13, 563-8	34
1633	Scientific gaps in the prediction and prevention of sudden cardiac death. <b>2002</b> , 13, 709-23	98
1632	Influence of QRS duration on the prognostic value of T wave alternans. <b>2002</b> , 13, 770-5	44

1631	Exercise is superior to pacing for T wave alternans measurement in subjects with chronic coronary artery disease and left ventricular dysfunction. <b>2002</b> , 13, 845-50	50
1630	Advanced rhythm discrimination for implantable cardioverter defibrillators using electrogram vector timing and correlation. <b>2002</b> , 13, 1092-7	52
1629	Inducible ventricular flutter and fibrillation predict for arrhythmia occurrence in coronary artery disease patients presenting with syncope of unknown origin. <b>2002</b> , 13, 1103-8	13
1628	Surgical Treatment of Heart Failure [A Changing Paradigm?]. <b>2002</b> , 34, 347-353	2
1627	Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. <b>2002</b> , 25, 183-90	18
1626	Experience with a dual chamber implantable defibrillator. <b>2002</b> , 25, 1041-8	18
1625	Measurement of body surface energy leakage of defibrillation shock by an implantable cardioverter defibrillator. <b>2002</b> , 25, 1212-8	4
1624	The relative lymphocyte count predicts death in patients receiving implantable cardioverter defibrillators. <b>2002</b> , 25, 1424-8	24
1623	Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. <b>2002</b> , 25, 1571-6	51
1622	1-year performance of a defibrillation lead with a small electrode surface for high impedance pacing: a randomized, controlled study. <b>2002</b> , 25, 1577-82	4
1621	Chronic threshold testing of implantable cardioverter defibrillators does not increase coagulation activity or platelet activation. <b>2002</b> , 25, 1594-8	
1620	High quality performance of pacemakers and implantable defibrillators. <b>2002</b> , 25, 1667-9	8
1619	How does an implantable cardioverter defibrillator (ICD) affect the lives of patients and their families?. <b>2002</b> , 8, 152-7	66
1618	The epidemiology of out-of-hospital 'sudden' cardiac arrest. <b>2002</b> , 52, 235-45	152
1617	Survivors of ventricular tachyarrhythmias due to a transient or reversible disorder have a high recurrence rate of lethal cardiac events. <b>2002</b> , 54, 237-43	13
1616	MADIT-II and implications for noninvasive electrophysiologic testing. <b>2002</b> , 7, 179-80	6
1615	Late QRS activity in signal-averaged magnetocardiography, body surface potential mapping, and orthogonal ECG in postinfarction ventricular tachycardia patients. <b>2002</b> , 7, 389-98	6
1614	Prevention of cardiac arrest: risk assessment after myocardial infarction. <b>2002</b> , 6, 9-14	1

1613	Arrhythmias associated with dilated cardiomyopathy. <b>2002</b> , 6, 18-25	9
1612	Arrhythmias in patients with congenital heart disease. <b>2002</b> , 6, 42-4	4
1611	Arrhythmic and sudden death in chronic ischemic heart disease--a review of epidemiological data. <b>2002</b> , 6, 5-8	7
1610	Primary prevention in chronic ischemic heart disease. <b>2002</b> , 6, 15-7	
1609	Implantable cardioverter defibrillator therapy for life-threatening arrhythmias in young patients. <b>2002</b> , 6, 235-44	85
1608	Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. <b>2002</b> , 7, 285-300	14
1607	Devices for the management of ventricular arrhythmias in cardiac failure. <b>2002</b> , 7, 301-10	2
1606	MADIT-II: clinical implications. <b>2002</b> , 6, 463-5	28
1605	The role of the transvenous catheter electrophysiologic study in the evaluation and management of ventricular tachyarrhythmias associated with ischemic heart disease. <b>2002</b> , 6, 458-62	3
1604	Worldwide utilization of implantable cardioverter/defibrillators now and in the future. <b>2003</b> , 7, 5-13	37
1603	Expanding indications for defibrillators after myocardial infarction: risk stratification and cost effectiveness. <b>2003</b> , 7, 43-8	15
1602	New device indications: practice and cost implications in Europe. <b>2003</b> , 7, 49-53	1
1601	Quality of life and psychological impact of implantable cardioverter defibrillators: focus on randomized controlled trial data. <b>2003</b> , 7, 63-70	28
1600	Is inappropriate implantable defibrillator shock therapy predictable?. <b>2003</b> , 8, 215-20	31
1599	Primary prevention of sudden cardiac death: trials in patients with coronary artery disease. <b>2003</b> , 9, 203-6	7
1598	Detection of the fingerprint of the electrophysiological abnormalities that increase vulnerability to life-threatening ventricular arrhythmias. <b>2003</b> , 9, 103-18	8
1597	T wave pacing inducing electrical storm and multiple shocks in an ICD-recipient: a novel complication of the automatic gain control function. <b>2003</b> , 9, 401-3	4
1596	Frequent ICD shocks due to double sensing in patients with bi-ventricular implantable cardioverter defibrillators. <b>2003</b> , 9, 377-81	12



1595	I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. <b>2003</b> , 10, 121-31	124
1594	Comparison of coronary venous defibrillation with conventional transvenous internal defibrillation in man. <b>2003</b> , 8, 65-70	6
1593	Successful implantation of cardiac defibrillators without induction of ventricular fibrillation using upper limit of vulnerability testing. <b>2003</b> , 8, 71-5	18
1592	[MADIT II--or how seriously do we take primary prevention of sudden cardiac death?]. <b>2003</b> , 115, 152-4	
1591	[The impact of the Multicenter Automatic Defibrillator Implantation Trial II in a university hospital--do all patients with myocardial infarction and reduced left ventricular function need an implantable cardioverter-defibrillator?]. <b>2003</b> , 115, 167-74	2
1590	Contemporary Medical, Surgical, and Device Therapies for End-stage Heart Failure. <b>2003</b> , 5, 487-499	7
1589	ICD Therapy for the Prevention of Sudden Cardiac Death in Post-MI Patients. <b>2003</b> , 5, 369-376	1
1588	Management issues for patients with coronary artery disease and heart failure. <b>2003</b> , 5, 216-22	
1587	T-wave alternans for risk stratification and prevention of sudden cardiac death. <b>2003</b> , 5, 350-7	12
1586	Catheter Ablation of Ventricular Fibrillation in Structurally Normal Hearts Targeting the RVOT and Purkinje Ectopy. <b>2003</b> , 28, 598-606	23
1585	[Cardiac resynchronization therapy-current status and future perspectives]. <b>2003</b> , 28, 607-14	4
1584	[Current treatment of chronic heart failure]. <b>2003</b> , 52, 612-8	7
1583	[Reduced pump function after myocardial infarct. Indication for defibrillator implantation? The MADIT II Study]. <b>2003</b> , 44, 110-2	
1582	Prognostic value of non-sustained ventricular tachycardias after acute myocardial infarction in the thrombolytic era: importance of combination with frequent ventricular premature beats. <b>2003</b> , 92, 164-72	9
1581	Herzrhythusstörungen nach kardiochirurgischen Eingriffen: Übersicht, aktueller Kenntnisstand, therapeutische Optionen. <b>2003</b> , 17, 149-155	
1580	Molekulare Mechanismen des plötzlichen Herztods und ihre klinische Bedeutung. <b>2003</b> , 14, 168-179	
1579	Congestive heart failure and Virchow's triad: a neglected association. <b>2003</b> , 153, 411-6	7
1578	Implantable cardioverter-defibrillator therapy in the management of patients with decreased left ventricular function. <b>2003</b> , 12, 77-79	

1577	The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): rationale, design and specific aims. <b>2003</b> , 7, 447-51	4
1576	Amiodarone versus Implantable Defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications. <b>2003</b> , 7, 452-6	8
1575	DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). <b>2003</b> , 7, 457-62	11
1574	Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?. <b>2003</b> , 7, 443-6	3
1573	Combination of QT variability and signal-averaged electrocardiography in association with ventricular tachycardia in postinfarction patients. <b>2003</b> , 36, 17-24	12
1572	T-wave alternans: marker, mechanism, and methodology for predicting sudden cardiac death. <b>2003</b> , 36 Suppl, 75-81	35
1571	Noninvasive risk stratification in postinfarction patients with severe left ventricular dysfunction and methodology of the MADIT II noninvasive electrocardiology substudy. <b>2003</b> , 36 Suppl, 101-8	36
1570	Better living through chemistry: does it still apply to patients after myocardial infarction?. <b>2003</b> , 23, 816-22	1
1569	Prevention and management of chronic heart failure with electrical therapy. <b>2003</b> , 91, 62F-73F	14
1568	Combining electrical therapies for advanced heart failure: the Milan experience with biventricular pacing-defibrillation backup combination for primary prevention of sudden cardiac death. <b>2003</b> , 91, 74F-80F	16
1567	Use of antiarrhythmics and implantable cardioverter-defibrillators in congestive heart failure. <b>2003</b> , 91, 45D-52D	12
1566	Device therapy for heart failure. <b>2003</b> , 91, 53D-59D	59
1565	Effect of elevated heart rate preceding the onset of ventricular tachycardia on antitachycardia pacing effectiveness in patients with implantable cardioverter defibrillators. <b>2003</b> , 92, 26-32	55
1564	Limited predictive value of inducible sustained ventricular tachycardia for future occurrence of spontaneous ventricular tachycardia in patients with coronary artery disease and relatively preserved cardiac function. <b>2003</b> , 36, 205-11	12
1563	Medical and surgical treatment of chronic heart failure. <b>2003</b> , 28, 229-60	2
1562	Modern management of acute myocardial infarction. <b>2003</b> , 28, 7-127	
1561	A brief history of sudden cardiac death and its therapy. <b>2003</b> , 100, 89-99	14
1560	Management of arrhythmias in heart failure. <b>2003</b> , 9, 91-9	13

1559	Sequential methods and group sequential designs for comparative clinical trials. <b>2003</b> , 17, 505-16	27
1558	Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence. <b>2003</b> , 14, S99-103	24
1557	MADIT-I and MADIT-II. <b>2003</b> , 14, S96-8	46
1556	Translation of clinical trials into clinical practice: use of results in formulating guidelines. <b>2003</b> , 14, S9-14	1
1555	Sudden death in the community. <b>2003</b> , 14, S104-7	7
1554	Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. <b>2003</b> , 14, 940-8	137
1553	Transvenous defibrillation leads: high incidence of failure during long-term follow-up. <b>2003</b> , 14, 38-43	108
1552	Clinical and electrophysiologic predictors of ventricular tachyarrhythmia recurrence in patients with implantable cardioverter defibrillators. <b>2003</b> , 14, 492-8	18
1551	Improved survival of cardiac transplantation candidates with implantable cardioverter defibrillator therapy: role of beta-blocker or amiodarone treatment. <b>2003</b> , 14, 578-83	20
1550	Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?. <b>2003</b> , 14, 574-7	7
1549	Ventricular flutter induced during electrophysiologic studies in patients with old myocardial infarction: clinical and electrophysiologic predictors, and prognostic significance. <b>2003</b> , 14, 913-9	5
1548	A bridge, but to where?. <b>2003</b> , 14, 584-6	1
1547	Risk stratification and management of sudden cardiac death: a new paradigm. <b>2003</b> , 14, 1113-9	10
1546	Distal right ventricular coil position reduces defibrillation thresholds. <b>2003</b> , 14, 1036-40	12
1545	Heart rate variability: back to the beginning. <b>2003</b> , 14, 800-2	9
1544	Antiarrhythmic drugs: past, present and future. <b>2003</b> , 14, 1389-96	20
1543	Usefulness of risk stratification for future cardiac events in infarct survivors with severely depressed versus near-normal left ventricular function: results from a prospective long-term follow-up study. <b>2003</b> , 8, 68-74	7
1542	Prevalence of sensing abnormalities in dual chamber implantable cardioverter defibrillators. <b>2003</b> , 8, 219-26	6

1541	Ventricular gradient as a risk factor in survivors of acute myocardial infarction. <b>2003</b> , 26, 373-6	24
1540	Cardiac arrhythmias and risk stratification after myocardial infarction: results of the CARISMA pilot study. <b>2003</b> , 26, 416-9	47
1539	Subthreshold test pulses versus low energy shock delivery to estimate high energy lead impedance in implanted cardioverter defibrillator patients. <b>2003</b> , 26, 457-60	7
1538	Implications of national guidance for implantable cardioverter defibrillation implantation in the United Kingdom. <b>2003</b> , 26, 479-82	10
1537	Safety of a single successful conversion of ventricular fibrillation before the implantation of cardioverter defibrillators. <b>2003</b> , 26, 483-6	27
1536	Prospective randomized comparison of two defibrillation safety margins in unipolar, active pectoral defibrillator therapy. <b>2003</b> , 26, 613-8	5
1535	Variability in implantable cardioverter defibrillator pulse generator longevity between manufacturers. <b>2003</b> , 26, 71-5	12
1534	Nonthoracotomy implantable defibrillator lead extraction: results and comparison with extraction of pacemaker leads. <b>2003</b> , 26, 1944-50	45
1533	Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. <b>2003</b> , 26, 2016-22	55
1532	Distinct clinical features in the recipients of the implantable cardioverter defibrillator in Taiwan: a multicenter registry study. <b>2003</b> , 26, 2083-90	11
1531	Mortality, morbidity, and complications in 3344 patients with implantable cardioverter defibrillators: results from the German ICD Registry EURID. <b>2003</b> , 26, 1511-8	94
1530	Patients with an ICD can safely resume work in industrial facilities following simple screening for electromagnetic interference. <b>2003</b> , 26, 1675-8	21
1529	A randomized prospective study of single coil versus dual coil defibrillation in patients with ventricular arrhythmias undergoing implantable cardioverter defibrillator therapy. <b>2003</b> , 26, 1684-90	44
1528	Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. <b>2003</b> , 55, 299-306	8
1527	Implantable cardioverter defibrillator events in patients with asymptomatic nonsustained ventricular tachycardia: is device implantation justified?. <b>2003</b> , 26, 2289-95	19
1526	Antiarrhythmic drugs: past, present, and future. <b>2003</b> , 26, 2340-9	1
1525	Incorporating data received after a sequential trial has stopped into the final analysis: implementation and comparison of methods. <b>2003</b> , 59, 701-9	8
1524	Metabolic modulation and optimization of energy consumption in heart failure. <b>2003</b> , 87, 493-507, xii-xiii	9

1523	Muerte sbita cardaca y MADIT II. <b>2003</b> , 27, 410-416		1
1522	[Myocardial infarction. Population case-fatality in seven Spanish autonomous communities: the IBERICA Study]. <b>2003</b> , 121, 606-12		5
1521	Implantable cardioverter-defibrillators. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1836-47	59.2	160
1520	Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. <b>2003</b> , 41, 1573-82		148
1519	Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. <b>2003</b> , 41, 1707-12		413
1518	Say no to primary prophylaxis with implantable cardioverter-defibrillators in asymptomatic nonischemic dilated cardiomyopathy?. <b>2003</b> , 41, 1713-5		0
1517	Short-term results of substrate mapping and radiofrequency ablation of ischemic ventricular tachycardia using a saline-irrigated catheter. <b>2003</b> , 41, 2228-36		128
1516	Dead is dead, but can we identify patients at increased risk for sudden cardiac death?. <b>2003</b> , 42, 659-60		7
1515	Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. <b>2003</b> , 42, 652-8		199
1514	Prognostic significance of morphometric endomyocardial biopsy analysis in patients with idiopathic dilated cardiomyopathy. <b>2003</b> , 146, 372-6		11
1513	Screening for structural heart disease: time to stop listening and start looking. <b>2003</b> , 146, 570-1		4
1512	Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie [Herz- und Kreislaufforschung (DGK). <b>2003</b> , 92, 501-521		60
1511	Demographics and concomitant disorders in heart failure. <b>2003</b> , 362, 147-58		118
1510	Ventricular reconstruction for ischemic cardiomyopathy. <b>2003</b> , 75, S6-12		17
1509	Can we predict which patients with implantable cardioverter defibrillators receive appropriate shock therapy? A study of 155 patients. <b>2003</b> , 88, 69-75		10
1508	Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitalization. <b>2003</b> , 87, 119-20		76
1507	Morbidity and mortality of UNOS status 1B cardiac transplant candidates at home. <b>2003</b> , 22, 419-26		20
1506	Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication. <b>2003</b> , 22, 411-8		25

1505	[Indication of automatic implantable defibrillator after primary percutaneous transluminal coronary angioplasty]. <b>2003</b> , 56, 1163-4	
1504	[Impact of primary angioplasty on the indication for implantable cardiac defibrillator in patients with myocardial infarction]. <b>2003</b> , 56, 1182-6	5
1503	[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure]. <b>2003</b> , 98, 326-34	
1502	Changing late prognosis of acute myocardial infarction: impact on management of ventricular arrhythmias in the era of reperfusion and the implantable cardioverter-defibrillator. <b>2003</b> , 107, 941-6	22
1501	Cardiac arrest outside of a hospital: how can we improve results of resuscitation?. <b>2003</b> , 107, 1948-50	31
1500	QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure. <b>2003</b> , 89, 1157-62	77
1499	Comprehensive cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: a randomised controlled trial. <b>2003</b> , 89, 155-60	98
1498	MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy. <b>2003</b> , 108, 1779-83	48
1497	Comparative follow up of patients with implanted cardioverter-defibrillators after induction of sustained monomorphic ventricular tachycardias or ventricular fibrillation by programmed stimulation. <b>2003</b> , 89, 629-32	4
1496	Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. <b>2003</b> , 108, 110-5	135
1495	Sudden cardiac death. <b>2003</b> , 18, 313-29	15
1494	Successful resuscitation of a patient with electrical storm. <b>2003</b> , 20, E4	3
1493	Ventricular resynchronization: a promising therapy for heart failure. <b>2003</b> , 12, 41-8	4
1492	Routine implantation of cardioverter/defibrillator devices in patients aged 75 years and older with prior myocardial infarction and left ventricular ejection fraction 2003, 12, 363-5	1
1491	Are implantable cardioverter-defibrillators always superior to amiodarone?. <b>2003</b> , 4, 2111-4	
1490	An audit of the implications of implementing NICE guidance on the use of implantable cardioverter-defibrillators. <b>2003</b> , 89, 787-8	6
1489	Inference about a secondary process following a sequential trial. <b>2003</b> , 90, 597-611	15
1488	Antiarrhythmic drug target choices and screening. <b>2003</b> , 93, 491-9	56

1487	Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. <b>2003</b> , 5, 419-25	23
1486	Racial differences in outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT): a comparison of whites versus blacks. <b>2003</b> , 108, 67-72	22
1485	[Primary prevention of sudden cardiac death]. <b>2003</b> , 128, 2547-52	0
1484	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-2003. An 82-year-old man with dyspnea and pulmonary abnormalities. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 1574-85	59.2 39
1483	MADIT-II and its implications. <b>2003</b> , 24, 16-8	23
1482	Editor's Mailbox. <b>2003</b> , 113, 20-103	
1481	. <b>2003</b> ,	
1480	Sudden cardiac death: implantable cardioverter defibrillators and pharmacological treatments. <b>2003</b> , 26, 45-9	3
1479	Implantable devices benefit patients with cardiovascular diseases. <b>2003</b> , 18, 337-42	2
1478	Implantable cardioverter-defibrillators in cardiovascular care: technologic advances and new indications. <b>2003</b> , 9, 362-8	2
1477	Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. <b>2003</b> , 163, 2301-5	112
1476	Home monitoring in ICD therapy: future perspectives. <b>2003</b> , 5, 139-42	40
1475	Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. <b>2003</b> , 17 Suppl 1, S96-122	25
1474	Special concerns in the cardiac catheterization lab. <b>2003</b> , 41, 63-7	4
1473	Is prophylaxis the best use of the ICD? Response to the letter to the editor (Sharma et al.). <b>2003</b> , 24, 880-1	
1472	Simultaneous use of bilateral subthalamic nucleus stimulators and an implantable cardiac defibrillator. Case report. <b>2003</b> , 99, 167-9	24
1471	Cardiac resynchronization therapy: overcoming ventricular dyssynchrony in dilated heart failure. <b>2003</b> , 11, 221-39	9
1470	Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. <b>2003</b> , 138, 445-52	180

1469	Perspectives in the management of chronic coronary artery disease. <b>2003</b> , 5, 365-7	1
1468	. <b>2003</b> ,	
1467	Plötzlicher Herztod. <b>2003</b> ,	
1466	New pacing technologies for heart failure. <b>2003</b> , 326, 1073-7	15
1465	Long-term follow-up of sudden cardiac arrest survivors and electrophysiologically guided antiarrhythmic therapy. <b>2003</b> , 99, 190-7	3
1464	Regional gap junction inhibition increases defibrillation thresholds. <b>2003</b> , 285, H10-6	16
1463	. <b>2004</b> ,	23
1462	. <b>2004</b> ,	7
1461	What is Heart Failure and What are the Treatment Options? Complex Questions. 1-38	1
1460	Implantable Defibrillators and Combined ICD-Resynchronization Therapy in Patients with Heart Failure. 177-208	
1459	Clinical Characteristics in Patients with Implantable Cardioverter-Defibrillator(ICD). <b>2004</b> , 34, 395	5
1458	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. <b>2004</b> , 110,	59
1457	Should patients with severely impaired left ventricular function following myocardial infarction receive an implantable defibrillator?. <b>2004</b> , 180, 287-8	
1456	Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease. <b>2004</b> , 17, 106-15	
1455	Microscopic T Wave Alternans. 439-447	
1454	Monitoring Ectopic Activity. 547-559	
1453	CRT only or CRT plus ICD?. <b>2004</b> , 6, D83-D87	2
1452	Perioperative cardiac arrhythmias. <b>2004</b> , 93, 86-94	30



1451	Prophylactic implantable cardioverter-defibrillators after myocardial infarction--not for everyone. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 2540-2	59.2	14
1450	Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 2151-8	59.2	1488
1449	[Clinical significance of stress reactivity for frequency of electric shock discharges in patients with implanted cardioverter-defibrillators]. <b>2004</b> , 129, 2291-4		1
1448	Guidelines of the Cardiogeriatrics Department of the Brazilian Cardiology Society: commentary by Editorial Board Members of The American Journal of Geriatric Cardiology. <b>2004</b> , 13, 209-16		
1447	Myocardial hibernation: a double-edged sword. <b>2004</b> , 94, 1005-7		11
1446	Primary prevention of sudden cardiac death: the time of your life. <b>2004</b> , 109, 1073-5		8
1445	Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. <b>2004</b> , 110, 1885-9		267
1444	Clinical relevance of arrhythmias during sleep: guidance for clinicians. <b>2004</b> , 90, 347-52		51
1443	Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. <b>2004</b> , 110, 522-7		307
1442	Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. <b>2004</b> , 110, 3760-5		456
1441	Balloon dilation of the stenotic fifth aortic arch in a newborn with double lumen aortic arch. <b>2004</b> , 90, 245		3
1440	Implantable defibrillators and sudden cardiac death. <b>2004</b> , 109, 2685-91		140
1439	Device therapy for the management of advanced heart failure. <b>2004</b> , 2, 573-80		
1438	The MADIT II and COMPANION studies: will they affect uptake of device treatment?. <b>2004</b> , 90, 243-5		5
1437	Echolucent neointimal hyperplasia "dark wall" after sirolimus eluting stent implantation. <b>2004</b> , 90, 1143		1
1436	Predicting sudden death in patients with mild to moderate chronic heart failure. <b>2004</b> , 90, 1137-43		38
1435	Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. <b>2004</b> , 292, 2874-9		290
1434	Incidence and electrophysiological characteristics of spontaneous ventricular tachyarrhythmias in high risk coronary patients and prophylactic implantation of a defibrillator. <b>2004</b> , 90, 667-71		18

1433	A 17 year experience of inappropriate shock therapy in patients with implantable cardioverter-defibrillators: are we getting any better?. <b>2004</b> , 90, 330-1	15
1432	Chronic kidney disease and sudden death: strategies for prevention. <b>2004</b> , 22, 136-42	44
1431	Life-years gained from defibrillator implantation: markedly nonlinear increase during 3 years of follow-up and its implications. <b>2004</b> , 109, 1848-53	54
1430	Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 2481-8	59.2 1063
1429	Clinical trials update from the American Heart Association meeting: Omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. <b>2004</b> , 6, 109-15	23
1428	Management of the elderly person after myocardial infarction. <b>2004</b> , 59, 1173-85	8
1427	Partners of ICD patients--an exploratory study of their experiences. <b>2004</b> , 3, 201-10	24
1426	Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. <b>2004</b> , 109, 1994-2000	306
1425	Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. <b>2004</b> , 6, 501-8	161
1424	Reasons for attending and not attending a support group for recipients of implantable cardioverter defibrillators and their carers. <b>2004</b> , 10, 127-33	20
1423	Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. <b>2004</b> , 27, 4-9	160
1422	Implantable cardioverter defibrillators in adults with congenital heart disease: a single center experience. <b>2004</b> , 27, 47-51	33
1421	Heart rate variability and diastolic heart failure. <b>2004</b> , 27, 299-303	30
1420	Feasibility of implantable cardioverter defibrillator use in elderly patients: a case series of octogenarians. <b>2004</b> , 27, 373-8	31
1419	The evolution of the implantable cardioverter defibrillator. <b>2004</b> , 27, 419-31	19
1418	Remote monitoring of implantable cardioverter defibrillators: a prospective analysis. <b>2004</b> , 27, 757-63	153
1417	Ethical issues with implantable defibrillators. <b>2004</b> , 27, 897-8	2
1416	Radiofrequency catheter ablation for arrhythmic storm in patients with an implantable cardioverter defibrillator. <b>2004</b> , 27, 971-5	50

1415	Inappropriate implantable cardioverter defibrillator discharge following consumption of a dietary weight loss supplement. <b>2004</b> , 27, 1317-20	7
1414	Long-term experience with subcutaneous ICD leads: a comparison among three different types of subcutaneous leads. <b>2004</b> , 27, 1355-61	35
1413	Cardiac resynchronization therapy and automatic implantable cardiac defibrillators in the treatment of heart failure: a review article. <b>2004</b> , 16, 441-50	4
1412	High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator. <b>2004</b> , 27, 924-32	127
1411	Examination of a middle cardiac vein defibrillation coil as stand-alone anode, auxiliary anode, and bystander electrode in a transvenous defibrillation circuit. <b>2004</b> , 27, 1089-93	2
1410	Better living through medical device technology. <b>2004</b> , 24, 298-305; discussion 305-6	
1409	Syncope. <b>2004</b> , 29, 152-229	34
1408	The implantable cardioverter defibrillator: technology, indications, and impact on cardiovascular survival. <b>2004</b> , 29, 303-56	9
1407	Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. <b>2004</b> , 93, 1192-4	63
1406	Temporal aspects of improved survival with the implanted defibrillator (MADIT-II). <b>2004</b> , 94, 312-5	18
1405	Usefulness of procainamide challenge for electrophysiologic arrhythmia risk stratification. <b>2004</b> , 94, 1435-8	1
1404	Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. <b>2004</b> , 18, 161-70	30
1403	Nonsurgical transthoracic epicardial approach in patients with ventricular tachycardia and previous cardiac surgery. <b>2004</b> , 10, 281-8	52
1402	Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia. <b>2004</b> , 11, 59-65	6
1401	T wave oversensing in implantable cardioverter defibrillators. <b>2004</b> , 11, 67-72	23
1400	Remote interrogation and monitoring of implantable cardioverter defibrillators. <b>2004</b> , 11, 161-6	69
1399	Outcome of right ventricular bifocal pacing in patients with permanent atrial fibrillation and severe dilated cardiomyopathy due to Chagas disease: three years of follow-up. <b>2004</b> , 11, 193-8	9
1398	Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. <b>2004</b> , 11, 199-204	89

1397	Determinants of the quality of life (QoL) in patients with an implantable cardioverter/defibrillator (ICD). <b>2004</b> , 13, 411-6	54
1396	Role of noninvasive studies in risk stratification for sudden cardiac death. <b>2004</b> , 27, 192-7	8
1395	Panic disorders and agoraphobia: side effects of treatment with an implantable cardioverter/defibrillator. <b>2004</b> , 27, 321-6	56
1394	Medikamentöse Therapie der Herzinsuffizienz im Kindesalter. <b>2004</b> , 152, 659-665	
1393	Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis. <b>2004</b> , 61, 301-25	140
1392	Update on implantable cardioverter defibrillator trials. <b>2004</b> , 6, 327-32	2
1391	Risk stratification and epidemiology of sudden death. <b>2004</b> , 6, 333-8	2
1390	Current role of device therapy to reduce sudden cardiac death in heart failure. <b>2004</b> , 1, 104-10	1
1389	Treatment of Arrhythmias in Patients with Congestive Heart Failure. <b>2004</b> , 6, 519-529	0
1388	Cardiac Resynchronization Therapy for Heart Failure. <b>2004</b> , 6, 365-370	
1387	Clinical experience with a new detection algorithm for differentiation of supraventricular from ventricular tachycardia in a dual-chamber defibrillator. <b>2004</b> , 15, 646-52	49
1386	Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. <b>2004</b> , 15, 72-6	227
1385	Utility of implantable cardioverter defibrillator electrograms to estimate repolarization alternans preceding a tachyarrhythmic event. <b>2004</b> , 15, 594-7	26
1384	Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. <b>2004</b> , 15, 170-6	56
1383	Implantable cardioverter defibrillators in children. <b>2004</b> , 15, 77-8	1
1382	Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism. <b>2004</b> , 15, 1162-6	11
1381	Come see the softer side of clinical outcomes: Quality-of-life measures in implanted defibrillator trials. <b>2004</b> , 15, 292-4	2
1380	Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. <b>2004</b> , 15, 1002-9	218

1379	Evolution of the implantable cardioverter defibrillator. <b>2004</b> , 15, 375-85	16
1378	Biventricular implantable cardioverter defibrillators improve survival compared with biventricular pacing alone in patients with severe left ventricular dysfunction. <b>2004</b> , 15, 862-6	13
1377	Prevention of sudden cardiac death: when is a woman just like a man?. <b>2004</b> , 15, 999-1001	1
1376	Can we predict antiarrhythmic efficacy or inefficacy of amiodarone or any other antiarrhythmic? What this patient needs is a doctor!. <b>2004</b> , 15, 1155-6	0
1375	Coronary anatomy and left ventricular ejection fraction in patients with type 2 diabetes admitted for elective coronary angiography. <b>2004</b> , 62, 432-8	11
1374	Should we be screening for myocardial hibernation in heart failure?. <b>2004</b> , 11, 114-7	3
1373	The evolution and revolution of the implantable cardioverter defibrillator. <b>2004</b> , 2, 461-4	
1372	Medical therapy for sudden death. <b>2004</b> , 51, 1379-87	3
1371	Sudden cardiac death and channelopathies: a review of implantable defibrillator therapy. <b>2004</b> , 51, 1289-303	19
1370	The evolution of the implantable cardioverter defibrillator. <b>2004</b> , 1, 102C-114C	
1369	Deaths associated with implantable cardioverter defibrillator failure and deactivation reported in the United States Food and Drug Administration Manufacturer and User Facility Device Experience Database. <b>2004</b> , 1, 399-405	74
1368	Outcomes and in-hospital treatment of out-of-hospital cardiac arrest patients resuscitated from ventricular fibrillation by early defibrillation. <b>2004</b> , 79, 613-9	22
1367	Efficacy of lower-energy biphasic shocks for transthoracic defibrillation: a follow-up clinical study. <b>2004</b> , 8, 262-7	6
1366	Clinical competency statement: Training pathways for implantation of cardioverter defibrillators and cardiac resynchronization devices. <b>2004</b> , 1, 371-5	61
1365	Prevalencia y evoluci3n en Espa1a de los pacientes con infarto agudo de miocardio y fracci3n de eyecci3n severamente deprimida, con criterios de implantaci3n de desfibrilador autom1tico. <b>2004</b> , 57, 705-708	1
1364	Trends in treated ventricular fibrillation out-of-hospital cardiac arrest: a 17-year population-based study. <b>2004</b> , 1, 255-9	107
1363	Antiarrhythmic drugs: past, present, and future. <b>2004</b> , 1, 57C-66C	0
1362	Prevalence and Clinical Course of Patients in Spain With Acute Myocardial Infarction and Severely Depressed Ejection Fraction Who Meet the Criteria for Automatic Defibrillator Implantation. <b>2004</b> , 57, 705-708	

1361	Risk Stratification and Prevention of Sudden Death in Patients With Heart Failure. <b>2004</b> , 57, 768-782	
1360	Therapy interactions in chronic heart failure: synergies and asynergies of medication and device interventions. <b>2004</b> , 1, 135-141	
1359	Fibrillation ventriculaire. <b>2004</b> , 1, 68-79	
1358	Filling the need for new antiarrhythmic drugs to prevent shocks from implantable cardioverter defibrillators. <b>2004</b> , 43, 44-6	7
1357	Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). <b>2004</b> , 43, 1459-65	277
1356	Is defibrillation testing required for defibrillator implantation?. <b>2004</b> , 44, 88-91	74
1355	Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators. <b>2004</b> , 43, 2293-9	95
1354	The World Trade Center attack: increased frequency of defibrillator shocks for ventricular arrhythmias in patients living remotely from New York City. <b>2004</b> , 44, 1265-7	65
1353	Cardiac arrhythmias: the quest for a cure: a historical perspective. <b>2004</b> , 44, 1155-63	7
1352	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). <b>2004</b> , 44, E1-E211	830
1351	Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. <b>2004</b> , 44, 2166-72	162
1350	Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. <b>2004</b> , 44, 2362-7	130
1349	Cost of Heart Failure in Patients Receiving beta-Blockers and Angiotensin-Converting Enzyme Inhibitors. <b>2004</b> , 24, 255-64	4
1348	Estratificaci3n del riesgo y prevenci3n de la muerte s3bita en pacientes con insuficiencia card3aca. <b>2004</b> , 57, 768-782	5
1347	International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. <b>2004</b> , 23, 1313-33	179
1346	Will all postinfarction patients receive defibrillators? Recent trials and expanding indications. <b>2004</b> , 1262, 360-363	1
1345	Significance of inducible ventricular flutter/fibrillation in risk stratification in patients with coronary artery disease. <b>2004</b> , 94, 67-71	3
1344	Implantable defibrillators: from the adult cardiac to the grown up congenital heart disease patient. <b>2004</b> , 97 Suppl 1, 117-22	5

1343	Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. <b>2004</b> , 147, 582-6	313
1342	Long-term prognosis of inducible ventricular flutter: not an innocent finding. <b>2004</b> , 147, 649-54	15
1341	Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. <b>2004</b> , 147, 837-40	79
1340	Novel approaches to clinical trials: device-related infections. <b>2004</b> , 147, 599-604	19
1339	Amiodarone versus implantable cardioverter defibrillator for asymptomatic nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy. <b>2004</b> , 147, 790-1	
1338	Highlights from the American College of Cardiology Annual Scientific Sessions 2004: March 9-12, 2004. <b>2004</b> , 148, 254	1
1337	[Diagnostic and therapeutic progress. Venous thromboembolism, cardiac insufficiency and radio contrast agents]. <b>2004</b> , 33, 623-30	1
1336	Psychosocial intervention for a geriatric patient to address fears related to implantable cardioverter defibrillator discharges. <b>2004</b> , 45, 140-4	12
1335	Risk stratification and survival in post myocardial infarction patients: a large prospective and multicenter study in Japan. <b>2004</b> , 93, 263-8	11
1334	Implantable cardioverter-defibrillators: expanding indications. <b>2004</b> , 19, 317-22	2
1333	Implantable cardioverter defibrillator therapy in postinfarction patients. <b>2004</b> , 19, 619-24	7
1332	The pharmacologic treatment of heart failure. <b>2004</b> , 11, 480-8	3
1331	Cardiac arrhythmias: The quest for a cureA historical perspective. <b>2004</b> , 44, 1155-1163	32
1330	Current status of cardiac resynchronization therapy. <b>2004</b> , 17, 75-83	2
1329	Risk stratification and primary prevention of sudden cardiac death: sudden death prevention. <b>2004</b> , 15, 404-18	6
1328	Expanding the scope of practice for cardiac rehabilitation: managing patients with implantable cardioverter defibrillators. <b>2004</b> , 24, 209-15	17
1327	EFFICACY OF LOWER-ENERGY BIPHASIC SHOCKS FOR TRANSTHORACIC DEFIBRILLATION: A FOLLOW-UP CLINICAL STUDY. <b>2004</b> , 8, 262-267	15
1326	Quality of life issues in patients with implantable cardioverter defibrillators: driving, occupation, and recreation. <b>2004</b> , 15, 478-89	21

1325	Update of implantable cardioverter/defibrillator and cardiac resynchronization therapy in heart failure. <b>2004</b> , 19, 264-9	2
1324	Cardiac defibrillation and resynchronization therapies: principles, therapies, and management implications. <b>2004</b> , 15, 340-61	2
1323	Cardiac resynchronization therapy for heart failure management. <b>2004</b> , 15, 326-39	4
1322	Ventricular dysrhythmias in heart failure. <b>2004</b> , 19, S11-26	2
1321	Do positive health expectations and optimism relate to quality-of-life outcomes for the patient with an implantable cardioverter defibrillator?. <b>2004</b> , 24, 324-31	57
1320	Innovations in Health Psychology: The Psychosocial Care of Adults With Implantable Cardioverter Defibrillators.. <b>2004</b> , 35, 520-526	5
1319	Do implantable cardioverter defibrillators lower mortality risk in patients with cardiomyopathy?. <b>2004</b> , 1, 16-7	1
1318	Indications for an implantable cardioverter defibrillator (ICD). <b>2004</b> , 43, 360-7	7
1317	Arrhythmia Management in the Elderly. <b>2005</b> , 261-300	1
1316	Alternative therapies for orthotopic heart transplantation. <b>2005</b> , 330, 88-101	3
1315	Epidemiology of Cardiac Arrest. 1-20	1
1314	Device therapy in the management of congestive heart failure. <b>2005</b> , 13, 130-8	6
1313	MADIT II/SCD-HeFT Results: Have They Already Achieved an Impact in Europe?. <b>2005</b> , 247-250	
1312	The use of implantable cardioverter defibrillators for the prevention of sudden cardiac death: a review of the evidence and implications. <b>2005</b> , 329, 238-46	17
1311	Cardiovascular device development: lessons learned from pacemaker and implantable cardioverter-defibrillator therapy. <b>2005</b> , 12, 183-5	7
1310	Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators. <b>2005</b> , 128, 2604-10	13
1309	Lessons learnt from the autopsies of 445 cases of sudden cardiac death in adults. <b>2005</b> , 16, 385-9	13
1308	Preventing sudden cardiac death in post myocardial infarction patients with left ventricular dysfunction. <b>2005</b> , 20, 397-404	0



1307	Psychological disturbances, adjustment, and the development of phantom shocks in patients with an implantable cardioverter defibrillator. <b>2005</b> , 20, 288-93	13
1306	Changes in causes of sudden deaths by decade in patients with coronary arterial lesions due to Kawasaki disease. <b>2005</b> , 15, 481-8	46
1305	Prevention of Sudden Cardiac Death. <b>2005</b> , 21-38	
1304	Implantable cardioverter defibrillator therapy. <b>2005</b> , 20, 276-87	1
1303	Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. <b>2005</b> , 142, 593-600	82
1302	Nifekalant hydrochloride suppresses severe electrical storm in patients with malignant ventricular tachyarrhythmias. <b>2005</b> , 69, 1508-13	20
1301	Prevention of sudden cardiac death: lessons from recent controlled trials. <b>2005</b> , 69, 625-9	18
1300	Two adults requiring implantable defibrillators because of ventricular tachycardia and left ventricular dysfunction caused by presumed Kawasaki disease. <b>2005</b> , 69, 870-4	23
1299	Selection of Patients for ICDs: Where Are We in 2005? <b>2005</b> , 14, 33-37	
1298	Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. <b>2005</b> , 28, 165-73	20
1297	Ventricular arrhythmias: a general cardiologist's assessment of therapies in 2005. <b>2005</b> , 28, 314-6	12
1296	Impact of a mis-specification of the response rate under standard treatment in sequential clinical trials. <b>2005</b> , 19, 569-78	1
1295	Cost-effectiveness of in-home automated external defibrillators for individuals at increased risk of sudden cardiac death. <b>2005</b> , 20, 251-8	21
1294	Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. <b>2005</b> , 28, 647-53	14
1293	The nature of the game. <b>2005</b> , 16, 483-5	5
1292	Value of pre-hospital discharge defibrillation testing in recipients of implanted cardioverter defibrillators. <b>2005</b> , 28 Suppl 1, S260-2	8
1291	Central venous occlusion is not an obstacle to device upgrade with the assistance of laser extraction. <b>2005</b> , 28, 661-6	37
1290	Temporal relationship of implantable cardioverter defibrillator discharges and environmental physical activity. <b>2005</b> , 28, 777-81	9

1289	Significance of inducible ventricular flutter-fibrillation after myocardial infarction. <b>2005</b> , 28, 938-43	11
1288	Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. <b>2005</b> , 28, 926-32	196
1287	Placement of transvenous pacemaker and ICD leads across total chronic occlusions. <b>2005</b> , 28, 921-5	42
1286	Electrophysiologic study-guided therapy with sotalol for life-threatening ventricular tachyarrhythmias. <b>2005</b> , 28, 285-90	5
1285	Rules of evidence: CMS and primary prevention of sudden cardiac death in systolic heart failure. <b>2005</b> , 28, 81-8	10
1284	Ethical issues with implantable defibrillators. <b>2005</b> , 28, 173-4; author reply 174	
1283	Does ICD therapy benefit women with a history of myocardial infarction and severe left ventricular dysfunction?. <b>2005</b> , 16, 1271-2	2
1282	Arrhythmias after cell transplantation for myocardial regeneration: natural history or result of the intervention?. <b>2005</b> , 16, 1255-7	13
1281	Determinants of recurrent ventricular arrhythmia or death in 300 consecutive patients with ischemic heart disease who experienced aborted sudden death: data from the Leiden out-of-hospital cardiac arrest study. <b>2005</b> , 16, 1049-56	24
1280	Prevention of sudden cardiac death. <b>2005</b> , 16 Suppl 1, S21-4	5
1279	Identifying the high risk patient with coronary artery disease--is ejection fraction all you need?. <b>2005</b> , 16 Suppl 1, S25-7	23
1278	Differences in outcomes between patients treated with single- versus dual-chamber implantable cardioverter defibrillators: a substudy of the Multicenter Automatic Defibrillator Implantation Trial II. <b>2005</b> , 10, 429-35	20
1277	Relationship of the implantable cardioverter defibrillator and chronic resynchronization therapy: the perfect marriage?. <b>2005</b> , 10, 24-33	1
1276	Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. <b>2005</b> , 95, 271-4	34
1275	Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). <b>2005</b> , 95, 1487-91	45
1274	Comparison of ventricular arrhythmia frequency in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy treated with implantable cardioverter defibrillators. <b>2005</b> , 96, 233-8	9
1273	[Cardiac resynchronisation therapy: what kind of equipment to use?]. <b>2005</b> , 54, 12-6	2
1272	[Risk stratification in congestive heart failure]. <b>2005</b> , 54, 172-8	2

1271 Arritmias y electrofisiología cardíaca: temas de actualidad en 2004. **2005**, 5, 55A-65A

1270 Resincronización en la insuficiencia cardíaca. ¿Con o sin desfibrilador?. **2005**, 5, 46B-52B

1269 Residual high incidence of ventricular arrhythmias after left ventricular reconstructive surgery. **2005**, 130, 1250-6 32

1268 Detection of repolarization alternans with an implantable cardioverter defibrillator lead in a porcine model. **2005**, 52, 1188-94 10

1267 Alzheimer's disease: the impact of age-related changes in reproductive hormones. **2005**, 62, 255-6 6

1266 ICD therapy in coronary artery disease. A reappraisal in 2005. **2005**, 30, 82-6 1

1265 [Therapeutic strategies in inappropriate ICD therapy]. **2005**, 30, 619-24 0

1264 [Cardiac resynchronization therapy-always with ICD?]. **2005**, 30, 596-600 0

1263 [Commentary on the guidelines the diagnosis and the therapy of syncope--the European Society of Cardiology 2001 and the update 2004]. **2005**, 94, 592-612 29

1262 [Cardiac resynchronization therapy: who is suitable? Who requires an additional ICD as a backup?]. **2005**, 94 Suppl 4, IV/60-64 1

1261 Cell-based cardiovascular repair--the hurdles and the opportunities. **2005**, 100, 504-17 30

1260 [Automated external defibrillators: perspectives and outlook]. **2005**, 16, 112-7 2

1259 Indications for implantable cardiac defibrillators in patients with congestive heart failure: implications of the sudden cardiac death in heart failure trial. **2005**, 7, 223-8

1258 Nonsustained ventricular tachycardia in dilated cardiomyopathy. **2005**, 7, 368-75 1

1257 The role of prophylactic implantable cardioverter defibrillators in heart failure: recent trials usher in a new era of device therapy. **2005**, 2, 40-5

1256 Mechanisms of ventricular arrhythmias in heart failure. **2005**, 2, 111-7 26

1255 Sudden death in nondilated cardiomyopathies: pathophysiology and prevention. **2005**, 2, 118-23 6

1254 Sudden cardiac death and the role of device therapy in dilated cardiomyopathy. **2005**, 2, 124-7 0

1253	Ventricular arrhythmias after LV remodelling: surgical ventricular restoration or ICD?. <b>2004</b> , 9, 299-306; discussion 347-51	28
1252	Prophylactic ICDs: can (and will) the medical marketplace decide their role?. <b>2005</b> , 12, 175-6	1
1251	Microwave ablation of an ischemic sustained ventricular tachycardia during aortocoronary bypass, mitral valve and tricuspid valve surgery guided by a three-dimensional non-fluoroscopic mapping system (CARTO). <b>2005</b> , 13, 243-7	6
1250	Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government. <b>2005</b> , 14, 71-8	65
1249	The leadless defibrillator or the return of the subcutaneous electrode: episode III in the ICD saga?. <b>2005</b> , 13, 179-80	3
1248	Federal guidelines for prophylactic ICD therapy in high risk populations for sudden cardiac death: is this a necessary course correction?. <b>2005</b> , 12, 5-7	2
1247	Efficacy and safety of ICD therapy in a population of elderly patients treated with optimal background medication. <b>2005</b> , 14, 169-73	26
1246	Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest. <b>2005</b> , 16, 478-82	12
1245	The use of the triangular test with response-adaptive treatment allocation. <b>2005</b> , 24, 1483-93	9
1244	. <b>2005</b> ,	
1243	. <b>2005</b> ,	7
1242	Techniques of Prediction of Arrhythmia Occurrence and Stratification for Sudden Cardiac Death. 84-90	
1241	New ICD Indications. 219-229	
1240	Indications for and long-term survival in patients with automatic implantable cardioverter-defibrillators. <b>2005</b> , 13, 50-1	3
1239	Bibliography. <b>2005</b> , 613-654	
1238	Heart Failure. 162-176	
1237	Implantable Devices. 220-236	
1236	Risk Stratification for SCD. 47-61	1

1235 Ischemic Heart Disease. 89-108

1234 Evaluation and Management of Arrhythmias in Athletes. **2005**, 491-500

1233 Cardiovascular Disease in the Elderly. **2005**,

1232 Outcome in patients with an ICD incorporating cardiac resynchronisation therapy: differences between primary and secondary prophylaxis. **2005**, 7, 1027-32 10

1231 Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThERapies (PainFREE Rx II) trial. **2005**, 111, 2898-905 225

1230 Patients, mean age 70 years, with automatic implantable cardioverter-defibrillators treated with dual-chamber rate responsive pacing (DDDR-70) have a higher mortality than patients with backup ventricular pacing (VVI-40) at 3.7-year follow-up. **2005**, 60, 603-4 8

1229 N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. **2005**, 7, 253-60 26

1228 Heart failure devices: implantable cardioverter-defibrillators and biventricular pacing therapy. **2005**, 111, 3327-35 32

1227 Prediction and prevention of sudden cardiac death in heart failure. **2005**, 91, 674-80 64

1226 Regional variation in ICD implantation rates: the shocking truth?. **2005**, 91, 1251-3 9

1225 Emerging Pathologies in Cardiology. **2005**, 1

1224 Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator. **2005**, 24, 42-51 28

1223 Educational governance for the regulation of industry sponsored continuing medical education in interventional and device based therapies. **2005**, 91, 710-2 7

1222 Device based treatment of heart failure. **2005**, 81, 286-91 2

1221 Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction 2005, 111, 2537-49; discussion 2537-49 74

1220 Sudden cardiac death: opportunities for prevention. **2006**, 92, 721-3 6

1219 Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. **2005**, 7, 904-9 90

1218 Welchen Stellenwert hat die Medikamentöse Therapie?. **2005**, 31, 527-531 1

1217	Do implantable cardioverter-defibrillators benefit patients immediately after acute myocardial infarction?. <b>2005</b> , 2, 192-3		
1216	Implications and problems of the Sudden Cardiac Death in Heart Failure Trial. <b>2005</b> , 1, 599-603		
1215	Prophylactic defibrillator implantation--toward an evidence-based approach. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 285-7	59.2	27
1214	Sudden death after myocardial infarction--who needs prophylaxis, and when?. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2638-40	59.2	23
1213	Cost-effectiveness of implantable cardioverter-defibrillators. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1471-80	59.2	417
1212	Rationelle Diagnostik und Therapie bei Herzinsuffizienz. <b>2005</b> ,		
1211	Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era. <b>2005</b> , 26, 762-9		183
1210	Welchen Stellenwert hat die Medikamentöse Therapie?. <b>2005</b> , 31, 527-531		1
1209	The fully automatic external cardioverter defibrillator: reality of a new meaningful scenario for in-hospital cardiac arrests. <b>2005</b> , 2, 33-9		1
1208	Role of electrophysiologic studies, signal-averaged electrocardiography, heart rate variability, T-wave alternans, and loop recorders for risk stratification of ventricular arrhythmias. <b>2005</b> , 14, 16-9		6
1207	Antiarrhythmic therapy in elderly persons: a device-based approach. <b>2005</b> , 14, 10-3; quiz 14		2
1206	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. <b>2005</b> , 26, 1115-40		1642
1205	Diagnosis and management of sudden cardiac death. <b>2005</b> , 91, 408-13		17
1204	Association of short-term ambient air pollution concentrations and ventricular arrhythmias. <b>2005</b> , 161, 1123-32		180
1203	Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 225-37	59.2	4876
1202	Handbook of Cardiac Anatomy, Physiology, and Devices. <b>2005</b> ,		15
1201	DEALE-ing with lung cancer and heart failure. <b>2005</b> , 25, 82-94		2
1200	Ventricular arrhythmias: antiadrenergic therapy for the patient with coronary artery disease. <b>2005</b> , 10 Suppl 1, S23-31		9

1199 Images in cardiology: Intramyocardial septal branches of a "dual LAD" selectively visualised within a no reflow area. **2005**, 91, 1253

1198 Sudden cardiac death: mechanisms, therapies and challenges. **2005**, 2, 352-60

10

1197 Primary prophylaxis with the implantable cardioverter-defibrillator: the need for improved risk stratification. **2005**, 294, 958-60

29

1196 Should every patient with left-ventricular systolic dysfunction receive implantable cardioverter-defibrillators?. **2005**, 2, 188-9

1195 Outcomes after ventricular fibrillation out-of-hospital cardiac arrest: expanding the chain of survival. **2005**, 80, 774-82

17

1194 Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. **2005**, 25, 189-95

40

1193 Registro Español de Desfibrilador Automático Implantable. Primer Informe Oficial del Grupo de Trabajo de Desfibrilador Implantable de la Sociedad Española de Cardiología (años 2002-2004). **2005**, 58, 1435-1449

44

1192 Tratamiento de la insuficiencia cardíaca crónica. **2005**, 9, 2318-2326

1191 Tratamiento de las taquiarritmias por métodos no farmacológicos. Técnicas de ablación. Desfibriladores. **2005**, 9, 2391-2399

1190 Indicaciones de estudio electrofisiológico cardíaco. **2005**, 9, 2418-2419

1189 Arritmias en situaciones especiales. Anciano. Enfermedades metabólicas e hidroelectrolíticas. Arritmias en la cardiopatía isquémica. **2005**, 9, 2455-2462

1188 Protocolo terapéutico de las arritmias asociadas a cardiopatía isquémica. **2005**, 9, 2478-2480

1187 Infarto agudo de miocardio. Criterios diagnósticos y pronósticos. Cardiopatía isquémica en la tercera edad. **2005**, 9, 2633-2642

1186 Tratamiento de las complicaciones del infarto de miocardio. **2005**, 9, 2671-2681

1185 [Home Monitoring with implantable ICD--a diagnostic innovation?]. **2005**, 16, 183-90

4

1184 Cell therapy for heart failure--muscle, bone marrow, blood, and cardiac-derived stem cells. **2005**, 17, 348-60

23

1183 Percent right ventricular pacing predicts outcomes in the DAVID trial. **2005**, 2, 830-4

249

1182 Long-term results after ablation of infarct-related ventricular tachycardia. **2005**, 2, 474-82

72

1181	Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion?. <b>2005</b> , 2, 456-61	148
1180	Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival. <b>2005</b> , 80, 774-782	15
1179	Clinical predictors of atrial defibrillation thresholds with a dual-coil, active pectoral lead system. <b>2005</b> , 2, 49-54	6
1178	Improved accuracy of low-power contrast echocardiography for the assessment of left ventricular remodeling compared with unenhanced harmonic echocardiography after acute myocardial infarction: comparison with cardiovascular magnetic resonance imaging. <b>2005</b> , 18, 1203-7	23
1177	Use of the implantable cardioverter-defibrillator in long-term survivors of orthotopic heart transplantation. <b>2005</b> , 2, 931-3	17
1176	One conversion of ventricular fibrillation is adequate for implantable cardioverter-defibrillator implant: an analysis from the Low Energy Safety Study (LESS). <b>2005</b> , 2, 117-22	24
1175	Internal defibrillation with minimal skeletal muscle activation: a new paradigm toward painless defibrillation. <b>2005</b> , 2, 1108-13	17
1174	Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era. <b>2005</b> , 10 Suppl 1, S45-58	7
1173	Quality of life in implanted cardioverter defibrillator recipients: the impact of a device shock. <b>2005</b> , 34, 169-78	93
1172	Implanted defibrillators and primary prevention of sudden cardiac death: where are we today?. <b>2005</b> , 98, 15-20	4
1171	Development of indications for cardiac resynchronisation therapy in the implantable cardioverter defibrillator population. <b>2005</b> , 99, 187-90	5
1170	Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. <b>2005</b> , 103, 248-55	38
1169	Sudden cardiovascular death following myocardial infarction: the importance of left ventricular systolic dysfunction and congestive heart failure. <b>2005</b> , 104, 184-9	14
1168	Benefits of cardiac rehabilitation in patients with implantable cardioverter-defibrillators: a patient survey. <b>2005</b> , 86, 1924-8	46
1167	En bloc exclusion of the pulmonary vein region in the pig using off pump, beating, intra-cardiac surgery: a pilot study of minimally invasive surgery for atrial fibrillation. <b>2005</b> , 80, 1417-23	34
1166	Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. <b>2005</b> , 149, 1020-34	45
1165	Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers. <b>2005</b> , 150, 1064	17
1164	Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. <b>2005</b> , 118, 752-8	66



1163	[Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. <b>2005</b> , 58, 1062-92	57
1162	Cardiac Arrhythmias. <b>2005</b> , 52-92	
1161	Cardiovascular Emergencies. <b>2005</b> , 205-226	
1160	Spanish Implantable Cardioverter-Defibrillator Registry. First Official Report of the Spanish Society of Cardiology Working Group on Implantable Cardioverter-Defibrillators (2002-2004). <b>2005</b> , 58, 1435-1449	
1159	Arrhythmias after orthotopic heart transplantation. <b>2005</b> , 11, 464-72	28
1158	N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. <b>2005</b> , 11, S47-53	18
1157	The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). <b>2005</b> , 45, 400-8	138
1156	Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. <b>2005</b> , 45, 1104-8	371
1155	Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. <b>2005</b> , 45, 1474-81	30
1154	QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators. <b>2005</b> , 46, 310-6	59
1153	The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. <b>2005</b> , 46, 1536-40	147
1152	Association of myocardial ischemia with mortality and implantable cardioverter-defibrillator therapy in patients with coronary artery disease at risk of arrhythmic death. <b>2005</b> , 46, 1721-6	29
1151	Cost advantage of dual-chamber versus single-chamber cardioverter-defibrillator implantation. <b>2005</b> , 46, 850-7	29
1150	Why should we care about CARE-HF?. <b>2005</b> , 46, 2199-203	25
1149	Who needs a defibrillator? The beat goes on. <b>2005</b> , 46, 1727-8	1
1148	Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. <b>2005</b> , 46, 2168-82	167
1147	Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. <b>2005</b> , 2, 367-73	17
1146	Should T-wave alternans testing be used to risk stratify candidates for prophylactic implantable cardioverter-defibrillator therapy?. <b>2005</b> , 2, 242-4	2

1145	Safety and efficacy of radiofrequency energy catheter ablation of atrial fibrillation in patients with pacemakers and implantable cardiac defibrillators. <b>2005</b> , 2, 1309-16	30
1144	The Sign of Four and the SDNN of one of three. <b>2006</b> , 3, 287-9	1
1143	Registro Español de Desfibrilador Automático Implantable. I Informe Oficial (años 2002-2004). <b>2006</b> , 13, 187-201	
1142	Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. <b>2006</b> , 3, 762-8	34
1141	Statistical Monitoring of Clinical Trials. <b>2006</b> ,	8
1140	Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. <b>2006</b> , 114, 32-9	592
1139	Assessing efficacy and therapeutic claims in emerging indications for recombinant factor VIIa: regulatory perspectives. <b>2006</b> , 43, S64-9	1
1138	Prediction versus prevention of sudden cardiac death. <b>2006</b> , 367, 1639-41	4
1137	Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. <b>2006</b> , 367, 1674-81	380
1136	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). <b>2006</b> , 34, 1748-307	972
1135	The Use of an Implantable Cardioverter Defibrillator in a Boxer Dog to Control Clinical Signs of Arrhythmogenic Right Ventricular Cardiomyopathy. <b>2006</b> , 20, 1232-1237	16
1134	Sudden cardiac death and ventricular arrhythmias. <b>2006</b> , 34, 268-273	1
1133	To catch a moving target. <b>2006</b> , 3, 638-9	
1132	Coronary sinus electrode does not reduce atrial defibrillation thresholds. <b>2006</b> , 3, 647-52	4
1131	Heart failure in older adults. <b>2006</b> , 90, 863-85, xi	30
1130	Fungal infection of implantable cardioverter-defibrillators: case series of five patients managed over 22 years. <b>2006</b> , 3, 919-23	10
1129	Equivalent arrhythmic risk in patients recently diagnosed with dilated cardiomyopathy compared with patients diagnosed for 9 months or more. <b>2006</b> , 3, 397-403	28
1128	Is there a role for amiodarone in the era of the implantable cardioverter-defibrillator?. <b>2006</b> , 3, 484-7	4

1127	Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. <b>2006</b> , 3, 1196-201	61
1126	Ventricular Arrhythmias in the Elderly. <b>2006</b> , 22, 19-30	2
1125	Cardiovascular emergencies in the elderly. <b>2006</b> , 24, 339-70, vi	8
1124	The National ICD Registry: now and into the future. <b>2006</b> , 3, 470-3	46
1123	A comparison of the output characteristics of several implantable cardioverter-defibrillators. <b>2006</b> , 3, 1053-9	10
1122	Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (ICPE). <b>2006</b> , 3, 1250-73	125
1121	Allelic variants of SCN5A and risk of sudden cardiac arrest in patients with coronary artery disease. <b>2006</b> , 3, 697-700	24
1120	Contrast echocardiography versus gated single photon emission computed tomography for the assessment of parameters of left ventricular remodeling after acute myocardial infarction. <b>2006</b> , 19, 280-4	7
1119	Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers. <b>2006</b> , 59, 537-544	1
1118	Cardiac Arrhythmias in Women. <b>2006</b> , 59, 609-618	4
1117	Desfibrilador automático en la miocardiopatía hipertrófica. Experiencia de 3 centros. <b>2006</b> , 59, 537-544	10
1116	Arritmias cardíacas en la mujer. <b>2006</b> , 59, 609-618	26
1115	[Primary prophylaxis with the implantable cardioverter-defibrillator in heart failure: a clinical point of view]. <b>2006</b> , 59 Suppl 3, 10-22	
1114	Guías de Práctica Clínica del ACC/AHA/ESC 2006 sobre el manejo de pacientes con arritmias ventriculares y la prevención de la muerte cardíaca súbita. Versión resumida. <b>2006</b> , 59, 1328.e1-1328.e51	3
1113	Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. <b>2006</b> , 47, 98-107	141
1112	T-wave alternans and the susceptibility to ventricular arrhythmias. <b>2006</b> , 47, 269-81	262
1111	Implantable cardioverter-defibrillator therapy in clinical practice. <b>2006</b> , 47, 1507-17	25
1110	Clinical research designs and implantable defibrillator indications: spend in the beginning or pay at the end. <b>2006</b> , 47, 108-11	12

1109	Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. <b>2006</b> , 47, 456-63	220
1108	Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. <b>2006</b> , 47, 1161-6	337
1107	Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. <b>2006</b> , 47, 1811-7	80
1106	The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. <b>2006</b> , 47, 2493-7	214
1105	Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. <b>2006</b> , 48, 112-21	55
1104	Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. <b>2006</b> , 48, 227-35	41
1103	The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. <b>2006</b> , 47, 2310-8	171
1102	American College of Cardiology/American Heart Association 2006 update of the clinical competence statement on invasive electrophysiologystudies,catheterablation,andcardioversion: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training developed in collaboration with the ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death	36
1101	Executive Summary. <b>2006</b> , 48, 1064-1108	110
1100	Electrophysiologic testing and the use of devices in heart failure. <b>2006</b> , 12, e70-5	
1099	Patient selection for primary prevention ICDs--are eps shocking patients into consent?. <b>2006</b> , 12, 413-5	2
1098	ICD therapy: what have we learned from the clinical trials?. <b>2006</b> , 15, 3-11	
1097	Survival in octogenarians receiving implantable defibrillators. <b>2006</b> , 152, 714-9	63
1096	Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) trial. <b>2006</b> , 152, 636-40	9
1095	Disparities in the use of primary prevention and defibrillator therapy among blacks and women. <b>2006</b> , 119, 167.e17-21	45
1094	Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance. <b>2006</b> , 151, 736-44	173
1093	Cardiac resynchronization therapy: a regulatory perspective. <b>2006</b> , 151, 757-61	1
1092	Prediction of arrhythmic events with positron emission tomography: PAREPET study design and methods. <b>2006</b> , 27, 374-88	48

1091	Implantable cardioverter-defibrillators: a new preventive medical option. <b>2006</b> , 9, 49-53; quiz 54-5	5
1090	Internet-based behavioral change and psychosocial care for patients with cardiovascular disease: a review of cardiac disease-specific applications. <b>2006</b> , 35, 374-82	40
1089	Implantable cardioverter defibrillator (ICD) in children. <b>2006</b> , 107, 30-5	66
1088	Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function. <b>2006</b> , 108, 26-30	7
1087	Risk stratification for arrhythmic death after myocardial infarction: current perspective and future direction. <b>2006</b> , 108, 155-64	8
1086	Microvolt T-wave alternans: a review of techniques, interpretation, utility, clinical studies, and future perspectives. <b>2006</b> , 109, 293-306	16
1085	Non-Invasive Parameters, Including a Low Left Ventricular Ejection Fraction, for Predicting Sudden Cardiac Death in Korean Post Myocardial Infarction Patients. <b>2006</b> , 36, 431	3
1084	Trajectory of end-stage heart failure: the influence of technology and implications for policy change. <b>2006</b> , 49, 10-8	58
1083	Viewpoint from Israel, February 7, 2006. <b>2006</b> , 113,	0
1082	. <b>2006</b> ,	10
1081	Cardiac rhythm management. 579-581	
1080	. <b>2006</b> ,	1
1079	Defibrillators. <b>2006</b> ,	
1078	. <b>2006</b> ,	1
1077	Cardiac Computed Tomography: Evaluation of Myocardial Function, Perfusion and Viability. 205-218	
1076	Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias. <b>2006</b> , 70, 977-84	15
1075	Clinical significance of the electrophysiologic study (EPS)-guided therapy for the secondary prevention of ventricular tachycardia. <b>2006</b> , 70, 268-72	3
1074	What is sudden death? A correct identification. <b>2006</b> , 3-13	

1073	Managing heart failure in the very old. <b>2006</b> , 2, 253-275	
1072	Antiarrhythmic Therapy in Heart Failure. 120-134	
1071	Implantable cardioverter-defibrillators: expanding indications and technologies. <b>2006</b> , 295, 809-18	197
1070	Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction. <b>2006</b> , 166, 2228-33	13
1069	Indications for ICD Implantation. 20-25	
1068	Arrhythmias. <b>2006</b> , 37-70	
1067	Sudden cardiac death. <b>2006</b> , 99, 502-10	5
1066	Full Length Article. <b>2006</b> , 3, 1196-1201	57
1065	Infarctus du myocarde. Diagnostic, prise en charge ^ la phase aiguë et complications. <b>2006</b> , 1, 1-13	
1064	Review Article. <b>2006</b> , 3, 1250-1273	104
1063	Lessons learned from neutral ICD trials. <b>2006</b> , 8, 393-7	2
1062	Erosion of an extrapericardial implantable cardioverter defibrillator patch through the gastric fundus with fistulous tract formation. <b>2006</b> , 14, e21-3	1
1061	Fibrillation ventriculaire. <b>2006</b> , 1, 1-7	
1060	Key clinical insights from the sudden cardiac death in heart failure trial. <b>2006</b> , 21, 463-8	4
1059	Value of microvolt T-wave alternans for predicting patients who would benefit from implantable cardioverter-defibrillator therapy. <b>2006</b> , 14, 173-9	1
1058	Genetic profiling as a marker for risk of sudden cardiac death. <b>2006</b> , 21, 42-6	9
1057	Sex-based differences in cardiac resynchronization therapy and implantable cardioverter defibrillator therapies: effectiveness and use. <b>2006</b> , 14, 292-8	26
1056	[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. <b>2006</b> , 33 Suppl 1, 125-30	

1055	Recent primary prevention implantable cardioverter defibrillator trials. <b>2006</b> , 21, 15-9	3
1054	Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. <b>2006</b> , 21, 517-25	2
1053	[Present status and future prospects in non-drug therapy for arrhythmia]. <b>2006</b> , 95, 1912-21	
1052	[Clinical therapy for arrhythmias and EBM]. <b>2006</b> , 95, 234-9	
1051	Design of the Primary Prevention Parameters Evaluation (PREPARE) trial of implantable cardioverter defibrillators to reduce patient morbidity [NCT00279279]. <b>2006</b> , 7, 18	12
1050	A review of the management of patients after percutaneous coronary intervention. <b>2006</b> , 60, 582-9	8
1049	Implantable or external defibrillators for individuals at increased risk of cardiac arrest: where cost-effectiveness hits fiscal reality. <b>2006</b> , 9, 292-302	5
1048	Infections of implantable cardioverter-defibrillators: frequency, predisposing factors and clinical significance. <b>2006</b> , 12, 533-7	17
1047	Advanced ICD troubleshooting: Part II. <b>2006</b> , 29, 70-96	48
1046	Innovative techniques for placement of implantable cardioverter-defibrillator leads in patients with limited venous access to the heart. <b>2006</b> , 29, 181-7	99
1045	Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on ventricular defibrillation threshold. <b>2006</b> , 29, 747-52	2
1044	Influence of drive cycle length on initiation of ventricular fibrillation during implantable cardioverter defibrillator threshold testing. <b>2006</b> , 29, 926-9	
1043	Long-term follow-up of patients supplied with single-chamber or dual-chamber cardioverter defibrillators. <b>2006</b> , 29, 946-52	19
1042	Impact of the main implantable cardioverter-defibrillator trials for primary and secondary prevention in Italy: a survey of the national activity during the years 2001-2004. <b>2006</b> , 29 Suppl 2, S20-8	20
1041	Hybrid therapies for ventricular arrhythmias. <b>2006</b> , 29 Suppl 2, S40-7	4
1040	Intrathoracic far-field electrocardiogram allows continuous monitoring of ischemia after total coronary occlusion. <b>2006</b> , 29, 1334-40	6
1039	Increased intra-QRS fragmentation in magnetocardiography as a predictor of arrhythmic events and mortality in patients with cardiac dysfunction after myocardial infarction. <b>2006</b> , 17, 396-401	33
1038	Simultaneous atrial and ventricular anti-tachycardia pacing as a novel method of rhythm discrimination. <b>2006</b> , 17, 695-701	8

1037	CRT-D therapy in heart failure: how much do NYHA class IV patients benefit?. <b>2006</b> , 17, 491-4	11
1036	Near fatal arrhythmia induction by an implantable cardioverter defibrillator. <b>2006</b> , 17, 1026-8	4
1035	Mortality following defibrillator implantation in patients with renal insufficiency. <b>2006</b> , 17, 940-3	45
1034	Clustering of ventricular tachyarrhythmias in heart failure patients implanted with a biventricular cardioverter defibrillator. <b>2006</b> , 17, 1299-306	17
1033	Selection of patients for CRT--prevention or reversal of remodeling as a therapeutic endpoint for CRT. <b>2006</b> , 17, 1293-4	3
1032	ICD arrhythmia detection and discrimination: are we there yet?. <b>2006</b> , 17, 1320-2	3
1031	Impact of the multicenter automatic defibrillator implantation trial on clinical practice. <b>2006</b> , 11, 20-7	1
1030	The history, science, and innovation of Holter technology. <b>2006</b> , 11, 85-94	19
1029	Electrocardiographic predictors of arrhythmic death. <b>2006</b> , 11, 327-37	6
1028	The impact of implantable cardiac defibrillators for primary prophylaxis in the community: baseline risk and clinically meaningful benefits. <b>2006</b> , 12, 190-5	7
1027	What are the professional and logistic demands to appropriately follow patients with an implantable cardioverter-defibrillator?. <b>2006</b> , 260, 88-92	4
1026	The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. <b>2006</b> , 260, 467-73	24
1025	Atrial tachyarrhythmias in primary and secondary prevention ICD recipients: clinical and prognostic data. <b>2006</b> , 29 Suppl 2, S48-53	6
1024	Discrimination when dual-chamber termination fails: a new paradigm for ICDs?. <b>2006</b> , 17, 702-4	
1023	Implantable cardiac arrhythmia devices--Part II: implantable cardioverter defibrillators and implantable loop recorders. <b>2006</b> , 29, 237-42	8
1022	Implantable cardioverter defibrillator implant-explant-implant case study: addressing the psychological adjustment to multiple shocks. <b>2006</b> , 29, 274-6	7
1021	Cellular alternans: a mechanism linking calcium cycling proteins to cardiac arrhythmogenesis. <b>2006</b> , 1080, 216-34	21
1020	Psychological indices and phantom shocks in patients with ICD. <b>2006</b> , 15, 185-90	30



1019	New perspective in arrhythmia and heart failure monitoring. <b>2006</b> , 95 Suppl 3, III1-2	3
1018	What evidence do we have to replace in-hospital implantable cardioverter defibrillator follow-up?. <b>2006</b> , 95 Suppl 3, III3-9	39
1017	IEGM-online based evaluation of implantable cardioverter defibrillator therapy appropriateness. <b>2006</b> , 95 Suppl 3, III22-8	5
1016	[Efficiency potential in the pacemaker/implantable cardioverter defibrillator outpatient clinic]. <b>2006</b> , 17, 26-34	1
1015	Fehlfunktionen von Defibrillatoren. <b>2006</b> , 9, 626-629	
1014	Will innervation imaging predict ventricular arrhythmias in ischaemic cardiomyopathy?. <b>2006</b> , 33, 862-5	8
1013	[Prevention of sudden cardiac death]. <b>2006</b> , 47, 1040, 1042-9	8
1012	Analysis of implantable cardioverter defibrillator signals for non conventional cardiac electrical activity characterization. <b>2006</b> , 44, 45-53	4
1011	New indications for implantable defibrillator therapy. <b>2006</b> , 8, 330-5	3
1010	Is there a role for antiarrhythmic drugs in patients with implantable defibrillators?. <b>2006</b> , 8, 365-9	0
1009	Indications for cardiac defibrillators in patients with congestive heart failure. <b>2006</b> , 3, 197-202	
1008	Managing congestive heart failure patient factors in the device era. <b>2006</b> , 12, 335-40	7
1007	Rhythm management in pediatric heart failure. <b>2006</b> , 1, 140-7	1
1006	High risk of ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy presenting with syncope. <b>2006</b> , 97, 416-20	17
1005	Relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks. <b>2006</b> , 97, 544-6	20
1004	Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. <b>2006</b> , 97, 480-4	49
1003	Prognostic value of a restrictive mitral filling pattern in patients with systolic heart failure and an implantable cardioverter-defibrillator. <b>2006</b> , 97, 676-80	16
1002	Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?. <b>2006</b> , 97, 1255-61	182

1001	Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. <b>2006</b> , 98, 485-90	164
1000	Association between usage of beta-blocking medication and benefit from implantable cardioverter therapy. <b>2006</b> , 98, 1245-7	6
999	[Cardioverter-defibrillator implantation and follow-up in a non-university hospital]. <b>2006</b> , 55, 342-5	
998	Resincronizaci3n y prevenci3n de la muerte s3bita en la insuficiencia cardiaca. De los ensayos a la pr3ctica cl3nica. <b>2006</b> , 6, 59F-70F	
997	Seizure versus syncope. <b>2006</b> , 5, 171-80	102
996	Right ventricular enlargement mimicking electrocardiographic left ventricular pacing. <b>2006</b> , 39, 180-2	419
995	Implantable electrocardiographic monitoring--clinical experiences. <b>2006</b> , 39, S47-9	2
994	Ventricular arrhythmias and sudden cardiac death. <b>2006</b> , 48, 426-44	8
993	A singular case of multiple myeloma and primary biliary cirrhosis strictly associated in pathogenesis and response to alkylating therapy. <b>2006</b> , 81, 557	1
992	Idiopathic myelofibrosis associated with dermatomyositis. <b>2006</b> , 81, 559-60	4
991	Development of secondary myelodysplastic syndrome in a patient with previous bladder carcinoma. <b>2006</b> , 81, 560	
990	Implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis. <b>2006</b> , 81, 560-1	6
989	Clinically significant pseudohyponatremia. <b>2006</b> , 81, 558-9	10
988	Myelodysplasia with erythroid hypoplasia. <b>2006</b> , 81, 557-8	2
987	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of	360
986	The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. <b>2006</b> , 8, C5-C12	1
985	Impact of implantable defibrillators and resynchronization therapy on outcome in patients with left ventricular dysfunction--a meta-analysis. <b>2006</b> , 106, 249-55	17
984	Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. <b>2006</b> , 113, 2810-7	177

983	More is better with cardiac resynchronization therapy--but is it enough?. <b>2006</b> , 27, 1891-2	10
982	Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. <b>2006</b> , 27, 3027-32	121
981	Passive electrode effect reduces defibrillation threshold in bi-filament middle cardiac vein defibrillation. <b>2006</b> , 8, 113-7	1
980	Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients. <b>2006</b> , 8, 566-72	29
979	Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study. <b>2006</b> , 8, 618-24	49
978	Inappropriate implantable cardioverter-defibrillator discharges unrelated to supraventricular tachyarrhythmias. <b>2006</b> , 8, 863-9	45
977	Influence of gender on ICD implantation for primary and secondary prevention of sudden cardiac death. <b>2006</b> , 8, 1054-6	17
976	[ICD-implantation--for which patients is its value for primary prevention secure?]. <b>2006</b> , 131, 2165-8	0
975	Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure. <b>2006</b> , 3, 86-93	4
974	Gap junctions and propagation of the cardiac action potential. <b>2006</b> , 42, 71-85	25
973	Congestive Heart Failure. <b>2006</b> , 79-104	
972	Who needs an implantable cardioverter defibrillator?. <b>2006</b> , 67, 594-8	0
971	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. <b>2006</b> , 114, 2871-91	93
970	Role of resynchronisation therapy and implantable cardioverter defibrillators in heart failure. <b>2006</b> , 82, 16-23	2
969	How sudden is sudden cardiac death?. <b>2006</b> , 114, 1146-50	151
968	Cardiopulmonary resuscitation: history, current practice, and future direction. <b>2006</b> , 114, 2839-49	89
967	Modern management of arrhythmias. <b>2006</b> , 82, 117-25	10
966	Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. <b>2006</b> , 113, 2851-60	109

965	Navigating the crossroads of coronary artery disease and heart failure. <b>2006</b> , 114, 1202-13	255
964	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death), developed in collaboration with the European Heart Rhythm Association and the Heart. <b>2006</b> , 114, e383-484	901
963	Antiarrhythmic drugs for all patients with an ICD?. <b>2006</b> , 295, 211-3	4
962	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular	392
961	Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators. <b>2006</b> , 27, 700-7	93
960	The RIONI study rationale and design: validation of the first stored electrograms transmitted via home monitoring in patients with implantable defibrillators. <b>2006</b> , 8, 288-92	13
959	Performance of a new single-chamber ICD algorithm: discrimination of supraventricular and ventricular tachycardia based on vector timing and correlation. <b>2006</b> , 8, 1057-61	14
958	Trans fatty acids and coronary heart disease. <b>2006</b> , 21, 505-12	38
957	American College of Cardiology/American Heart Association 2006 update of the clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training: developed in collaboration with the Heart Rhythm Society. <b>2006</b> , 114, 1654-68	19
956	Implantable cardioverter-defibrillators should be used routinely in the elderly. <b>2006</b> , 15, 361-4; quiz 365-6	6
955	Pacemakers and defibrillators: recent and ongoing studies that impact the elderly. <b>2006</b> , 15, 82-7	5
954	Why cardioverter-defibrillator implantation might not be the best idea for your elderly patient. <b>2006</b> , 15, 367-71	7
953	Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged?. <b>2006</b> , 15, 88-92	8
952	Who should be treated with implantable cardioverter-defibrillators?. <b>2006</b> , 15, 336-7	2
951	Device implant technique and consideration of body image: specific procedures for implantable cardioverter defibrillators in female patients. <b>2006</b> , 15, 830-5	27
950	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Executive Summary. <b>2006</b> , 114, 1088-1132	71
949	Cardiac Arrhythmias 2005. <b>2006</b> ,	3
948	Electrophysiological interventions for treatment of congestive heart failure in pediatrics and congenital heart disease. <b>2007</b> , 5, 111-8	8

947	Primary and secondary prevention of sudden cardiac death: who should get an ICD?. <b>2007</b> , 93, 1478-83	12
946	Uncertainty on the use of aldosterone antagonists for primary therapy for sudden cardiac death in the setting of implanted devices. <b>2007</b> , 115, 2983-9; discussion 2989	1
945	Bubbles in the left cardiac cavities after diving. <b>2008</b> , 94, 445	4
944	Handbook of Cardiac Electrophysiology. <b>2007</b> ,	1
943	Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction. <b>2007</b> , 3, 23-33	
942	Developing new anti-arrhythmics: clues from the molecular basis of cardiac ryanodine receptor (RyR2) Ca <sup>2+</sup> -release channel dysfunction. <b>2007</b> , 13, 3195-211	11
941	The cost of implantable defibrillators: perceptions and reality. <b>2007</b> , 28, 392-7	30
940	QT variability strongly predicts sudden cardiac death in asymptomatic subjects with mild or moderate left ventricular systolic dysfunction: a prospective study. <b>2007</b> , 28, 1344-50	128
939	Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevation myocardial infarction after revascularization with either fibrinolysis or primary angioplasty. <b>2007</b> , 28, 407-14	20
938	Incidence of ventricular tachyarrhythmias during permanent pacemaker therapy in low-risk patients results from the German multicentre EVENTS study. <b>2007</b> , 28, 2238-42	8
937	Gray zone problem in athletes. <b>2007</b> , 28, 2415-6	
936	Implantation of cardioverter defibrillator in post-myocardial infarction patients: when and how?. <b>2007</b> , 28, 2416	
935	Role of delayed enhancement MRI in patients with acute coronary syndrome and unobstructed coronary arteries. <b>2007</b> , 28, 2416-7; author reply 2417	
934	Comparison of ventricular arrhythmia burden, therapeutic interventions, and survival, in patients $\geq$ 75 years of age treated with implantable cardioverter defibrillators. <b>2007</b> , 9, 270-4	15
933	Prevalence and prognostic impact of comorbidities in heart failure patients with implantable cardioverter defibrillator. <b>2007</b> , 9, 681-6	23
932	The quick-implantable-defibrillator trial. <b>2007</b> , 9, 1144-50	4
931	Predictive value of programmed ventricular stimulation in patients with ischaemic cardiomyopathy: implications for the selection of candidates for an implantable defibrillator. <b>2007</b> , 9, 1151-7	18
930	Enhanced infarct border zone function and altered mechanical activation predict inducibility of monomorphic ventricular tachycardia in patients with ischemic cardiomyopathy. <b>2007</b> , 245, 712-9	36

929	Electrophysiological interventions for inherited arrhythmia syndromes. <b>2007</b> , 116, 1062-80	22
928	Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. <b>2007</b> , 115, 2474-80	466
927	Cardiac resynchronization therapy implantation: a blend of skill and technology. <b>2007</b> , 9, 1107-1112	1
926	What is the role of risk stratification for sudden death in the defibrillator era?. <b>2007</b> , 9, 159-165	3
925	Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly. <b>2007</b> , 9, 380-4	15
924	BACK MATTER. <b>2007</b> , 268-404	
923	Phase-rectified signal averaging for the detection of quasi-periodicities and the prediction of cardiovascular risk. <b>2007</b> , 17, 015112	72
922	Mechanisms of sudden cardiac death in myocardial infarction survivors: insights from the randomized trials of implantable cardioverter-defibrillators. <b>2007</b> , 115, 2451-7	68
921	Significance of Wedensky Modulation testing in the evaluation of non-invasive risk stratification for ventricular tachyarrhythmia in patients with coronary artery disease and implantable cardioverter-defibrillator. <b>2008</b> , 94, e16	6
920	Decision to implant a cardioverter defibrillator after myocardial infarction: the role of ejection fraction v. other risk factor markers. <b>2007</b> , 27, 151-60	7
919	Sudden death prevention with implantable devices. <b>2007</b> , 116, 561-71	39
918	Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. <b>2007</b> , 115, 2976-82; discussion 2982	25
917	Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. <b>2007</b> , 115, 204-12	160
916	Addendum to "Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology"; public safety issues in patients with implantable defibrillators: a scientific	58
915	All patients with hemodynamically tolerated postinfarction ventricular tachycardia do not require an implantable cardioverter-defibrillator. <b>2007</b> , 116, 1204-12	8
914	Management of end stage cardiac failure. <b>2007</b> , 83, 395-401	29
913	Feasibility and clinical decision-making with 3D echocardiography in routine practice. <b>2008</b> , 94, 440-5	44
912	The ethical and legal implications of deactivating an implantable cardioverter-defibrillator in a patient with terminal cancer. <b>2007</b> , 33, 538-40	21

911	Current News in Cardiology. <b>2007</b> ,	
910	Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. <b>2007</b> , 115, 2006-14	625
909	Patients with hemodynamically tolerated ventricular tachycardia require implantable cardioverter defibrillators. <b>2007</b> , 116, 1196-203	7
908	Non-pharmacological management of ventricular tachycardia. <b>2007</b> , 71 Suppl A, A97-105	2
907	Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. <b>2007</b> , 147, 251-62	124
906	Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. <b>2007</b> , 298, 1517-24	191
905	A prospective study on the risk-stratification for patients with non-sustained ventricular tachycardia using a novel algorithm. <b>2007</b> , 71, 1107-14	4
904	Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. <b>2007</b> , 298, 1525-32	278
903	Implantable cardioverter-defibrillator use and benefit in women. <b>2007</b> , 15, 298-303	6
902	Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEFibrillator (CAMI GUIDE) study. <b>2007</b> , 8, 293-9	7
901	Application of the main implantable cardioverter-defibrillator trials and the 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <b>2007</b> , 8, 320-3	4
900	Ethical dilemmas in device treatment for advanced heart failure. <b>2007</b> , 1, 267-73	9
899	Implantable cardioverter defibrillators. <b>2007</b> , 7, 397-400	
898	Offsite anesthesiology in the cardiac catheterization lab. <b>2007</b> , 20, 352-8	22
897	Assessment of left ventricular ejection fraction after myocardial infarction using contrast echocardiography. <b>2008</b> , 9, 250-4	18
896	Prediction of sudden death in heart failure patients: a novel perspective from the assessment of the peak ectopy rate. <b>2007</b> , 9, 385-90	4
895	Optimizing therapy for heart failure patients: cardiac resynchronization and defibrillator therapy. <b>2007</b> , 22, 118-24	3
894	Traitement des syndromes coronaires aigus avec et sans sus-ST. <b>2007</b> , 2, 1-19	

893	Anxiety and marital adjustment in patients with implantable cardioverter defibrillator and their spouses. <b>2007</b> , 27, 46-9	25
892	The fight against sudden cardiac death: consensus guidelines as a reference. <b>2007</b> , 9, 150-158	2
891	A 59-year-old man considering implantation of a cardiac defibrillator. <b>2007</b> , 297, 1909-16	5
890	Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: a systematic review and economic evaluation. <b>2007</b> , 23, 63-70	15
889	Inequitable distribution of implantable cardioverter defibrillators in Ontario. <b>2007</b> , 23, 354-61	12
888	Stress testing in patients with implantable cardioverter-defibrillators: a preliminary report. <b>2007</b> , 10, 92-5	4
887	Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator. <b>2007</b> , 153, 120-6	34
886	Highlights from the 20th Scientific Sessions of the American Heart Association: November 12 to 15, 2006, Chicago, Illinois. <b>2007</b> , 153, 213-223	1
885	Sudden cardiac death: the role of risk stratification. <b>2007</b> , 153, 25-33	28
884	Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. <b>2007</b> , 153, 951-9	9
883	Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death. <b>2007</b> , 153, 941-50	36
882	Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome?. <b>2007</b> , 26, 447-52	53
881	A new method to investigate the response to the morphology discrimination algorithm in patients with ICD. <b>2007</b> , 114, 323-31	1
880	Sudden death prophylaxis in heart failure. <b>2007</b> , 119, 291-6	5
879	Heart rate variability in myocardial infarction and heart failure. <b>2007</b> , 120, 289-96	96
878	Catheter ablation for atrial fibrillation: should it be first-line therapy?. <b>2007</b> , 153, 74-80	260
877	Stability and cause of anxiety in patients with an implantable cardioverter-defibrillator: a longitudinal two-year follow-up. <b>2007</b> , 36, 87-95	23
876	Obstructive Sleep Apnea: Pathophysiology, Comorbidities and Consequences. <b>2007</b> ,	4



875	Treatment of arrhythmias and use of implantable cardioverter-defibrillators to improve survival in elderly patients with cardiac disease. <b>2007</b> , 23, 205-19	16
874	Perioperative Critical Care Cardiology. <b>2007</b> ,	
873	The Microvolt T-Wave Alternans Test. <b>2007</b> , 14, 213-219	
872	Clinical review: beyond immediate survival from resuscitation-long-term outcome considerations after cardiac arrest. <b>2007</b> , 11, 235	16
871	History of electrical therapy for the heart. <b>2007</b> , 9, 13-110	19
870	Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. <b>2007</b> , 4, 1395-402	152
869	Effect of bundle branch block on microvolt T-wave alternans and electrophysiologic testing in patients with ischemic cardiomyopathy. <b>2007</b> , 4, 904-12	25
868	Infarto de miocardio. Diagnóstico, tratamiento de la fase aguda y complicaciones. <b>2007</b> , 11, 1-13	
867	Treatment of arrhythmias and use of implantable cardioverter-defibrillators to improve survival in elderly patients with cardiac disease. <b>2007</b> , 3, 519-28	
866	An updated review of implantable cardioverter/defibrillators, induced anxiety, and quality of life. <b>2007</b> , 30, 677-88	71
865	Cardiac resynchronization therapy for treatment of heart failure in the elderly. <b>2007</b> , 23, 193-203	2
864	Where are we, and where are we heading in the device management of ventricular tachycardia/ventricular fibrillation?. <b>2007</b> , 4, 99-103	4
863	A practical guide for clinicians who treat patients with amiodarone: 2007. <b>2007</b> , 4, 1250-9	178
862	Biventricular pacing and defibrillator use in chronic heart failure. <b>2007</b> , 25, 595-603; vii	5
861	Addendum to "Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology". Public safety issues in patients with implantable defibrillators. A Scientific statement from the American Heart Association and the Heart Rhythm Society. <b>2007</b> , 4, 386-93	17
860	Cardiac resynchronization therapy for treatment of heart failure in the elderly. <b>2007</b> , 3, 511-8	3
859	Increased incidence of subacute lead perforation noted with one implantable cardioverter-defibrillator. <b>2007</b> , 4, 439-42	90
858	Cardiac transplantation: any role left?. <b>2007</b> , 3, 321-47	7

857	Primary Prevention of Sudden Cardiac Death in Patients with Ischemic Heart Disease Possible Role of the Shock Device in the Asia 2007, 23, 264-268	
856	Implantable cardioverter-defibrillators improve survival after coronary artery bypass grafting in patients with severely impaired left ventricular function. 2007, 2, 6	4
855	Assessment, significance and mechanism of ventricular electrical instability after myocardial infarction. 2007, 16, 149-55	3
854	Inverse relationship of blood pressure levels to sudden cardiac mortality and benefit of the implantable cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. 2007, 49, 1427-33	25
853	Predictive value of microvolt T-wave alternans in patients with left ventricular dysfunction. 2007, 50, 166-73	53
852	Learning from a real-world analysis of implantable cardioverter-defibrillator recipients: comorbidities matter. 2007, 49, 2416-8	1
851	Sudden Cardiac Death and Risk Stratification. 202-213	1
850	Arrhythmias. 2007, 316-341	0
849	Engineering and Construction of Pacemaker and Implantable Cardioverter-Defibrillator Leads. 2007, 161-200	2
848	Incidence of shock and quality of life in young patients with implantable cardioverter-defibrillator. 2007, 88, 258-64	24
847	[Implantable cardioverter defibrillator: an update]. 2007, 23, 88-92	1
846	Transthoracic defibrillation. 470-481	0
845	. 2007,	
844	. 2007,	2
843	Interim Analyses. 2007,	
842	Ventricular Tachycardia. 255-286	
841	A 25-year review of sequential methodology in clinical studies. 2007, 26, 237-52	40
840	On the equivalence of some medical cost estimators with censored data. 2007, 26, 4520-30	38

839	Novel electrode design for potentially painless internal defibrillation also allows for successful external defibrillation. <b>2007</b> , 18, 1095-100	10
838	A Comparison of ICD implantations in the United States versus Italy. <b>2007</b> , 30 Suppl 1, S143-6	8
837	A clinical risk score to predict the time to first appropriate device therapy in recipients of implantable cardioverter defibrillators. <b>2007</b> , 30, 385-9	5
836	The ICD shock and stress management program: a randomized trial of psychosocial treatment to optimize quality of life in ICD patients. <b>2007</b> , 30, 858-64	90
835	Relative and absolute benefits: main results should be reported in absolute terms. <b>2007</b> , 30, 935-7	8
834	Sustained polymorphic arrhythmias induced by programmed ventricular stimulation have prognostic value in patients receiving defibrillators. <b>2007</b> , 30, 1067-75	3
833	Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients. <b>2007</b> , 30, 1091-5	27
832	Follow-up of CRT-ICD: implications for the use of remote follow-up systems. Data from the InSync ICD Italian Registry. <b>2008</b> , 31, 38-46	25
831	A novel algorithm for determining endocardial VT exit site from 12-lead surface ECG characteristics in human, infarct-related ventricular tachycardia. <b>2007</b> , 18, 161-8	41
830	Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. <b>2007</b> , 18, 833-8	111
829	QT dispersion significantly increases after implantable cardioverter-defibrillator shocks. <b>2007</b> , 12, 44-9	7
828	Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy. <b>2007</b> , 12, 171-80	23
827	Depressive coping is a predictor for emotional distress and poor quality of life in a German-Austrian sample of cardioverter-defibrillator implant recipients at 3 months and 1 year after implantation. <b>2007</b> , 29, 526-36	13
826	Sudden cardiac death: epidemiology, mechanisms, and therapy. <b>2007</b> , 32, 501-46	61
825	Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. <b>2007</b> , 99, 232-8	74
824	Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). <b>2007</b> , 100, 76-83	12
823	Comparison of defibrillation efficacy and survival associated with right versus left pectoral placement for implantable defibrillators. <b>2007</b> , 100, 243-6	34
822	Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction. <b>2007</b> , 100, 635-9	18

821	Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of . <b>2007</b> , 100, 924-9	55
820	Treatment of ventricular dysrhythmias and sudden cardiac death: a guideline-based approach for patients with chronic left ventricular dysfunction. <b>2007</b> , 13, 228-35	4
819	Structural and electrical remodeling as therapeutic targets in heart failure. <b>2007</b> , 40, S1-7	12
818	The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation. <b>2007</b> , 134, 38-46, 46.e1	15
817	Implantable cardioverter defibrillators for prevention of sudden cardiac death. <b>2007</b> , 30, 3-8	5
816	Examination of research trends on patient factors in patients with implantable cardioverter defibrillators. <b>2007</b> , 30, 64-8	10
815	Reducing events in patients with chronic heart failure (REDUCEhf) study design: continuous hemodynamic monitoring with an implantable defibrillator. <b>2007</b> , 30, 567-75	46
814	Clinical usefulness of SonoVue contrast echocardiography: the Thoraxcentre experience. <b>2007</b> , 15, 55-60	11
813	Clinical implementation of guidelines for cardioverter defibrillator implantation: lost in translation?. <b>2007</b> , 15, 129-32	19
812	Indications for implantable cardioverter defibrillator use for primary prevention of sudden cardiac death. <b>2007</b> , 9, 371-80	1
811	Outcome of cardioverter-defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy. <b>2007</b> , 22, 184-92	27
810	Quality of life and psychological status of patients with implantable cardioverter defibrillators. <b>2006</b> , 17, 65-72	35
809	Are women worldwide under-treated with regard to cardiac resynchronization and sudden death prevention?. <b>2006</b> , 17, 169-75	10
808	Sudden cardiac death: epidemiologic and financial worldwide perspective. <b>2006</b> , 17, 199-203	40
807	Socio-economic analysis of cardiac resynchronization therapy. <b>2006</b> , 17, 225-36	2
806	Indications for predissmissal testing with arrhythmia-induction in patients receiving an implantable cardioverter defibrillator. <b>2007</b> , 96, 613-20	12
805	[Guideline invasive electrophysiological diagnostics]. <b>2007</b> , 96, 634-51	14
804	SCD in patients with cardiomyopathy: use of microvolt T-wave alternans and other noninvasive tests for risk stratification and prevention of SCD. <b>2007</b> , 9, 345-55	1

803 ICD-Therapie. **2007**, 1, 149-164

802 Plötzlicher Herztod. **2007**, 1, 261-271

10

801 Cost-effectiveness of implantable cardioverter-defibrillators in Brugada syndrome treatment. **2008**, 32, 51-7

10

800 The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective. **2008**, 21, 3-11

11

799 Regenerative therapies in electrophysiology and pacing. **2008**, 22, 87-98

3

798 Age and gender trends in implantable cardioverter defibrillator utilization: a population based study. **2008**, 22, 65-70

39

797 Adjudication of mortality events in a heart failure-arrhythmia trial by a multiparameter descriptive method: comparison with methods used in heart failure trials and methods used in arrhythmia trials. **2008**, 23, 101-10

5

796 Arrhythmias. **2018**, 276-286.e3

2

795 Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 15, e253-e274

10

794 Shock Reduction With Antitachycardia Pacing Before and During Charging for Fast Ventricular Tachycardias in Patients With Implantable Defibrillators. **2018**, 71, 709-717

1

793 Feasibility of extravascular pacing with a novel substernal electrode configuration: The Substernal Pacing Acute Clinical Evaluation study. **2018**, 15, 536-542

15

792 Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. **2018**, 104, 144-150

25

791 Perioperative Management of the Patient with an Implantable Cardioverter Defibrillator. **2018**, 77-89

790 Prevalence and Prognostic Significance of Nonsustained Ventricular Tachycardia in Patients With a Left Ventricular Ejection Fraction from 35% to 50. **2018**, 121, 330-335

2

789 Routine DFT testing in patients undergoing ICD implantation does not improve mortality: A systematic review and meta-analysis. **2018**, 34, 598-606

3

788 Prevention of Sudden Cardiac Death. **2018**, 321-336

787 OBSOLETE: Ischemic Cardiomyopathy. **2018**,

786 OBSOLETE: Modern Considerations in ICD Therapy. **2018**,

785	Incidence, Predictors, and Outcomes of Implantable Cardioverter-Defibrillator Discharge Among People Living With HIV. <b>2018</b> , 7, e009857		7
784	Who Benefits From a Defibrillator-Balancing the Risk of Sudden Versus Non-sudden Death. <b>2018</b> , 15, 376-389		2
783	Long-term reliability of the defibrillator lead inserted by the extrathoracic subclavian puncture. <b>2018</b> , 34, 541-547		1
782	Atrial Fibrillation Is Associated With Higher Overall Mortality in Patients With Implantable Cardioverter-Defibrillator: A Systematic Review and Meta-Analysis. <b>2018</b> , 7, e010156		13
781	Frequency of Need for Antitachycardia or Antibradycardia Pacing or Cardiac Resynchronization Therapy in Patients With a Single-Chamber Implantable Cardioverter-Defibrillator. <b>2018</b> , 122, 2068-2074		3
780	Wearable Cardioverter-Defibrillator after Myocardial Infarction. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1205-1215	59.2	127
779	Differences in amiodarone efficacy in relation to ejection fraction and basal rhythm in patients with implantable cardioverter defibrillators. <b>2018</b> , 51, 1111-1115		2
778	Measuring defibrillator surface potentials: The validation of a predictive defibrillation computer model. <b>2018</b> , 102, 402-410		4
777	The modular cardiac rhythm management system: the EMPOWER leadless pacemaker and the EMBLEM subcutaneous ICD. <b>2018</b> , 29, 355-361		21
776	Clinical Predictors of Recurrent Ventricular Arrhythmias in Secondary Prevention Implantable Cardioverter Defibrillator Recipients With Coronary Artery Disease - Lower Left Ventricular Ejection Fraction and Incomplete Revascularization. <b>2018</b> , 82, 3037-3043		8
775	Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure. <b>2018</b> , 15, 368-375		12
774	Sudden Cardiac Death and Arrhythmias. <b>2018</b> , 7, 111-117		59
773	Avoiding inappropriate therapy of single-lead implantable cardioverter-defibrillator by using atrial-sensing electrodes. <b>2018</b> , 29, 1682-1689		9
772	Cardiology Consult Manual. <b>2018</b> ,		
771	Supraventricular and ventricular arrhythmias: medical management. <b>2018</b> , 46, 632-639		
770	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <b>2018</b> , 39, 3810-3820		18
769	Risk Stratification in Nonischemic Dilated Cardiomyopathy in the Era of Personalized Medicine: Can Cardiac Magnetic Resonance With Late Gadolinium Imaging "Enhance" Our Strategy?. <b>2018</b> , 11, 1285-1287		2
768	Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry. <b>2018</b> , 29, 1540-1547		2

767	A Contemporary Survey on Energy Harvesting Techniques for Next Generation Implantable Bio-Medical Devices. <b>2018</b> , 9, 11-28	
766	Right Ventricular Dysfunction and Long-Term Risk of Sudden Cardiac Death in Patients With and Without Severe Left Ventricular Dysfunction. <b>2018</b> , 11, e006091	20
765	Arthur J. Moss (1931-2018). <b>2018</b> , 23, e12556	78
764	Risk Factors and Temporal Trends of Complications Associated With Transvenous Implantable Cardiac Defibrillator Leads. <b>2018</b> , 7,	28
763	If We Knew Then What We Know Now: Change in Ejection Fraction Post-Myocardial Infarction and Outcome. <b>2018</b> , 4, 683-685	
762	In memoriam Dr Arthur J. Moss. <b>2018</b> , 20, 1060-1062	
761	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <b>2018</b> , 20, 1031-1038	18
760	Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA. <b>2018</b> , 20, 1882-1897	15
759	Decompensated Heart Failure With Ventricular Arrhythmia: How Useful Is VT Ablation?. <b>2018</b> , 15, 201-213	
758	Ischemic Cardiomyopathy. <b>2018</b> , 145-154	0
757	Differential multivariable risk prediction of appropriate shock versus competing mortality - A prospective cohort study to estimate benefits from ICD therapy. <b>2018</b> , 272, 102-107	15
756	Electronics and orthopaedic surgery. <b>2018</b> , 49 Suppl 1, S102-S104	2
755	Left ventricular sphericity index analysis for the prediction of appropriate implantable cardioverter-defibrillator therapy. <b>2018</b> , 41, 1192-1196	4
754	Risk factors and prognostic role of an electrical storm in patients after myocardial infarction with an implanted ICD for secondary prevention. <b>2018</b> , 14, 500-509	2
753	Cardiac Arrhythmia in Heart Failure. <b>2018</b> , 394-410	
752	Evaluation of a novel automatic screening tool for determining eligibility for a subcutaneous implantable cardioverter-defibrillator. <b>2018</b> , 272, 97-101	9
751	Clinical Usefulness of Wearable Cardioverter Defibrillator (WCD) and Current Understanding of Its Clinical Indication in Japan. <b>2018</b> , 82, 1481-1486	8
750	A peripheral blood transcriptome biomarker test to diagnose functional recovery potential in advanced heart failure. <b>2018</b> , 12, 619-635	7

749	Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz. <b>2018</b> , 32, 381-390	
748	Safety, Efficacy and Evidence Base for Use of the Subcutaneous Implantable Cardioverter Defibrillator. <b>2018</b> , 7,	8
747	Removal of subcutaneous defibrillator shocking coils: Lessons to learn for future extraction of subcutaneous defibrillator systems. <b>2018</b> , 41, 1341-1344	5
746	Predictors of long-term mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. <b>2018</b> , 41, 1358-1366	3
745	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <b>2018</b> , 72, e91-e220	411
744	The multiple arrhythmia dataset evaluation database (M.A.D.A.E.). <b>2018</b> , 51, S106-S112	1
743	Current indications for transplantation: stratification of severe heart failure and shared decision-making. <b>2018</b> , 7, 56-66	11
742	Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation. <b>2018</b> , 111, 758-765	3
741	FDA perspective on assessing the clinical benefit of cardiac resynchronization and implantable cardioverter-defibrillator devices. <b>2018</b> , 51, S22-S24	
740	Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in Older Adults With Heart Failure. <b>2019</b> , 67, 2193-2199	4
739	For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death. <b>2019</b> , 21, 106	3
738	Basic Principles of Cardiac Electrophysiology. <b>2019</b> , 103, 767-774	6
737	Cardiac Implantable Electronic Device Therapy: Permanent Pacemakers, Implantable Cardioverter Defibrillators, and Cardiac Resynchronization Devices. <b>2019</b> , 103, 931-943	12
736	Ventricular Arrhythmias in Ischemic Cardiomyopathy: Is Imaging-Based Entropy a Biologically Relevant Risk Marker?. <b>2019</b> , 5, 490-492	1
735	Digitalis Therapy and Risk of Recurrent Ventricular Tachyarrhythmias and ICD Therapies in Atrial Fibrillation and Heart Failure. <b>2019</b> , 142, 129-140	3
734	Common Postcardiothoracic Surgery Arrhythmias. <b>2019</b> , 31, 367-388	2
733	Non-ST Elevation Myocardial Infarction: Diagnosis and Management. <b>2019</b> ,	2
732	Association between the Charlson comorbidity index and outcomes after implantable cardioverter defibrillator generator replacement. <b>2019</b> , 42, 1236-1242	2



731	Percutaneous Coronary Intervention With Drug-Eluting Stent Versus Optimal Medical Therapy for Chronic Total Occlusion: Systematic Review and Meta-Analysis. <b>2019</b> , 70, 908-915	5
730	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. <b>2019</b> , 21, 1843-1850	5
729	Twiddler's Syndrome. <b>2019</b> , 3, 299-300	0
728	Heart failure as a substrate and trigger for ventricular tachycardia. <b>2019</b> , 56, 229-247	17
727	Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients. <b>2019</b> , 19, 230	0
726	Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2019</b> , 12, e007600	9
725	GDMT for heart failure and the clinician's conundrum. <b>2019</b> , 42, 1155-1161	4
724	Are Atrial High-Rate Episodes Associated With Increased Risk of Ventricular Arrhythmias and Mortality?. <b>2019</b> , 5, 1197-1208	10
723	Minimal defibrillation thresholds and the correlation with implant position in subcutaneous implantable-defibrillator patients. <b>2019</b> , 30, 2441-2447	6
722	Effects of dietary crude protein and tannic acid on nitrogen excretion, urinary nitrogenous composition and urine nitrous oxide emissions in beef cattle. <b>2019</b> , 103, 1675-1683	3
721	Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. <b>2019</b> , 21, 1248-1258	15
720	Clinical Indications for Therapeutic Cardiac Devices. <b>2019</b> ,	0
719	Cardiopulmonary Exercise Testing in Patients with Implantable Cardioverter-Defibrillator: A Retrospective Study. <b>2019</b> ,	
718	Sudden Cardiac Death: Who Is at Risk?. <b>2019</b> , 103, 913-930	16
717	Who Should Receive a Wearable Defibrillator Vest at Hospital Discharge?. <b>2019</b> , 21, 125	
716	The Effect of Shock Burden on Heart Failure and Mortality. <b>2019</b> , 1, 161-167	4
715	A Population-Based Study of Device Eligibility, Use, and Reasons for Nonimplantation in Patients at Heart Function Clinics. <b>2019</b> , 1, 173-181	0
714	The clinical effect of arrhythmia monitoring after myocardial infarction (BIO-GUARD MI):study protocol for a randomized controlled trial. <b>2019</b> , 20, 563	3

713	Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients. <b>2019</b> , 8,	19
712	The subcutaneous implantable cardioverter-defibrillator in review. <b>2019</b> , 217, 131-139	16
711	Transcoronary mapping and chemical ablation of ventricular tachycardia in no-entry left ventricle. <b>2019</b> , 20, 138-141	2
710	Cardiac Implantable Electronic Device Therapy in Heart Failure. <b>2019</b> , 124, 1584-1597	17
709	The wearable cardioverter-defibrillator vest: Indications and ongoing questions. <b>2019</b> , 62, 256-264	2
708	Increasing age is associated with recurrent ventricular tachyarrhythmias and appropriate ICD therapies secondary to documented index ventricular tachyarrhythmias. <b>2019</b> , 10, 567-576	0
707	Sex difference in inappropriate therapy and survival among 1471 implantable cardioverter-defibrillator recipients. <b>2019</b> , 30, 1620-1625	7
706	The Benefit of Prophylactic Implantable Cardioverter Defibrillator Implantation in Asymptomatic Heart Failure Patients With a Reduced Ejection Fraction. <b>2019</b> , 124, 560-566	1
705	Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018). <b>2019</b> , 40, 1862-1869	70
704	[Fitness to drive in patients with cardiovascular implantable electronic devices]. <b>2019</b> , 30, 150-155	
703	Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. <b>2019</b> , 12, e006951	5
702	Metal Artifact Reduction in Cardiovascular MRI for Accurate Myocardial Scar Assessment in Patients With Cardiac Implantable Electronic Devices. <b>2019</b> , 213, 555-561	8
701	Whom to further monitor in remote monitoring?. <b>2019</b> , 19, 98-99	
700	Optogenetic Hyperpolarization of Cardiomyocytes Terminates Ventricular Arrhythmia. <b>2019</b> , 10, 498	17
699	Cluster Randomized Trial Examining the Impact of Automated Best Practice Alert on Rates of Implantable Defibrillator Therapy. <b>2019</b> , 12, e005024	4
698	Does the heart transplant have a future?. <b>2019</b> , 55, i38-i48	18
697	New Approaches in the Management of Sudden Cardiac Death in Patients with Heart Failure-Targeting the Sympathetic Nervous System. <b>2019</b> , 20,	12
696	Impact of chronic kidney disease on recurrent ventricular tachyarrhythmias in ICD recipients. <b>2019</b> , 34, 1811-1822	5

695	The Design of a Thermoelectric Generator and Its Medical Applications. <b>2019</b> , 3, 22	31
694	The subcutaneous implantable cardioverter-defibrillator: Current trends in clinical practice between guidelines and technology progress. <b>2019</b> , 65, 6-11	1
693	Evolution of extravascular implantable defibrillator technologies. <b>2019</b> , 62, 249-255	2
692	Device Therapy in the Heart Failure. <b>2019</b> , 129-153	1
691	Primary prevention ICD generator at end of life: to replace or not to replace?. <b>2019</b> , 11, e011167	78
690	Nine contemporary therapeutic directions in heart failure. <b>2019</b> , 11, e011150	1
689	Update on heart failure management and future directions. <b>2019</b> , 34, 11-43	48
688	Algorithm-based reduction of inappropriate defibrillator shock: Results of the Inappropriate Shock Reduction with PARAD+ Rhythm DiScrimination-Implantable Cardioverter Defibrillator Study. <b>2019</b> , 16, 1429-1435	6
687	Optical Mapping of Arrhythmogenic Remodeling in the Failing Human Heart. <b>2019</b> , 431-447	
686	The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. <b>2019</b> , 21, 900-908	7
685	An update on the CardioMEMS pulmonary artery pressure sensor. <b>2019</b> , 13, 1753944719826826	14
684	Heart Failure. <b>2019</b> ,	
683	Does stress echocardiography add incremental value to baseline ejection fraction for the early identification of candidates for implantable defibrillators?. <b>2019</b> , 6, e001053	
682	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <b>2019</b> ,	30
681	Coronary risk stratification of patients with newly diagnosed heart failure. <b>2019</b> , 6, e001074	1
680	Ventricular Tachycardia Ablation: Past, Present, and Future Perspectives. <b>2019</b> , 5, 1363-1383	27
679	Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology. <b>2019</b> , 9,	5
678	Comparable survival in ischemic and nonischemic cardiomyopathy secondary to ventricular tachyarrhythmias and aborted cardiac arrest. <b>2019</b> , 30, 303-311	3

677	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. <b>2019</b> , 83, 2084-2184	228
676	Added Value of 3- Versus 2-Dimensional Echocardiography Left Ventricular Ejection Fraction to Predict Arrhythmic Risk in Patients With Left Ventricular Dysfunction. <b>2019</b> , 12, 1917-1926	5
675	Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis. <b>2019</b> , 274, 163-169	2
674	Ventricular tachycardia prediction in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. <b>2019</b> , 19, 57-62	
673	Contemporary Treatment of Heart Failure. <b>2019</b> , 11, 21-37	3
672	Cardiac implantable electronic device (CIED) infections are expensive and associated with prolonged hospitalisation: UK Retrospective Observational Study. <b>2019</b> , 14, e0206611	14
671	The Difficult Extra Beats Cases. <b>2019</b> , 27-36	
670	Modes of death and prognostic outliers in chronic heart failure. <b>2019</b> , 208, 100-109	5
669	Sudden Death Risk-Stratification in 2018-2019: The Old and the New. <b>2019</b> , 28, 57-64	11
668	Non-ischemic cardiomyopathy in the elderly: A shocking conundrum. <b>2019</b> , 19, 1-3	
667	Can we rely on Danish? Real-world data on patients with nonischemic cardiomyopathy from the German Device Registry. <b>2019</b> , 34, 1196-1202	2
666	Perceived control and quality of life among recipients of implantable cardioverter defibrillator. <b>2019</b> , 32, 383-390	3
665	Catheter Ablation of Post-Infarct VT: Mechanisms, Strategies and Outcomes. <b>2019</b> , 28, 76-83	3
664	Current Device Therapies for Sudden Cardiac Death Prevention - the ICD, Subcutaneous ICD and Wearable ICD. <b>2019</b> , 28, 65-75	11
663	Common Atrial and Ventricular Arrhythmias. <b>2019</b> , 419-447	
662	Reflections on the early invasive clinical cardiac electrophysiology era through fifty manuscripts: 1967-1992. <b>2019</b> , 35, 7-17	3
661	Conscious sedation during subcutaneous implantable cardioverter-defibrillator implantation using the intermuscular technique. <b>2019</b> , 54, 59-64	7
660	Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects. <b>2019</b> , 207, 1-9	12

659	Recommendations for the use of electrophysiological study: Update 2018. <b>2019</b> , 60, 82-100	10
658	Probabilistic reachability for multi-parameter bifurcation analysis of cardiac alternans. <b>2019</b> , 765, 158-169	5
657	Investigation of the factorial structure and psychometrics of the German version of the Florida Shock Anxiety Scale. <b>2020</b> , 25, 344-353	0
656	Impact of defibrillation threshold testing on burden of heart failure hospitalizations. <b>2020</b> , 75, 226-232	
655	Prediction of Sudden Cardiac Death in Implantable Cardioverter Defibrillators: A Review and Comparative Study of Heart Rate Variability Features. <b>2020</b> , 13, 5-16	6
654	No light without the dark: Perspectives and hindrances for translation of cardiac optogenetics. <b>2020</b> , 154, 39-50	9
653	Sex Differences in Electrophysiology, Ventricular Tachyarrhythmia, Cardiac Arrest and Sudden Cardiac Death Following Acute Myocardial Infarction. <b>2020</b> , 29, 1025-1031	8
652	Technological and Clinical Challenges in Lead Placement for Cardiac Rhythm Management Devices. <b>2020</b> , 48, 26-46	4
651	Declining clinical benefit of ICD in heart failure patients: Temporal trend of mortality outcomes from randomized controlled trials. <b>2020</b> , 75, 148-154	6
650	Risk stratification for cardiac mortality using electrocardiographic markers based on 24-hour Holter recordings: the JANIES-SHD study. <b>2020</b> , 75, 155-163	8
649	Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry. <b>2020</b> , 109, 508-512	3
648	Management of Arrhythmias and Device Therapy in Heart Failure. <b>2020</b> , 549-567	
647	New perspectives and future directions in the treatment of heart failure. <b>2020</b> , 25, 147-159	17
646	Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators. <b>2020</b> , 43, 196-200	3
645	The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome. <b>2020</b> , 41, 2003-2011	11
644	Temporal changes of noninvasive electrocardiographic risk factors for sudden cardiac death in post-myocardial infarction patients with preserved ejection fraction: Insights from the PRESERVE-EF study. <b>2020</b> , 25, e12701	3
643	Long-term follow-up of implantable cardioverter defibrillator patients with regard to appropriate therapy, complications, and mortality. <b>2020</b> , 43, 245-253	4
642	Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS-QI 33). <b>2020</b> , 36, 153-163	3

- 641 Videos to reduce racial disparities in ICD therapy Via Innovative Designs (VIVID) trial: Rational, design and methodology. **2020**, 220, 59-67 0
- 640 Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy. **2020**, 7, 279-283 6
- 639 Chronic heart failure. **2020**, 153-168
- 638 The role of amiodarone in contemporary management of complex cardiac arrhythmias. **2020**, 151, 104521 20
- 637 Contemporary approach to treating heart failure. **2020**, 30, 507-518 3
- 636 Prospective evaluation of outcome of Indian patients who meet MADIT II (Multicenter Automatic Defibrillator Implantation Trial) criteria for implantable cardioverter defibrillator implantation: is it appropriate for Indian patients?. **2020**, 72, 172-178 0
- 635 Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. **2020**, 8, 844-855 18
- 634 Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. **2020**, 133, 116-125 2
- 633 MAGNETO cardiography parameters to predict future Sudden Cardiac Death (MAGNETO-SCD) or ventricular events from implantable cardioverter defibrillators: study protocol, design and rationale. **2020**, 10, e038804 0
- 632 Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design. **2020**, 11, 2739-2755 0
- 631 Age, Sex, and Remote Monitoring Differences in Device Acceptance for Patients With Implanted Cardioverter Defibrillators in Canada. **2020**, 2, 483-489 4
- 630 Cause-specific death and risk factors of one-year mortality after implantable cardioverter-defibrillator implantation: a nationwide study. **2020**, 1 1
- 629 Sex-specific arrhythmia risk of post-MI follow-up. **2020**, 583-593
- 628 Sex differences in implantable cardioverter defibrillators. **2020**, 843-853
- 627 Short-Term Variability of the QT Interval Can be Used for the Prediction of Imminent Ventricular Arrhythmias in Patients With Primary Prophylactic Implantable Cardioverter Defibrillators. **2020**, 9, e018133 4
- 626 The secret of success of heart failure therapy: A lesson for ACHD?. **2020**, 1, 100003
- 625 Global longitudinal strain for prediction of ventricular arrhythmia in patients with heart failure. **2020**, 7, 2956-2961 5
- 624 Long-term follow-up of the two-incision implantation technique for the subcutaneous implantable cardioverter-defibrillator. **2020**, 43, 1476-1480 6

623	Subcutaneous or Transvenous Defibrillator Therapy. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 526-536.	99.2
622	Value of Blood-Based microRNAs in the Diagnosis of Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. <b>2020</b> , 11, 691	5
621	The subcutaneous ICD for prevention of sudden cardiac death: Current evidence and future directions. <b>2020</b> , 43, 1421-1427	2
620	Evaluation of a Novel Educational Intervention to Improve Conversations About Implantable Cardioverter-Defibrillators Management in Patients with Advanced Heart Failure. <b>2020</b> , 23, 1619-1625	2
619	Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper. <b>2020</b> , 113, 359-366	2
618	Cardiac arrhythmias in low- and middle-income countries. <b>2020</b> , 10, 350-360	4
617	Cardiac MRI for Patients With Cardiac Implantable Electronic Devices. <b>2020</b> , 215, 374-381	0
616	A Qualitative Analysis of Patient-Related Factors Associated With Implantable Cardioverter Defibrillator Acceptance. <b>2020</b> , 9, 421-432	1
615	Recommendations for driving after implantable cardioverter defibrillator implantation and the use of a wearable cardioverter defibrillator : Different viewpoints around the world. <b>2020</b> , 132, 770-781	0
614	Long-term follow-up of abandoned transvenous defibrillator leads: a nationwide cohort study. <b>2020</b> , 22, 1097-1102	1
613	Prevention of Sudden Cardiac Death: Focus on the Subcutaneous Implantable Cardioverter-Defibrillator. <b>2020</b> , 27, 291-297	
612	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <b>2020</b> , 36, 553-607	25
611	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <b>2020</b> , 36, 553-607	11
610	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <b>2020</b> , 17, e269-e316	7
609	Tachyarrhythmia discriminator for implantable cardioverter-defibrillators in bundle branch block. <b>2020</b> , 17, 1561-1565	
608	Improving the care for female subcutaneous ICD patients: A qualitative study of gender-specific issues. <b>2020</b> , 317, 91-95	0
607	Impact of different selection policies on subcutaneous ICD implants and therapies. <b>2020</b> , 43, 558-565	1
606	Substrate Spatial Complexity Analysis for the Prediction of Ventricular Arrhythmias in Patients With Ischemic Cardiomyopathy. <b>2020</b> , 13, e007975	11

605	Driving restriction in patients with cardiac implantable electronic devices: an overview of worldwide regulations. <b>2020</b> , 17, 297-308	2
604	Handling of Ventricular Fibrillation in the Emergency Setting. <b>2019</b> , 10, 1640	4
603	Non-ischemic compared to ischemic cardiomyopathy is associated with increasing recurrent ventricular tachyarrhythmias and ICD-related therapies. <b>2020</b> , 59, 174-180	1
602	Infections of Cardiac Implantable Devices. <b>2020</b> ,	1
601	Clinical outcomes after primary prevention defibrillator implantation are better predicted when the left ventricular ejection fraction is assessed by cardiovascular magnetic resonance. <b>2020</b> , 22, 48	3
600	One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. <b>2020</b> , 22, 859-867	10
599	Programming implantable cardioverter-defibrillator in primary prevention: Guideline concordance and outcomes. <b>2020</b> , 17, 1101-1106	9
598	Prognosis of Type 2 Myocardial Infarction Patients Implanted With a Prophylactic Defibrillator (from the Very-High-Rate Registry). <b>2020</b> , 125, 1001-1005	1
597	Device Therapy for Sudden Cardiac Death Prophylaxis After Acute Coronary Syndrome: When and Why?. <b>2020</b> , 22, 4	
596	Implementation, feasibility, and acceptability of quality of life therapy to improve positive emotions among patients with implantable cardioverter defibrillators. <b>2020</b> , 43, 968-978	3
595	Impact of Left Ventricular Ejection Fraction on Recurrent Ventricular Tachyarrhythmias in Recipients of Implantable Cardioverter Defibrillators. <b>2020</b> , 145, 359-369	1
594	Implantable Cardioverter-Defibrillators in Trials of Drug Therapy for Heart Failure: A Systematic Review and Meta-Analysis. <b>2020</b> , 9, e015177	1
593	Practice guidelines for the diagnosis and management of systolic heart failure in low- and middle-income countries. <b>2013</b> , 8, 141-70	4
592	Defibrillation threshold testing during implantable cardioverter defibrillator implantation: 5-year follow-up. <b>2021</b> , 60, 485-491	
591	Implantable Cardioverter Defibrillators and Chronic Kidney Disease. <b>2021</b> , 46, 100639	1
590	Recent Developments in Cardiology Procedures for Adult Congenital Heart Disease: The Anesthesiologist's Perspective. <b>2021</b> , 35, 741-751	3
589	Knowing Times: Temporalities of Evidence for Implantable Cardioverter Defibrillators. <b>2021</b> , 46, 628-654	0
588	Implantable cardiac devices in adult patients with repaired tetralogy of Fallot. <b>2021</b> , 55, 22-28	



587	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. <b>2021</b> , 143, 7-17	29
586	Biventricular pacemaker and defibrillator implantation in patients with chronic heart failure in China. <b>2021</b> , 8, 546-554	2
585	Heart rate variability feature selection method for automated prediction of sudden cardiac death. <b>2021</b> , 65, 102310	7
584	Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator. <b>2021</b> , 18, 404-410	3
583	Reassessment of practical usage and accumulation of real-world data of wearable cardioverter defibrillator (WCD) in Japan-Design paper for J-WCDR study. <b>2021</b> , 37, 226-230	
582	Sudden cardiac death in dialysis patients: different causes and management strategies. <b>2021</b> , 36, 396-405	16
581	Ventricular Arrhythmias. <b>2021</b> , 331-347	
580	Role of ICD and CRT. <b>2021</b> , 349-362	
579	Indications and Use of the Wearable Cardioverter-Defibrillator. <b>2021</b> , 265-273	
578	Lessons Learned from Implantable Cardioverter-Defibrillator Recordings. <b>2021</b> , 259-286	
577	Precision prevention with ICDs: can a simple score improve patient selection?. <b>2021</b> , 42, 1685-1686	1
576	Novel Approaches to Risk Assessment for Ventricular Tachycardia Induction and Therapy. <b>2021</b> , 15, 1	
575	The benefits of defibrillator in heart failure patients with cardiac resynchronization therapy: A meta-analysis. <b>2021</b> , 44, 225-234	0
574	Regional Disparities in Adherence to Guidelines for the Treatment of Chronic Heart Failure. <b>2021</b> , 60, 525-532	0
573	Prognosis of Japanese Patients With Coronary Artery Disease Who Underwent Implantable Cardioverter Defibrillator Implantation - The JID-CAD Study. <b>2021</b> , 3, 69-76	
572	The impact of transvenous cardioverter-defibrillator implantation on quality of life, depression and optimism in dialysis patients: report on the secondary outcome of QOL in the randomized controlled ICD2 trial. <b>2021</b> , 30, 1605-1617	1
571	Comparison of 2-year outcomes between primary and secondary prophylactic use of defibrillators in patients with coronary artery disease: A prospective propensity score-matched analysis from the Nippon Storm Study. <b>2021</b> , 2, 5-11	3
570	Novel Implantable Cardioverter Defibrillator Programming With High Rate Cut-Off, Long Detection Intervals and Multiple Anti-Tachycardia Pacing Reduces Mortality. <b>2021</b> , 85, 291-299	1

- 569 Factors associated with recurrent postinfarction ventricular tachycardia following ablation. **2021**, 69, 50-60
- 568 The efficacy of catheter ablation versus ICD for prevention of ventricular tachycardia in patients with ischemic heart disease: a systematic review and meta-analysis. **2021**, 61, 435-443 1
- 567 Cardiac resynchronization therapy with or without defibrillation: a long-standing debate. **2021**,
- 566 Indications for Pacemakers, Implantable Cardioverter-Defibrillators, and Cardiac Resynchronization Therapy. **2021**, 86-124
- 565 Highlights and comments on EHRA/HRS/APHRS/LAQRS expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome. **2021**, 62, 461-467
- 564 Coste-efectividad del desfibrilador automático implantable para la prevención primaria de la muerte súbita cardíaca. **2021**, 2
- 563 The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape. **2021**, 37, 644-654 2
- 562 Sudden Cardiac Death in Patients with Heart Disease and Preserved Systolic Function: Current Options for Risk Stratification. **2021**, 10, 4
- 561 Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study. **2021**, 24, 648-657 2
- 560 The Defibrillation Conundrum: New Insights into the Mechanisms of Shock-Related Myocardial Injury Sustained from a Life-Saving Therapy. **2021**, 22, 1
- 559 Epicardial Ablation of Ventricular Tachycardia by Re-median Sternotomy in a Patient with Double Mechanical Heart Valves. **2021**, 50, 174-177
- 558 Cardiac sympathetic denervation and mental health. **2021**, 232, 102787 1
- 557 Association between integrated backscatter and arrhythmia in patients with ischemic dilated cardiomyopathy. **2021**, 44, 1010-1017
- 556 The relation between QRS complex fragmentation and segmental abnormalities of the myocardial contractility in patients with coronary artery disease. **2021**, 73, 325-330
- 555 RR interval variability in the evaluation of ventricular tachycardia and effects of implantable cardioverter defibrillator therapy. **2021**, 37, 1052-1060
- 554 Ablative radiosurgery for cardiac arrhythmias - A systematic review. **2021**, 25, 373-379
- 553 JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. **2021**, 85, 1104-1244 17
- 552 CHADS-VASC score predicts coronary artery disease progression and mortality after ventricular arrhythmia in patients with implantable cardioverter-defibrillator. **2021**, 34, 100802 1

551	Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. <b>2021,</b>	0
550	Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. <b>2021, 18, 1012-1023</b>	11
549	JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. <b>2021, 37, 709-870</b>	22
548	The Subcutaneous ICD: A Review of the UNTOUCHED and PRAETORIAN Trials. <b>2021, 10, 108-112</b>	1
547	Characterization of the Electrophysiologic Remodeling of Patients With Ischemic Cardiomyopathy by Clinical Measurements and Computer Simulations Coupled With Machine Learning. <b>2021, 12, 684149</b>	3
546	CHA2DS2-VASc and HAS-BLED scores are not associated with cardiac defibrillators therapies. <b>2021, 63, 304-311</b>	
545	The mortality analysis of primary prevention patients receiving a cardiac resynchronization defibrillator (CRT-D) or implantable cardioverter-defibrillator (ICD) according to guideline indications in the improve SCA study. <b>2021, 32, 2285-2294</b>	0
544	Assessment of primary prevention patients receiving an ICD - Systematic evaluation of ATP: APPRAISE ATP. <b>2021, 2, 405-411</b>	1
543	Electrical Stimulation for Low-Energy Termination of Cardiac Arrhythmias: a Review. <b>2021, 1</b>	1
542	Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary Implantable Cardioverter-Defibrillator Therapy. <b>2021,</b>	1
541	Comparison of mortality prediction scores in elderly patients with ICD for heart failure with reduced ejection fraction. <b>2021, 1</b>	1
540	Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. <b>2021, 26, 4600</b>	9
539	Preventive implantable cardioverter defibrillator therapy in contemporary clinical practice: need for more stringent selection criteria. <b>2021, 8, 3656-3662</b>	1
538	Predictors of Total Mortality and Serious Arrhythmic Events in Non-Ischemic Heart Failure Patients: The Role of Galectin-3. <b>2021, 117, 531-541</b>	0
537	Outcomes for patients with anterior myocardial infarction and prior cardiac arrest in the home automated external defibrillator trial (HAT). <b>2021, 168, 75-83</b>	0
536	The ECG in Other Heart Diseases. <b>2021, 498-519</b>	
535	Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PET. <b>2021, 46, 807-813</b>	10
534	Tachykarde Rhythmusstörungen. <b>2021, 148-177</b>	

533	Home Monitoring bei Patienten mit implantiertem Defibrillator und kardialer Resynchronisationstherapie. <b>2006</b> , 47-54	1
532	Guidelines for the Prevention of Sudden Cardiac Death: Filling the Gap. <b>2005</b> , 223-230	1
531	Management of Postoperative Arrhythmias. <b>2010</b> , 209-227	2
530	Sudden Cardiac Arrest: A Biopsychosocial Approach to Patient Management of Ventricular Fibrillation and Implantable Cardioverter Defibrillators. <b>2012</b> , 25-43	4
529	Temporary and Permanent Pacemakers and Automated Internal Defibrillators. <b>2014</b> , 3019-3047	1
528	Senescence and Arrhythmogenesis. <b>2013</b> , 317-332	1
527	Clinical Trials. <b>1998</b> , 197-209	1
526	Clinical Results. <b>1996</b> , 477-500	1
525	Congestive Heart Failure. <b>2012</b> , 91-111	3
524	Hypertrophic Cardiomyopathy. <b>2007</b> , 1261-1284	1
523	Clinical Cardiac Electrophysiology. <b>2010</b> , 1133-1161	1
522	Heart Failure due to Left Ventricular Systolic Dysfunction. <b>2020</b> , 149-175	1
521	Cardiac Implantable Electronic Devices. <b>2017</b> , 285-294	2
520	Approach to Arrhythmia in Heart Failure. <b>2016</b> , 243-267	1
519	Devices for Heart Failure: Implantable Cardioverter Defibrillator. <b>2016</b> , 269-291	1
518	Open-Source Environment for Interactive Finite Element Modeling of Optimal ICD Electrode Placement. <b>2007</b> , 373-382	2
517	Plötzlicher Herztod. <b>2004</b> , 437-448	0
516	Sudden cardiac death. <b>2000</b> , 621-645	1

515	Implantable Cardioverter-Defibrillator Therapy. <b>2000</b> , 287-416	0
514	The Madit Trial: What was Wrong?. <b>1998</b> , 121-124	2
513	Prophylactic Implantation of Implantable Cardioverter/Defibrillators in Post-Myocardial Infarction Patients. <b>1998</b> , 305-310	2
512	Sudden Cardiac Death. <b>2004</b> , 720-731	9
511	Class III Antiarrhythmic Drugs: Amiodarone, Ibutilide, and Sotalol. <b>2004</b> , 932-941	8
510	Implantable Cardiac Pulse Generators: Pacemakers and Cardioverter-Defibrillators. <b>2010</b> , 1387-1409	1
509	Clinical Trials of Defibrillator Therapy. <b>2007</b> , 357-384	2
508	Antiarrhythmic Drugs and Strategies. <b>2009</b> , 235-292	2
507	Cardiac Arrest and Sudden Cardiac Death. <b>2012</b> , 845-884	6
506	Arythmies ventriculaires, mort subite et insuffisance cardiaque. <b>2010</b> , 194, 997-1008	2
505	Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure. <b>2021</b> , 28, 110-123	5
504	Ventricular Tachycardia and Sudden Cardiac Death. <b>2009</b> , 1133-1172	1
503	Recipient selection and management before cardiac transplantation. <b>1997</b> , 314, 139-52	16
502	Pacing therapy for congestive heart failure: is it ready for prime time?. <b>1999</b> , 14, 1-3	8
501	Technologic advances in implantable cardioverter defibrillators. <b>1999</b> , 14, 9-14	7
500	Air pollution and incidence of cardiac arrhythmia. <b>2000</b> , 11, 11-7	512
499	Prescribing exercise training for patients with defibrillators. <b>2000</b> , 79, 292-7	23
498	Patients with implantable cardioverter defibrillators: transition to home. <b>2000</b> , 14, 42-52	16

497	Sudden cardiac death in heart failure. <b>2000</b> , 14, 38-56	7
496	Supportive communication with implantable cardioverter defibrillator patients: seven principles to facilitate psychosocial adjustment. <b>2000</b> , 20, 109-14	26
495	Fear of exertion following ICD storm: considering ICD shock and learning history. <b>2001</b> , 21, 47-9	15
494	Living with an implantable cardioverter-defibrillator: a review of the current literature related to psychosocial factors. <b>2001</b> , 12, 156-63	44
493	Original research: deactivation of ICDs at the end of life: a systematic review of clinical practices and provider and patient attitudes. <b>2011</b> , 111, 26-35	78
492	Ejection fraction and QRS width as predictors of event rates in patients with implantable cardioverter defibrillators. <b>2005</b> , 98, 513-7	3
491	Left Ventricular Ejection Fraction for Sudden Death Risk Stratification and Guiding Implantable Cardioverter-defibrillators Implantation. <b>2010</b> , 55, 450-455	31
490	Minimizing Population Health Loss in Times of Scarce Surgical Capacity.	1
489	Experiences of adults living with an implantable cardioverter defibrillator for cardiovascular disease: a systematic review of qualitative evidence. <b>2020</b> , 18, 2231-2301	1
488	Pacemaker and Defibrillator Infections. 247-264	17
487	Strong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice. <b>2001</b> , 86, 218-9	7
486	Treatment of sudden cardiac death. Current understandings from randomized trials and future research directions. <b>1997</b> , 95, 2694-9	39
485	Saving Time Saves Lives. <b>2001</b> , 104, 2506-2508	6
484	Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction. <b>2016</b> , 57, 182-7	9
483	Thoracoscopic Implantation of An Array Electrode in the Pericardium Transverse Sinus to Reduce Defibrillation Threshold. <b>2017</b> , 12, e6-e9	1
482	Heart Rate Turbulence and Variability in Patients with Ventricular Arrhythmias. <b>2007</b> , 3, 182618680700300	2
481	Prediction of sudden death in elderly patients with heart failure. <b>2018</b> , 15, 185-192	8
480	Wearable Cardioverter Defibrillator - Initial Experience in the Outpatient Setting in Japan. <b>2020</b> , 2, 137-142	1

479	Recent advances in the entirely subcutaneous ICD System. <b>2015</b> , 7, 46	3
478	Development of a novel shock wave catheter ablation system--the first feasibility study in pigs. <b>2015</b> , 10, e0116017	6
477	Subcutaneous Implantable Cardioverter Defibrillators Implantation Without Defibrillation Threshold Testing: A Single Center Experience. <b>2017</b> , 8, 319-326	13
476	Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention. <b>2012</b> , 1, 46-50	4
475	The Entirely Subcutaneous Defibrillator - A New Generation and Future Expectations. <b>2015</b> , 4, 116-21	11
474	Sex Differences in Utilisation and Response to Implantable Device Therapy. <b>2015</b> , 4, 129-35	14
473	Arrhythmogenic Inflammatory Cardiomyopathy: A Review. <b>2018</b> , 7, 181-186	5
472	Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature. <b>2020</b> , 9, 175-181	2
471	The Limitations of Symptom-based Heart Failure Management. <b>2019</b> , 5, 74-77	4
470	The Subcutaneous Implantable Cardioverter-Defibrillator: New Insights and Expanding Populations. <b>2018</b> , 12, 66-70	1
469	Safety and efficiency of emergency department interrogation of cardiac devices. <b>2016</b> , 3, 239-244	4
468	Design of Korean Noninvasive Risk Evaluation Study for Sudden Cardiac Death from Infarction or Heart Failure [Myocardial infarction study of K-REDEFINE registry - <b>2017</b> , 18, 6-15	1
467	Implantable Cardioverter-Defibrillator of Korean Patients in a Single Center Registry. <b>2017</b> , 18, 155-167	2
466	Renal sympathetic denervation guided by renal nerve stimulation to treat ventricular arrhythmia in CKD patients with ICD. <b>2017</b> , 8, 37296-37307	8
465	Inappropriate ICD Shocks in Pediatric and Congenital Heart Disease Patients. <b>2017</b> , 8, 2898-2906	1
464	Risk Stratification of Sudden Cardiac Death After Acute Myocardial Infarction. <b>2018</b> , 9, 3035-3049	4
463	Efficacy of Implantable Cardioverter-defibrillators for Secondary Prevention of Sudden Cardiac Death in Patients with End-stage Renal Disease. <b>2020</b> , 11, 4199-4208	0
462	The evidence base for revascularisation of chronic total occlusions. <b>2014</b> , 10, 88-98	8

461	Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease. <b>2018</b> , 14, 60-66	5
460	Subcutaneous Implantable Cardioverter Defibrillators: An Overview of Implantation Techniques and Clinical Outcomes. <b>2019</b> , 15, 38-48	7
459	A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF). <b>2015</b> , 11, 23-32	15
458	Therapy of Acute Myocardial Infarction. <b>2008</b> , 293-326	2
457	Management of the Older Patient After Myocardial Infarction. <b>2008</b> , 327-350	2
456	Ventricular Arrhythmias in the Elderly. <b>2008</b> , 605-626	3
455	Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. <b>2014</b> , 18, 1-560	46
454	Zřady pro implantace kardiostimulátorů implantabilních kardioverter-defibrilátorů systémů pro srdeční resynchronizaci. <b>2009</b> , 51, 602-614	13
453	Komorová arytmie. <b>2011</b> , 53, 53-77	1
452	Usefulness of Sacubitril/Valsartan in reduction of atrial fibrillation burden in a patient with ICD delivering inappropriate therapies. A new possibility?. <b>2020</b> , 62, 336-339	5
451	Cardiac Implantable Electronic Miniaturized and Micro Devices. <b>2020</b> , 11,	5
450	Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death. <b>2016</b> , 90, 115-120	2
449	Notas sobre Tanacetum corymbosum s. l. (Asteraceae). 37, 013	1
448	Underutilization of Implantable Cardioverter Defibrillator in Primary Prevention of Sudden Cardiac Arrest. <b>2011</b> , 2, 1-6	3
447	Value of The Wearable Cardioverter Defibrillator (WCD) as a Bridging-Therapy before Implantation of a Cardioverter Defibrillator (ICD). <b>2016</b> , 8, 1247	1
446	The Wearable Cardioverter/Defibrillator - Toy Or Tool?. <b>2016</b> , 8, 1367	9
445	Quality of Life and Psychological Status of Patients With Implantable Cardioverter Defibrillators. <b>2006</b> , 15, 389-398	73
444	Sudden Cardiac Death: Clinical Perspectives from the University of Maiduguri Teaching Hospital, Nigeria. <b>2015</b> , 05, 95-106	3



443	Risk factors for sudden cardiac death to determine high risk patients in specific patient populations that may benefit from a wearable defibrillator. <b>2019</b> , 11, 103-119	2
442	Utility of electrophysiological studies to predict arrhythmic events. <b>2015</b> , 7, 344-50	21
441	Wearable cardioverter defibrillator: Bridge or alternative to implantation?. <b>2017</b> , 9, 531-538	9
440	Non-Sustained Ventricular Tachycardia Episodes Predict Future Hospitalization in ICD Recipients with Heart Failure. <b>2017</b> , 109, 284-289	3
439	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. <b>2019</b> , 35, 244-283	31
438	Stereotactic Arrhythmia Radioablation (STAR) of Ventricular Tachycardia: A Treatment Planning Study. <b>2016</b> , 8, e694	14
437	Cardiac Prognostic Impact of Implantable Cardioverter-Defibrillator Shock in Patients with Ventricular Arrhythmias.	
436	Characterization of the electrophysiological substrate in patients with Barlow's disease. <b>2021</b> , 32, 3179-3186	o
435	Antiarrhythmic Agents. <b>2000</b> , 54-84	
434	Risk Stratification for Serious Arrhythmic Events in Post-Infarction Patients. <b>2000</b> , 351-360	
433	Is the Implantable Defibrillator Cost-effective?. <b>2000</b> , 326-333	
432	Extrasystolie. <b>2000</b> , 105-112	
431	Pathogenese der Herzrhythmusstörungen. <b>2000</b> , 445-451	
430	Outpatient Therapy. <b>2000</b> , 149-200	
429	The BEST + ICD Trial: Is ICD Also Effective in the Presence of Optimized $\beta$ -Blocking Therapy?. <b>2000</b> , 386-397	
428	Methods of Non-Linear Dynamics. <b>2000</b> , 413-420	
427	EKG-Klassifikation: Bradykardien. <b>2000</b> , 461-467	
426	SEDET Trial: Is Noninvasive Evaluation Sufficient to Identify Patients at High Risk of Arrhythmia?. <b>2000</b> , 398-402	

- 425 Invasive Untersuchungsmethoden bei Vorhofflimmern/Vorhofflattern. **2000**, 51-63
- 424 Does Electrophysiologic Study Allow Further Risk Stratification in Survivors of Acute Myocardial Infarction?. **2000**, 379-385
- 423 An Overview of Secondary Prevention Implantable Cardioverter-Defibrillator Trials: AVID, CIDS and CASH. **2000**, 311-318
- 422 Therapie: Bradykardien. **2000**, 487-497
- 421 QT-Dispersion: Role in Clinical Decision Making. **2000**, 123-130
- 420 What Are the Clinical Implications of MUSTT?. **2000**, 407-412
- 419 Therapie: Tachykardien. **2000**, 499-521
- 418 Ventricular Fibrillation and Sudden Cardiac Death. **2000**, 763-792
- 417 Herzrhythmusstörungen. **2000**, 511-516
- 416 Antiarrhythmic Drug Therapy for Sudden Cardiac Death in CHF Guided by the Sicilian Gambit. **2000**, 121-125
- 415 T. **2001**, 428-453
- 414 A Retrospective Musing on Surgery for Cardiac Arrhythmias. **2001**, 537-560
- 413 Leitlinien zur Implantation von Defibrillatoren. **2001**, 78-86
- 412 Management of Cardiac Failure in the Intensive Care Unit. **2001**, 189-201
- 411 Indications for ICD Therapy. **2001**, 19-34
- 410 RBF Network Classification of ECGs as a Potential Marker for Sudden Cardiac Death. **2001**, 167-214
- 409 Richtlinien für die Durchführung der nichtinvasiven Diagnostik von Rhythmusstörungen. **2001**, 69-77
- 408 Tachykarde Rhythmusstörungen bei herzkranken Patienten: Wann sind sie nicht behandlungsbedürftig?. **2001**, 41-46

407 Implantable cardioverter-defibrillators. **2001**, 86, 221-226

406 Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: implications for UK electrophysiology centres; activity modelling from the UK-HEART study. **2001**, 86, 219-20 1

405 Patients Undergoing ICD Implantation: How Many Need Biventricular Pacing?. **2002**, 163-169

404 Multisite Pacing in ICD Patients: Which Benefits?. **2002**, 170-180

403 Adjunctive Antiarrhythmic Drug Therapy. **2002**, 245-257

402 Elektrokardiographie. **2002**, 105-177 1

401 T-Wave Alternans, a Powerful Index for Malignant Ventricular Arrhythmias-Fact or Fiction?. **2002**, 237-247

400 Implantation. **2002**, 77-112

399 Long-Term Follow-Up. **2002**, 161-243

398 Indication for ICD Therapy. **2002**, 1-14

397 Sophisticated Pacemaker Diagnostics: Are They Really Useful in Clinical Practice?. **2002**, 608-612

396 How Great Is the Arrhythmic Risk for Heart Failure Patients and Does Resynchronization Therapy Modify It?. **2002**, 151-156

395 Prevention of Sudden Death in Different Realities: Can We Reach a Consensus?. **2002**, 248-253

394 Syncope and ICD: What Are the Implications and Recommendations for Driving?. **2002**, 67-74

393 Amiodarone and  $\beta$ Blockers: Why This Combination?. **2002**, 261-265

392 Anxiety and Depression. **2002**, 351-394

391 New ICD Perspectives in the Congestive Heart Failure Patient. **2003**, 81-92

390 A Review of the SCD-HEFT, COMPANION, and CARE-HF Trials. **2003**, 395-400

389 Cardiovascular Emergencies. **2003**, 684-692

388 Cardiac Arrhythmias. **2003**, 644-662

387 T-Wave Alternans. **2003**, 507-530

386 Tachykarde Rhythmusstörungen. **2003**, 188-211

385 Ventricular Tachycardia in Patients with Hypertrophy and Heart Failure. **2004**, 608-617

384 Ventricular Arrhythmias in Hypertrophic Cardiomyopathy. **2004**, 601-607

383 Use of Long-term (Holter) Electrocardiographic Recordings. **2004**, 772-787

o

382 Langzeitelektrokardiographie. **2004**, 211-218

381 Post-infarction Patients with Left Ventricular Ejection Fraction of 30%-40%, Non-sustained Ventricular Tachycardia, and without Inducible Tachyarrhythmias: Is ICD Therapy Necessary?. **2004**, 481-487

380 Recent advances in arrhythmia treatment. **2004**, 50, 223-235

379 Primary Prevention of Sudden Death in Post-Infarction Patients: When ICD Implantation is Really Cost-effective. **2004**, 497-504

378 The Real Economic Impact of the MADIT-II Study on the European Medical Community. **2004**, 475-480

377 Left Ventricular Dysfunction and Electrophysiologic Study in the Primary and Secondary ICD Trials. **2004**, 463-468

376 Nicht-medikamentöse Therapie von Herzrhythmusstörungen. **2004**, 1009-1046

375 Herz, Gefäß, Lunge. **2004**, 81-196

374 Late ventricular potentials in risk assessment of the occurrence of complex ventricular arrhythmia in patients with myocardial infarction and heart failure. **2004**, 61, 589-97

o

373 Results of Clinical Trials of Automatic External Defibrillators and Implantable Cardioverter-Defibrillators in Patients at Risk for Sudden Death. **2004**, 901-909

372 Expanding ICD Indications: Can We Afford It?. **2004**, 511-517

371 Is ICD Implantation Useful in Patients with Arrhythmogenic Right-ventricular Cardiomyopathy?. **2004**, 323-329

370 Heart failure: an epidemic of the 21st century. **2004**, 3, 194-204

9

369 Cognitive behavioural therapy for patients with implantable cardioverter-defibrillators.

1

368 Pacing in Heart Failure. **2005**, 123-154

367 Evidence-based medicine and population-based care: caring for patients with heart failure. **2005**, 9, 65-9

366 Cardiac Arrhythmias and the Perioperative Period. **2005**, 323-366

365 Taquicardia ventricular. **2006**, 196-204

364 Marcapasos y desfibriladores cardíacos. **2006**, 248-255

363 Management of Ventricular Arrhythmias in Heart Failure. **2006**, 183-202

362 Sudden Death in Heart Failure: Risk Stratification and Treatment Strategies. **2007**, 1-20

361 Heart Failure. **2007**, 281-294

360 Syncope. **2007**, 2019-2037

359 Primary Prevention of Sudden Cardiac Death in Patients with Ischemic Heart Disease-Possible Role of the Shock Device in the Asia-. **2007**, 23, 264-268

358 Aging and the Cardiovascular System. **2007**, 2439-2451

357 Erkrankungen des Herzens. **2007**, 917-965

356 Aritmie en Asynchronie Bij Hartfalen: Geneesmiddelen en Implantaten. **2007**, 95-122

355 The Medical Management of Heart Failure. **2007**, 1397-1416

354 The Implantable Cardioverter-Defibrillator. **2007**, 2119-2138

- 353 Clinical usefulness of electrophysiologic study (EPS)-guided risk stratification for life-threatening arrhythmia in patients with heart failure. **2007**, 48, 155-63 1
- 352 Implantable Devices for the Management of Heart Failure. **2007**, 363-372
- 351 Intensive Care Unit Arrhythmias. **2007**, 431-443
- 350 Sudden Cardiac Death. **2007**, 2039-2083
- 349 The Role of Implantable Cardioverter-Defibrillators in Primary and Secondary Prevention of Sudden Cardiac Death. **2007**, 459-471 1
- 348 ST-Elevation Myocardial Infarction. **2007**, 246-289
- 347 Arrhythmias. **2007**, 323-335
- 346 Prevention and Treatment of Endocarditis. **2007**, 767-786
- 345 Heart rate turbulence and variability in patients with ventricular arrhythmias. **2007**, 3, 51
- 344 Ventricular Arrhythmias in Patients After Myocardial Infarction. **2008**, 190-203
- 343 Indications for Implantable Cardioverter Defibrillators. **2008**, 495-546
- 342 Current status of implantable defibrillator devices in patients with left ventricular dysfunction-The first report from the online registry database. **2008**, 24, 133-140 5
- 341 Complex Issues in the Follow-up of CRT Devices. **2008**, 495-505
- 340 38 De implanteerbare cardioverter-defibrillator. **2008**, 331-340
- 339 33 Ventriculaire ritmestoornissen. **2008**, 279-290
- 338 Management of Complications. **2008**, 280-299
- 337 Sudden Cardiac Death in Advanced Ischemic Heart Disease. **2009**, 37-47
- 336 An implantable defibrillator with dual-chamber pacing for a dialysis patient with diminished cardiac function following coronary artery bypass grafting and mitral valve replacement and maintenance of an acceptable level of activities of daily living. **2009**, 42, 105-111

335 Genetics and Genomics of Arrhythmias. **2009**, 729-754

334 ??????????????????. **2009**, 29, 189-199

0

333 RHYTHM DISORDERS. **2009**, 367-387

332 Obstructive sleep apnea syndrome. **2009**, 6, 15-21

331 Occupational and Regulatory Aspects of Heart Disease. **2009**, 1359-1370

330 Implantable Cardioverter-Defibrillators. **2010**, 155-184

329 Defibrillation Theory and Practice. 141-158

328 Effects of Wall Stress on the Dynamics of Ventricular Fibrillation: A Computer Simulation Study of Mechanoelectric Feedback. **2010**, 387-419

327 Sudden Cardiac Death. **2010**, 251-260

0

326 Heart Failure. **2010**, 1036-1053

325 Acute Decompensated Cardiac Failure. **2010**, 323-342

324 Anesthesia for Correction of Cardiac Arrhythmias. **2010**, 1977-1984

1

323 33 Ambulatory Electrocardiogram Monitoring. **2010**, 1417-1486

322 Clinical outcome of monomorphic ventricular tachycardias after electrophysiological study in patients with maintained left ventricular ejection fraction. **2010**, 30, 385-394

321 Ventricular Tachycardia. **2010**, 241-249

320 Rhythm and Conduction Disorders. **2010**, 201-256

319 Cardiac Pacing and Defibrillation. **2010**, 90-115

318 Primary prevention of sudden cardiac death - ICDs for every patient with ventricular dysfunction?. **2010**, 52, 30-35

1

- 317 Clinical Cardiac Electrophysiology: An Overview of Its Evolution. **2010**, 1-38
- 316 Ventricular Tachycardia. **2010**, 1291-1336
- 315 Cardiac Devices for the Treatment of Bradyarrhythmias and Tachyarrhythmias. **2010**, 1305-1327
- 314 Diagnostische Methoden. **2010**, 61-87
- 313 Cognitive behavioural therapy for patients with implantable cardioverter-defibrillators.
- 312 Common Atrial and Ventricular Arrhythmias. **2011**, 459-496
- 311 Nonsustained Ventricular Tachycardia. **2011**, 225-241
- 310 Ventricular Tachycardia and Fibrillation: Pharmacologic Therapy. **2011**, 243-255
- 309 Indications for Implantable Cardioverter-Defibrillators. **2011**, 283-303
- 308 Predictors of implantable cardioverter-defibrillator use in patients with ischemic cardiomyopathy. **2010**, 4, 206-13
- 307 Ventricular tachycardia. **2011**, 543-547
- 306 Non-farmacologische therapie : CRT(-D) en ICD. **2011**, 185-199
- 305 The Electrophysiology Laboratory and Electrophysiologic Procedures. **2011**, 243-288
- 304 Cardiac Pacing and Defibrillation. **2011**, 790-806
- 303 5.?????????????????????. **2011**, 31, 376-386
- 302 Implantable cardioverter defibrillators in patients with coronary artery disease. **2011**, 417-427
- 301 Management of ST-elevation myocardial infarction. **2011**, 474-484
- 300 Device Therapy in Heart Failure. **2011**, 694-703



299 Cardiac Electrophysiology. **2011**, 74-95

298 Clinical Trials of Defibrillator Therapy. **2011**, 257-278

297 Sudden Cardiac Death. **2011**, 594-603

296 Substrate Assessment: Echocardiography, MRI, and CCT. **2012**, 191-215

295 Arrhythmias. **2012**, 51-80

294 Assessment and management of the breathless patient. **2011**, 103-113

293 Ambulatory Electrocardiogram Monitoring. **2012**, 1-70

292 Ventricular Tachycardia. **2012**, 211-256

291 Clinical Cardiac Electrophysiology. **2012**, 53-81

290 Research in acute decompensated heart failure: challenges and opportunities. **2011**, 1, 1361-1373

289 Congestive Heart Failure. **2012**, 281-324

288 Prevention of Sudden Cardiac Death with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy. **2012**, 1239-1252

287 Implantable Cardiac Devices. **2012**, 253-265

286 Analysis of Sequential Clinical Trials. **2012**, 81-125

285 Diagnosis and management of ischemic cardiomyopathy. **2012**, 18, 226-232

1

284 Risk Stratification for Sudden Cardiac Death. **2012**, 997-1006

283 Ventricular and Supraventricular Tachyarrhythmias Associated with Hypertrophic Cardiomyopathy. **2012**, 809-818

282 Nonsustained Ventricular Tachycardia. **2012**, 625-640

- 281 Fundamental Concepts in Defibrillation. **2012**, 187-200
- 280 Device Therapy for Heart Failure Patients ; the Present Status and the Future. **2012**, 32, 400-409
- 279 Arrhythmias. **2012**, 247-256.e3
- 278 Devices for Monitoring and Managing Heart Failure. **2012**, 578-585
- 277 Arrhythmias in Coronary Artery Disease. **2012**, 825-834
- 276 Ventricular Fibrillation. **2012**, 681-706
- 275 Sudden Cardiac Death. **2012**, 709-719
- 274 Heart Failure. **2012**, 217-226.e4
- 273 Prediction of inappropriate implantable cardioverter-defibrillator therapies through parameters obtained in a simple exercise stress test. **2012**, 53, 276-81 1
- 272 Cardiovascular Disease. **2012**, 478-549
- 271 Electrophysiological Evaluation of Ventricular Fibrillation. **2012**, 327-332
- 270 Implantable Cardioverter-Defibrillators. **2012**, 1203-1218
- 269 The ECG in Other Heart Diseases. 473-493
- 268 Electrophysiology and Pacing. 174-204
- 267 Arrhythmias. 90-134
- 266 Indications for Pacemakers, ICDs and CRT: Identifying Patients Who Benefit from Cardiac Rhythm Devices. 93-132
- 265 Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death. **2013**, 501-524
- 264 What Is the Clinical Course of Advanced Heart Failure and How Do Implanted Cardiac Devices Alter This Course?. **2013**, 330-335

- 263 Invasive Electrophysiologic Testing: Role in Sudden Death Prediction. **2013**, 271-287
- 262 The Implantable Cardioverter Defibrillator: Technical and Clinical Considerations. **2013**, 611-620
- 261 Heart Failure and Sudden Death. **2013**, 395-412
- 260 Novel Predictors of Sudden Cardiac Death. **2013**, 301-314
- 259 Algorithm for Treatment of Advanced Heart Failure. **2013**, 9-34
- 258 Ventricular Arrhythmias and Defibrillators. **2014**, 414-422
- 257 Diagnosis and Management of Acute Heart Failure. **2014**, 238-254 0
- 256 Programmed Stimulation During Mapping and Ablation of VT. **2014**, 497-507
- 255 Stratification of the risk of sudden death in nonischemic heart failure. **2014**, 103, 348-57 9
- 254 Implantable Cardioverter-Defibrillator Shocks ; A Marker of Poor Prognosis but Themselves Do Not Affect Mortality. **2014**, 33, 421-428
- 253 Future Clinical Challenges. **1996**, 525-532
- 252 Bioelectronics and Instruments. **1997**,
- 251 Have MADIT and Recent Post Myocardial Infarction Amiodarone Studies Changed the Classical Indications for ICD Implantation?. **1998**, 264-269
- 250 How to Treat High-Risk Post Myocardial Infarction Patients Based on MADIT and Other Recent Trials. **1998**, 245-250
- 249 Sekundärprävention der koronaren Herzkrankheit in der Praxis. **1998**, 926-956
- 248 Therapeutic Strategies in Patients Suffering from Mycardiopathy (Awaiting Transplantation). **1998**, 241-252
- 247 Risk Stratification of Post-MI Patients. What Are the Limitations of MADIT? What Does the Future Hold in Store?. **1998**, 276-282
- 246 Recognition and Management of Cardiac Arrhythmias: Part I. General Principles and Supraventricular Tachyarrhythmias. **1998**, 13, 15-31 1

245 Survival Benefits of Implantable Cardioverter/Defibrillators in Different Groups of Patients. **1998**, 291-294

244 Survival Analysis and Classification of Death in Patients under Antiarrhythmic Treatment. **1998**, 125-129

243 Continuing Evolution of Implantable Cardioverter/Defibrillators: Smaller Size, Longer Life, Improved Cost-Effectiveness. **1998**, 295-300

242 Prophylactic Implantation of the Implantable Defibrillator in Asymptomatic Patients. **1998**, 301-304

241 What Have We Learned from the US Experience on the Prophylactic Use of ICDs Following MADIT?. **1998**, 270-275

240 Can Alternative Pacing Therapy Solve the Problem of Heart Failure Death in ICD Patients?. **1998**, 258-263

239 Appropriate Indications for the Implantable Defibrillator. **1998**, 345-350

238 Historical Perspectives on Cardioversion and Defibrillation. **1998**, 245-256

237 Risk Stratification: Exercise Testing, Imaging, and Cardiac Catheterization. **1999**, 383-405

236 Ruhe-Elektrokardiogramm. **1999**, 23-38

235 ICD-Therapie. **1999**, 285-301

234 Tachykardie Rhythmusstörungen. **1999**, 199-222

233 Management of Patients with Life-Threatening Ventricular Tachyarrhythmias: Focus on the Preeminent Role of the Implantable Cardioverter-Defibrillator. **1999**, 283-304

232 Ventricular fibrillation with small amplitude of activation and its implications for implantable cardioverter defibrillator treatment. **1999**, 40, 87-90

1

231 New treatment strategies in patients with impaired left ventricular systolic function. Part II: Treatment of moderate to severe cardiac dysfunction. **1999**, 317, 312-7

230 Nuclear Cardiology 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging. **2015**, 463-528

229 Akute Herzinsuffizienz und kardiogener Schock, Herzbeuteltamponade. **2015**, 649-669

228 Imaging Sympathetic Innervation of the Heart: Therapeutic Strategies SPECT/CT and PET/CT. **2015**, 367-385

227 Device Therapy in Heart Failure. **2015**, 167-177

226 Risk for Sudden Cardiac Death in Heart Failure: Underlying Mechanisms and Therapeutic Modalities. **2015**, 129-149

225 Implantierbare Kardioversions-Defibrillationsgeräte (ICD) Von der Indikation zur Nachsorge. **2015**, 1-16

224 Intensivtherapie bei akuter Herzinsuffizienz, kardiogenem Schock und Herzbeutelamponade. **2015**, 1-38

223 The role of the implantable cardioverter defibrillator for primary prevention in the adult with congenital heart disease. **2015**, 43-60

222 Initial experience of subcutaneous implantable cardioverter defibrillators in Singapore: a case series and review of the literature. **2015**, 56, 580-5

221 Changing Views: Safety and Efficacy of Implantable Cardioverter- Defibrillator Therapy in Athletes. **2015**, 23 Suppl, S74-7 0

220 Cardiac Implantable Electronic Devices in the Short Stay Management of Atrial Fibrillation. **2016**, 133-144

219 NYHA Class II or III Heart Failure: Who Will Need an Implantable Cardioverter Defibrillator (ICD)?. **2016**, 06, 372-381 0

218 Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy. **2016**, 90, 210-216 1

217 A Primer on Cardiac Devices: Psychological and Pharmacological Considerations. **2016**, 46, 683-690

216 Sexual Function in Adults with Implantable Cardioverter-Defibrillators/Pacemaker Recipients. **2017**, 101-111 1

215 Effectiveness of Implantation of Cardioverter-Defibrillators Therapy in Patients with Non-Ischemic Heart Failure: an Updated Systematic Review and Meta-Analysis. **2017**, 32, 417-422 4

214 Sudden Cardiac Death: Methods of Risk Prediction. **2017**, 61-73

213 Arrhythmias in Cardiomyopathy. **2017**, 285-321

212 Early Repolarization Syndrome and Implantable Cardioverter-Defibrillators. **2018**, 85-96

211 Extraction of a dual-chamber pacemaker and inserting of a new automatic implantable cardioverter defibrillator: The easy procedure almost became catastrophic: a case report. **2017**, 96, e7919

210 Implantable Cardioverter-defibrillator Therapy in the Patient with a Left Ventricular Assist Device: Still a Black Box. **2017**, 8, 2965-2968

- 209 Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator. **2019**, 6, 40-47
- 208 The Value of the Tei Index in Predicting Implantable Cardioverter Defibrillator Shocks. **2018**, 52, 36-40 0
- 207 Therapie von tachykarden Herzrhythmusstörungen. **2018**, 128-153
- 206 Modern Considerations in ICD Therapy. **2018**, 381-387
- 205 OBSOLETE: Lead-Related Complications. **2018**,
- 204 Optimal Strategies for Mitigating Sudden Cardiac Death Risk in At-risk Patients with Structural Heart Disease. **2018**, 9, 3025-3032
- 203 OBSOLETE: Cardiac Arrhythmias in Heart Failure. **2018**,
- 202 Pacemakers and Implantable Cardioverter Defibrillators. **2018**, 323-335
- 201 Transvenous Implantation of an Implantable Cardioverter Defibrillator in a Patient Who Had Undergone Tricuspid Valve Replacement. **2018**, 93, 211-215
- 200 Management of Common Arrhythmia in the Neurological Intensive Care Unit. **2018**, 11, 7-12
- 199 Ineffective ICD Shocks for Ventricular Fibrillation in a Patient with a Left Ventricular Assist Device: Continuous Flow During the Electrical Storm. **2018**, 11, 1883 1
- 198 The Innovation of Medical Devices. **2019**, 13-60
- 197 Implantable cardioverter-defibrillator in hypertrophic cardiomyopathy. **2018**, 2018, 31 1
- 196 ICDs, VADs, and Total Artificial Heart Implantation. **2019**, 215-224
- 195 Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy. **2018**, 12, CD012738 5
- 194 . **2018**, 58, 76-84 0
- 193 Single coronary artery and sudden cardiac death. **2019**, 18, 40-42 0
- 192 Appropriateness of Prescription and Safety of Wearable Cardioverter Defibrillators: A Single-center Experience. **2019**, 11, e4854

- 191 Aspectos diferenciales en la insuficiencia cardiaca en la mujer. **2019**, 54, 253-261 1
- 190 Implantable Cardioverter-defibrillator Therapy for Syncope: An Educational Example of a Multicomponent Electrocardiographic Differential Diagnosis and the Application of Clinical Trial Data to an Individual Patient. **2019**, 10, 3860-3864
- 189 Ventricular Tachycardia and Fibrillation: Pharmacologic Therapy. **2020**, 421-436
- 188 The implantable cardioverter-defibrillator. **2020**, 315-356
- 187 The Care of Patients With Atrial Fibrillation and Heart Failure. **2021**, 20, 93-99 0
- 186 Cancer and implantable cardiac defibrillator. Causality, confusion or chance?. **2021**, 157, 459-459
- 185 Mortality among ischemic and nonischemic heart failure patients with a primary implantable cardioverter-defibrillator. **2021**, 37, 1537-1545
- 184 The past, present, and future of implantable cardioverter-defibrillators. **2020**, 669-681
- 183 Noninvasive Risk Stratification for Sudden Cardiac Death. **2020**, 377-391
- 182 Prevention of Device Infection: New Implantable Devices. **2020**, 153-175 1
- 181 Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients. **2020**, 61, 942-950
- 180 The Implantable Defibrillator: A Historical Overview and its Use in Secondary and Primary Prevention. **2020**, 345-357
- 179 Uses, Overuses, and Problems Associated with the Implantable Defibrillator. **2020**, 359-373
- 178 Ventricular Tachycardia. **2020**, 197-212
- 177 ERKRANKUNGEN DES HERZENS UND DES KREISLAUFS. **2020**, D-1-D17-4
- 176 Bradycardia. **2020**, 213-223
- 175 Indications for Implantable Cardioverter Defibrillators. **2020**, 479-494
- 174 Gender Differences in Implantable Cardioverter-Defibrillator Utilization for Primary Prevention of Sudden Cardiac Death. **2021**, 23, 1

173 Ergänzende invasive Untersuchungsverfahren bei Vorhofflimmern/Vorhofflattern. **2007**, 105-119

172 Pacemaker and Internal Cardioverter-Defibrillator Therapies. **2007**, 175-194

171 Noninvasive Risk Stratification of Sudden Death: T-Wave Alternans. **2007**, 179-189

170 Which Patient and when Should Receive an ICD? Evolving New Indications on the Horizon. **2007**, 215-219

169 Tachykarde Rhythmusstörungen. **2005**, 198-224

168 Therapie der chronischen Herzinsuffizienz. **2005**, 149-268

167 Rhythmusstörungen des Herzens. **2006**, 143-204

166 Herzrhythmusstörungen. **2004**, 277-299

165 Spezielle therapeutische Probleme im höheren Alter. **2005**, 98-122

164 Herzrhythmusstörungen. **2006**, 375-417

163 Primärprophylaxe des plötzlichen Herztods. **2006**, 144-153

162 After DEFINITE, SCD-HeFT, COMPANION: Do We Need to Implant an ICD in All Patients With Heart Failure?. **2006**, 425-434

161 Intensive Care Unit Arrhythmias. **2007**, 431-443

160 Assessment of Single-Shock Defibrillation Testing of Biventricular ICDs. **2008**, 269-279

159 CRT-Pacing Only Versus CRT-Defibrillator. **2008**, 63-67

158 Pacing and Defibrillation. **2005**, 323-348

157 Treatment of Cardiac Arrhythmias. **2005**, 305-328

156 Senescence and Arrhythmogenesis. **2008**, 247-260



- 155 Invasive Electrophysiologic Testing: Role in Sudden Death Prediction. **2008**, 409-423
- 154 Novel Predictors of Sudden Cardiac Death. **2008**, 434-443
- 153 Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death. **2008**, 733-759
- 152 The Implantable Cardioverter Defibrillator: Technical and Clinical Considerations. **2008**, 772-780 1
- 151 Heart Failure and Sudden Death. **2008**, 873-887
- 150 Advances in nonpharmacologic therapies for ventricular arrhythmias. **2006**, 3, 125-138
- 149 Herzrhythmusstörungen. **2007**, 273-290
- 148 Basis of Cardiac Imaging 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging in Coronary Artery Disease and Congestive Heart Failure. **2006**, 352-394
- 147 Clinical Cardiac Electrophysiology [An Overview. **2009**, 145-154
- 146 Ventricular Arrhythmias, Defibrillators, Sudden Cardiac Death and Syncope. **2021**, 339-363
- 145 Diagnosis and Management of Acute Heart Failure. **2021**, 497-515
- 144 [Cancer and implantable cardiac defibrillator. Causality, confusion or chance?]. **2021**, 157, 459-463
- 143 Implantable defibrillators with and without resynchronization for patients with left ventricular dysfunction. **2005**, 32, 358-61
- 142 Radiofrequency ablation for post infarction ventricular tachycardia. **2004**, 4, 63-72 1
- 141 Predictors of appropriate ICD therapy in patients with implantable cardioverter-defibrillator. **2006**, 6, 17-24 1
- 140 Selecting dual chamber or single chamber implantable defibrillators: what is the golden rule?. **2003**, 3, 261-7 1
- 139 Preventing sudden death and the use of prophylactic implanted defibrillators. **2003**, 3, 60-6
- 138 T wave alternans and ventricular tachyarrhythmia risk stratification: a review. **2003**, 3, 67-73 8

- 137 Quality of life in patients with implantable cardioverter defibrillators. **2006**, 6, 173-81 22
- 136 Single-chamber versus dual-chamber implantable cardioverter defibrillators: do we need physiologic pacing in the course?. **2006**, 6, 153-62 1
- 135 Potential impact of antiarrhythmic drugs versus implantable defibrillators on the management of ventricular arrhythmias: the Midlands trial of empirical amiodarone versus electrophysiologically guided intervention and cardioverter implant registry data. **1998**, 80, 68-70 3
- 134 Early risk stratification for arrhythmic death in patients with ST-elevation myocardial infarction. **2007**, 7, 19-25 4
- 133 Defibrillation testing of the implantable cardioverter defibrillator: when, how, and by whom?. **2007**, 7, 166-75 5
- 132 The need for studies to evaluate the reproducibility of the T-wave alternans (TWA), and the rationale for a correction index of the TWA. **2007**, 7, 176-83 20
- 131 Risk of death and recurrent ventricular arrhythmias in survivors of cardiac arrest concurrent with acute myocardial infarction. **2008**, 8, 5-13 2
- 130 Design of a modular, extensible decision support system for arrhythmia therapy. **1998**, 693-7
- 129 Primary prevention: prime time?: ICD trials (and tribulations). **2004**, 12, 261-264
- 128 Sudden cardiac death and heart failure: can we make a difference?. **2005**, 13, 205-207
- 127 Clinical benefit, survival and adverse events in patients with implantable cardioverter defibrillators: the initial Rotterdam experience. **2001**, 9, 216-221
- 126 Prevention of sudden cardiac death in high-risk patients: implications of the results of primary prevention studies. **2002**, 10, 491-494
- 125 Sudden cardiac death: time to make a difference: Pro ICD. **2006**, 14, 417-419
- 124 QRS width and its impact on inducibility of ventricular arrhythmia at the time of electrophysiology study. **2005**, 97, 695-8 3
- 123 Primary prevention of fatal ventricular arrhythmias with implantable cardioverter-defibrillator therapy--an analysis of implications based on MADIT II criteria. **2006**, 9, 14-8
- 122 Attenuation of post-shock increases in brain natriuretic Peptide with post shock overdrive pacing. **2010**, 10, 122-38
- 121 Factors likely to affect the long-term results of ventricular stimulation after myocardial infarction. **2010**, 10, 162-72
- 120 Electrophysiologic study: its predictive value for ventricular arrhythmias. **2010**, 37, 291-6 1

119	Comparative effectiveness research: a cornerstone of healthcare reform?. <b>2010</b> , 121, 141-54; discussion 154-5	5
118	Use of an implantable loop recorder in the investigation of arrhythmias in adult captive chimpanzees ( <i>Pan troglodytes</i> ). <b>2011</b> , 61, 71-5	5
117	Cardiac implantable electrical devices: bioethics and management issues near the end of life. <b>2011</b> , 11, 342-7	3
116	Physicians' knowledge and attitudes regarding implantable cardioverter-defibrillators. <b>2010</b> , 17, 267-73	18
115	Implantable cardioverter-defibrillators: indications and unresolved issues. <b>2012</b> , 39, 335-41	9
114	Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis. <b>2005</b> , 5, 1-74	5
113	Heart failure in elderly: progress in clinical evaluation and therapeutic approach. <b>2013</b> , 10, 165-77	9
112	Current Concepts of Premature Ventricular Contractions. <b>2013</b> , 3, 26-33	11
111	ICD Implantation Practice Within Europe: How To Explain The Differences Beyond Economy?. <b>2015</b> , 8, 1262	
110	ICD Therapy In RVOT-VT And Early Stage ARVD/C Patients. <b>2014</b> , 7, 1086	
109	The development and application of the implantable cardioverter defibrillator. <b>2010</b> , 107, 48-52	1
108	Clinical Management for Survivors of Sudden Cardiac Death. <b>2001</b> , 5, 18-32	
107	Prognostic Awareness and Goals of Care Discussions Among Patients With Advanced Heart Failure. <b>2020</b> , 13, e006502	3
106	Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: An Analysis of All Appropriate Therapy in the PRAETORIAN trial. <b>2021</b> ,	3
105	The Impact of Charlson Comorbidity Index on De Novo Cardiac Implantable Electronic Device Procedural Outcomes in the United States. <b>2021</b> ,	
104	Cardiovascular therapeutics: A new potential for anxiety treatment?. <b>2022</b> ,	0
103	Patterned Illumination Techniques in Optogenetics: An Insight Into Decelerating Murine Hearts.. <b>2021</b> , 12, 750535	2
102	Is it time to revisit ICD indications?. <b>2022</b> , 1	0

- 101 Rationale and study design of the MINERVA study: Multicentre Investigation of Novel Electrocardiogram Risk markers in Ventricular Arrhythmia prediction-UK multicentre collaboration.. **2022**, 12, e059527
- 100 Which Patients Benefit Most From Primary Prevention ICDs?: A Call for More Nuanced Risk Stratification.. **2022**, 8, 12-14
- 99 Perplexing Results From the PRAETORIAN Trial: Revisiting the Debate About the Value of Antitachycardia Pacing.. **2022**, 145, 330-332 0
- 98 Effect of implantable cardioverter-defibrillators in patients with non-ischaemic systolic heart failure and concurrent coronary atherosclerosis.. **2022**, 1
- 97 Wearable cardioverter defibrillator multicentre experience in a large cardiac surgery cohort at transient risk of sudden cardiac death.. **2022**, 1
- 96 An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning.. **2022**, 1 1
- 95 Evolution of Devices to Prevent Sudden Cardiac Death: Contemporary Clinical Impacts.. **2022**, 0
- 94 Current clinical practice of subcutaneous implantable cardioverter-defibrillator: Analysis using the JROAD-DPC database.. **2022**, 0
- 93 Ventricular arrhythmias in ischemic versus nonischemic chronic heart failure. Is the equal sign between arrhythmia mechanisms and treatment strategies applicable?. **2011**, 32-37
- 92 Management of ventricular arrhythmias in heart failure: Current perspectives.. **2021**, 2, 796-806 1
- 91 Preimplantation screening of patients-candidates for implantation of a subcutaneous cardioverter-defibrillator: predictors of the outcomes. **2021**, 16, 58
- 90 Sudden Death and Ventricular Arrhythmias in Heart Failure With Preserved Ejection Fraction.. **2022**, 52, 251-264 0
- 89 Clinical electrophysiology of the aging heart.. **2022**, 20, 123-139
- 88 Arrhythmias in Female Patients: Incidence, Presentation and Management.. **2022**, 130, 474-495 2
- 87 A real-world experience of subcutaneous and transvenous implantable cardiac defibrillators-comparison with the PRAETORIAN study.. **2022**, 38, 199-212 1
- 86 JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.
- 85 Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?. **2022**, 1 0
- 84 Anti-tachycardia Pacing: Mechanism, History and Contemporary Implementation. **2022**, 24, 27-40 0

83	Arrhythmias in Chronic Kidney Disease.. <b>2022</b> , 17, e05	0
82	Periodic Repolarization Dynamics Identifies ICD-responders in Non-ischemic Cardiomyopathy: A DANISH Substudy. <b>2021</b> ,	0
81	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.. <b>2022</b> , CJ-20-1212	6
80	Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.. <b>2022</b> , 22,	1
79	Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest.. <b>2022</b> , 12, 5685	0
78	Sudden cardiac death in heart failure with preserved ejection fraction: an updated review. <b>2022</b> , 23,	0
77	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022</b> , 101161CIR0000000000001063	35
76	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022</b> ,	49
75	Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium.. <b>2021</b> ,	1
74	Novel active fixation lead guided by electrical delay can improve response to cardiac resynchronization therapy in heart failure.. <b>2021</b> ,	1
73	Heart Failure in Older Adults: Medical Management and Advanced Therapies.. <b>2022</b> , 7,	
72	The Canadian Women’s Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women-Chapter 6: Sex- And Gender-Specific Diagnosis and Treatment. <b>2022</b> ,	0
71	Implantable Cardioverter Defibrillator in Primary and Secondary Prevention of SCD-What We Still Don’t Know.. <b>2022</b> , 9,	
70	Prediction of Fatal or Near-Fatal Cardiac Arrhythmias: Where Are We Now?. <b>2022</b> , 8, 424-425	
69	Data_Sheet_1.PDF. <b>2019</b> ,	
68	Image_1.TIF. <b>2020</b> ,	
67	Image_2.TIF. <b>2020</b> ,	
66	Image_3.TIF. <b>2020</b> ,	

- 65 History and evolution of pacing and devices.. **2022**, 108, 794-799 0
- 64 Identifying high risk patients post myocardial infarction with reduced left ventricular function using loop recorders INSPIRE-ELR clinical study.. **2022**,
- 63 2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.. **2022**, 1
- 62 Contemporary Management of Complex Ventricular Arrhythmias. 11,
- 61 Antiarrhythmic drugs and strategies. **2013**, 272-331 2
- 60 Comparison of Frequency of Ventricular Tachyarrhythmia in Men-Versus-Women in Patients with Implantable Cardioverter-Defibrillator for Primary Prevention. **2022**,
- 59 Multifunctional flexible electro-optical arrays for simultaneous spatiotemporal cardiac mapping and modulation.
- 58 Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy.
- 57 Implantable cardioverted defibrillators: 40 years of history and beyond. 1-4
- 56 Supraventricular and ventricular arrhythmias: medical management. **2022**,
- 55 Sudden Cardiac Death - a Predictable, Avoidable and Treatable Event?. **1998**, 28, 350-356 0
- 54 Non-Pharmacological Management of Cardiac Arrhythmias. **1999**, 29, 94-100 0
- 53 In Memoriam: Morton Mower, MD, January 31, 1933-April 25, 2022. **2022**, 19, 1403-1404
- 52 The role of multimodality imaging in the selection for implantable cardioverter-defibrillators in heart failure: A narrative review. 0
- 51 Patient-Reported Outcomes in a Multidisciplinary Electrophysiology-Psychology Ventricular Arrhythmia Clinic. **2022**, 11, 1
- 50 Impact of signal-averaged electrocardiography findings on appropriate shocks in prophylactic implantable cardioverter defibrillator patients with nonischemic systolic heart failure. **2022**, 22,
- 49 Correlation of exit sites of inducible ventricular tachycardia post- ST elevation myocardial infarction on electrophysiology study, with region of infarct.
- 48 Impact of socioeconomic aspects on cardiac implantable electronic device treatment and application of the EHRA guidelines. 2

47	Sex differences and adherence of patients treated with wearable cardioverter-defibrillator: insights from an international multicenter register.	0
46	2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.	37
45	LIVING WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR. <b>2000</b> , 35, 1019-1030	5
44	Validation of the Implantable Cardioverter-Defibrillators Indication Criteria for Nonischemic Cardiomyopathy [Why? When? How?] <b>2022</b> ,	0
43	Safety and Tolerability of Implanted Subcutaneous Cardioverter-Defibrillator Systems. <b>2022</b> , 18, 427-432	0
42	From evidence-based medicine to digital twin technology for predicting ventricular tachycardia in ischaemic cardiomyopathy. <b>2022</b> , 19,	0
41	In situ diagnosis and simultaneous treatment of cardiac diseases using a single-device platform. <b>2022</b> , 8,	1
40	Flexible Electro-Optical Arrays for Simultaneous Multi-Site Colocalized Spatiotemporal Cardiac Mapping and Modulation. 2201331	2
39	Sex Differences in Outcomes of Tetralogy of Fallot Patients With Implantable Cardioverter-Defibrillators. <b>2022</b> ,	0
38	Improve the Prevention of Sudden Cardiac Arrest in Patients With Post-acute Myocardial Infarction. <b>2022</b> ,	0
37	Catheter ablation of ventricular tachycardia associated with structural heart disease: Current status and perspectives. <b>2022</b> ,	0
36	Heart Transplantation. <b>2022</b> , 1271-1291	0
35	Mechanical circulatory support in ventricular arrhythmias. 9,	0
34	Clinical outcomes of subcutaneous vs. transvenous implantable defibrillator therapy in a polymorbid patient cohort. 9,	0
33	Impact of late gadolinium enhancement extent, location, and pattern on ventricular tachycardia and major adverse cardiac events in patients with ischemic vs. non-ischemic cardiomyopathy. 9,	0
32	Risk factors for cardiac implantable electronic device infections: a nationwide Danish study.	1
31	The development of a decision aid for shared decision making in the Dutch implantable cardioverter defibrillator patient population: A novel approach to patient education. 9,	0
30	JCS 2021 Guideline on the Clinical Application of Echocardiography. <b>2022</b> ,	2

- 29 Ventricular Arrhythmias Following Coronary Artery Bypass Grafting for Ischemic Cardiomyopathy: When to insert an implanted cardiac defibrillator?. **2022,** ○
- 28 Pathophysiology and Management of Heart Failure in the Elderly. ○
- 27 Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan. **2022,** ○
- 26 Impairment of Quality of Life in Patients with Implanted Subcutaneous Cardioverter Defibrillator (S-ICD) Compared to Implanted Transvenous Cardioverter Defibrillator Therapy. Volume 16, 3027-3033 ○
- 25 Laser Doppler flow for the hemodynamic differentiation of tachycardia. ○
- 24 Multicenter assessment of the outcomes of subcutaneous ICD implantation in patients with prior or future sternotomy. ○
- 23 Best Practices for the Catheter Ablation of Ventricular Arrhythmias. **2022,** 14, 571-607 ○
- 22 Effect of Implanted Defibrillator on Mortality in Patients With Chronic Kidney Disease. **2023,** 188, 36-40 ○
- 21 Programming of implantable cardioverter defibrillators for primary prevention: outcomes at centers with high vs. low concordance with guidelines. ○
- 20 Management of ventricular arrhythmias in heart failure: current perspectives. **2022,** 21, 139-149 ○
- 19 Influence of Atrial Fibrillation on Two-Year Survival of Patients with Implanted Cardioverter Defibrillator. **2022,** ○
- 18 Inter-American Society of Cardiology (CIFACAH-ELECTROSIAC) and Latin-American Heart Rhythm Society (LAHRS): multidisciplinary review on the appropriate use of implantable cardioverter defibrillator in heart failure with reduced ejection fraction. ○
- 17 Brugada syndrome in Thailand: Three decades of progress. **2022,** 3, 743-751 ○
- 16 Racial and ethnic differences in implantable cardioverter-defibrillator patient selection, management, and outcomes. **2022,** 3, 807-816 ○
- 15 Temporal Trends and Outcomes of Implantable Cardioverter Defibrillators in Systolic Heart Failure Stratified by Chronic Kidney Disease in the United States. **2022,** 101548 ○
- 14 Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. ○
- 13 Programmed ventricular stimulation in structural heart disease: Implications of patterns of ventricular arrhythmias induced to long-term outcomes. **2022,** ○
- 12 Risk Stratification for Sudden Cardiac Death after Acute Myocardial Infarction. **2010,** 39, 237-246 ○



- 11 A case of supraventricular tachycardia misdiagnosis after dual-chamber implantable cardioverter defibrillator implantation with His bundle pacing. ○
- 10 Tikagrelor Yönelmesi Yapılan Akut Koroner Sendrom Hastalarında Fragmente QRS Kompleksinin Bir Yıllık Mortalitedeki Prediktif Değeri. **2022**, 6, 366-372 ○
- 9 Diretriz Brasileira de Dispositivos Cardíacos Eletrônicos Implantáveis 2023. **2023**, 120, ○
- 8 IMPLANTABLE DEFIBRILLATORS AND/OR AMIODARONE: ALTERNATIVES OR COMPLEMENTARY THERAPIES. **1998**, 52, 425-428 ○
- 7 Cardioverter-defibrillator reduces mortality risk in eligible ischemic and non-ischemic cardiomyopathy patients: Sub-analysis of the multi-center Improve SCA study. **2023**, 75, 115-121 ○
- 6 Management of Ventricular Arrhythmias Worldwide. **2023**, ○
- 5 Sudden cardiac death prevention in the era of novel heart failure medications. **2023**, 27, 100281 ○
- 4 Implantable Cardioverter-Defibrillator for Primary Prevention in Asia. **2023**, ○
- 3 Implantable cardiac defibrillators in octogenarians. **2023**, 20, 23-31 ○
- 2 Heart Failure with Reduced Ejection Fraction. **2023**, 67-88 ○
- 1 Defibrillator exchange in the elderly. **2023**, ○